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Commercialization of Genetic Testing 
Services: The FDA, Market Forces, and 
Biological Tarot Cards 
Michael J. Malinowski 
Robin J .R. Blatt* 
Many women fear being diagnosed with breast cancer; and rightfully so. Despite the 
capabilities of modem medicine, the cumulative lifetime risk of getting the disease has risen to 
one in eight and, despite decades of researr:h, no cures exist. In this Article, the autlwrs explore 
the commerr:ializ.ation of so-called breast cancer gene tests, based upon generic alterations 
linked to the disease. Although the authors fully address this specific technology, they use what 
constitutes the seminal case of predictive genetic testing to analyze the adequacy of the existing 
regulatory framework. The authors conclude that the present regulatory system is inadequate 
and places a dangerous amount of reliance on primary care physicians. Their conclusion is 
grounded in the observation that most primary care physicians lack sufficient knowledge about 
this evolving investigative technology-which is highly subject to misinterpretation, and, 
though potentially helpful to some "high risk" patients, offers questionable clinical value for 
the general public. The authors set forth numerous proposals to promote both the quality and 
clinical value of predictive genetic testing so that it confonns to public health standards and 
can be properly integrated as a reliable component o f  medical care in specific situations. 
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I. INIRODUCTION 
OncorMed, Inc. (OncorMed), a small Gaithersburg, Maryland, 
biotechnology company involved in general cancer testing, announced 
in January 1996 that it had begun selling a testing service1 to identify 
1. We employ definitions pertaining to genetic testing adopted by the Task Force 
on Genetic Testing, which was created through the Ethical, Legal, and Social Implications 
(ELSI) Subprogram of the Human Genome Project (HGP). The ELSI Task Force has 
defined "predictive genetic test" as the "test of a person's or fetus's genes or gene products 
for the purpose of determining the presence of abnormalities, including carrier status, that 
are known to be associated with an increased risk of development of a disease or disorder." 
Meeting Minutes from the Second Meeting of the Task Force on Genetic Testing 3 (Nov. 14-
15, 1995) [hereinafter Meeting Minutes]. As recognized by the ELSI Task Force, the 
predictive element of this definition must be underscored: 
Genetic tests are already an important part of medical practice. In patients 
with overt manifestations of disease, they can rule out mistaken diagnoses or 
establish the correct diagnosis promptly, avoiding needless referrals and elaborate 
workups (e.g. [sic] a test for cystic fibrosis in a child with recurrent pulmonary 
infections). 
ELSI TASK FORCE ON GENETIC TEsTING, INTERIM PRINCIPLES 2 (1996). We emphasize the 
distinction between predictive genetic testing and presymptomatic diagnostic testing. The 
latter assumes predictability. See infra note 12 for further clarification of these terms. We 
also recognize that breast cancer is not 100% gender-specific, meaning that men too may be 
stricken with the disease. However, for the sake of simplicity and to reflect the vast majority 
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the presence of genetic alterations linked to breast and ovarian cancer.2 
Within a few months, Genetics & IVF Institute (NF) of Fairfax, 
Virginia, began to offer a variation of the test3 to any Jewish4 woman 
of breast cancer patients, throughout this Article we use the female gender to refer to breast 
cancer patients. 
2. The stated purpose of the test is to determine the presence of a specific genetic 
alteration, or allele, linked to breast and ovarian cancer. The testing process consists of 
extracting DNA from a blood sample and sequencing the DNA to detennine whether the 
genetic alteration is present. This technology is based upon the discovery that a gene called 
BRCAl (breast cancer 1), found on chromosome 17, codes for a protein that has a tumor­
suppressor function. See Yoshio Miki et al., A Strong Candidate for the Breast and Ovarian 
Susceptibility Gene BRCAJ, 266 SCIENCE 66, 66-71 (1994); Stephen C. Rubin et al., 
Clinical and Pathological Features of Ovarian Cancer in Women with Genn-Line 
Mutations of BRCAJ ,  335 NEW ENG. J. MED. 1413, 1413 (1996) (reporting, however, that 
this form of inherited cancer is more responsive to clinical treatment); see also Frances S. 
Collins, BRCAJ-Lots of Mutations, Lots of Dilemmas, 334 NEW ENG. J. ME D. 186, 186 
(1996) (emphasizing the scientific unreliability of current testing capability). Alterations in 
the gene may interfere with the production of this protein or with the gene's function in 
some other way, and thus cause an increased risk of developing breast cancer. Already 
more than 130 different mutations have been found in the breast cancer gene. 
Some are probably meaningless, and others deadly, but most have not been 
studied yet. Standard gene tests available today detect only . .. a few of the more 
common mutations, so a negative test doesn't guarantee that a woman is safe. 
Rick Weiss, Tests' Availability Tangles Ethical and Genetic Codes, WASH. POST, May 26, 
1996, at Al; see also D. Shattuck-Eidens et al., A Collaborative Study of 80 Mutations in 
the BRCAJ Breast and Ovarian Cancer Susceptibility Gene, 273 JAMA 535, 535-41 (1995) 
(stating that over 100 distinct mutations of BRCAl have been identified). A second gene, 
known as BRCA2, also has been linked to breast and ovarian cancer. See Richard Saltus, 2d 
Cancer Gene Cited in I of 100 Ashkenazi Jewish Women , BOSTON GLOBE, Oct. 2, 1996, at 
Al8 (citing Oct. 2, 1996 issue of Nature Genetics). In early 1997, a third gene, CHK, was 
lined to breast cancer. See Judy Foreman, Another Gene with Breast Cancer Role Identified, 
BOSTON GLOBE , Jan. 16, 1997' at A23. 
3. IVF uses allele-specific hybridization techniques rather than sequencing. 
4. One BRCAl mutation, 185deIAG, is believed to occur in one percent of the 
people who are of Ashkenazi (Eastern European) Jewish ancestry. See J.P. Struewing et al., 
The Carrier Frequency of the BRCAJ 185delAG Mutation is Approximately J Percent in 
Ashkenazi Jewish Individuals, 11 NATURE GENETICS 198, 198-200 (1995). Research is 
ongoing, as other ethnic groups may be more susceptible to inherited breast cancer and, 
further, inherited susceptibility may be offset by environmental factors not yet identified. 
Still, according to recent data, one in 50 Ashkenazi women carry at least one of the BRCAI 
and BRCA2 mutations that are believed to raise a woman's susceptibility to inherited breast 
and ovarian cancer. See Saltus, supra note 2, at Al 8. However, only five to ten percent of 
incidents of breast cancer are believed attributable to inherited genes. See id. See generally 
The Scientific Questions, 18 PERSP. GENETIC COUNSELING 4 (1996) (estimating that 10% of 
breast cancers are due to gennline mutations); David S. Hilzenrath, Md. Finn s Gene Test to 
Intensify Bioethics Debate, WASH. POST, July 25, 1996, at D14 (describing a service to 
detect predisposition to breast and ovarian cancer). For discussion of the danger of "ethnic 
genetics," see Ruth Hubbard & Wendy McGoodwin, The Danger of "Ethnic Genetics," 
BOSTON GLOBE, Oct. 13, 1995, at 3. See also E.J. Kessler, The Secret Shake-Up in the 
Shiduch, Forward, CANCER & Us, July 26, 1996, at 11, 13 (reporting from New York City's 
Orthodox Jewish Community that, "[d]iagnosed with breast cancer-a terrifying disease 
1214 TULANE I.AW REVIEW [Vol. 71:1211 
willing to pay $295.5 OncorMed then expanded its service to include 
tests for genetic alterations of BRCA 1 and BRCA2 for between $400 
and $1,200 (the latter for combinations of the genetic alterations).6 In 
the fall of 1996, Myriad Genetic Laboratories, Inc. (Myriad), a Salt 
Lake City subsidiary of Myriad Genetics, also began selling a 
combined test for several alterations of the two genes for $2,400.7 All 
of these companies are actively developing markets for their testing 
services. According to one report, "[i]n the future, OncorMed is 
expected to market its testing service to disease management facilities 
and insurance companies, which would benefit from information 
about patients' susceptibility to breast and ovarian cancer, as well as 
other diseases."8 NF, Myriad, and OncorMed have not submitted and 
do not intend to submit their testing services to the Food and Drug 
under any circumstances-these women feel they.must hide their trouble, traveling far from 
home for treatment and disguising their hospital stays as out-of-town visits, lest the news of 
their affliction poison the marriage prospects of their daughters"). It is important to note that 
OncorMed has directly addressed some of the implications of singling out Ashkenazi Jews 
for BRCA testing through the formation of a special protocol and information packet to 
accompany its "Heritage Panel" test, a test for three BRCA mutations found at an elevated 
level in families of Ashkenazi Jewish descent. See OncorMed Heritage Panel Education and 
Testing Packet (undated) (on file with authors). 
5. See Meredith Wadman, Women Need Not Apply, WASH. POST, May 5, 1996, at 
C3 (reporting that, in collaboration with IVF, Dr. Joseph Schulman is offering the test to 
Jewish women referred by a physician for $295); Weiss, supra note 2, at A I. 
6. See Hilzenrath, supra note 4, at D 1 4  ("OncorMed . . . plans next week to 
introduce a new service that will raise the stakes in one of biotechnology's biggest ethical 
debates . ... "); Ridgely Ochs, New Test Of ered for Cancer Gene, NEWSDAY, July 24, 1996, 
atA7. 
7. See MYRIAD LABORATORIES, INC., BRCA l: GENETIC SUSCEPTIBil.ITY FOR BREAST 
AND OVARIAN CANCER 2 ( 1 996); see also Saltus, supra note 2, at A 18; Sean Taytigian et al., 
The Complete BRCA2 Gene and Mutations in Chromosome 13q-Linked Kindreds, 12 
N ATURE GENETICS 333, 333-37 (1996) (publishing full sequence of BRCA2 breast cancer 
gene by Myriad Genetics). To advance compilation of the data needed to raise the clinical 
value of its BRCA testing, Myriad has established a registry at the Dana-Farber C ancer 
Institute. See Richard Saltus, Gene Test for Cancer Risk is Offered, BOSTON GLOBE, Oct. 25, 
1996, at Al. 
8. OncorMed BRCAJ Testing Service Commercialization Enters Second Phase 
Through New !RB Protocol, 39 BLUE SHEET 6, 6-7 ( l  996) (hereinafter OncorMed BRCAJ 
Testing Service]. In contrast, Europe is considering an outright ban on the use of genetic 
testing information by insurers in the absence of comprehensive self-regulation. See 
Insurers Risk Ban Over the Use of Genetic Testing, DAILY EXPRESS, July 19, 1996, available 
in Westlaw, 1996 WL 6714032 [hereinafter Insurers Risk Ban]. 
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Administration (FDA) for review.9 According to their interpretation of 
existing FDA and other federal regulations, they are not required to.10 
The commercialization of these so-called "breast cancer tests"'' 
marks the advent of a generation of predictive12 genetic testing 
products derived from discoveries reported intensely in the media 
during the past several years. 13 The public is demanding more 
9. We note, however, that these companies have taken very different approaches to 
many of the patient issues raised in this Article. We commend the work of OncorMed and, 
in particular, Dr. Patricia Murphy in developing meaningful protocols for genetic testing. 
See App. I. 
l 0. See Proposed Recommendations of the Task Force on Genetic Testing, Meeting 
Notice, 62 Fed. Reg. 4539, 4544 (1997) ('The Task Force recognizes that developers of 
genetic tests who do not rely on federal funds are under no legal obligation to submit 
protocols to the proposed NGB and have not always obtained IRB approval for validation 
protocols of tests they plan to market as laboratory services."). However, the FDA has not 
completely acceded that it lacks the statutory authority to regulate genetic testing. See 
OncorMed BRCAJ Testing Service, supra note 8, at 7 ("Currently, the FDA is not regulating 
the testing; the agency maintains that it has such authority but Jacks the resources to review 
the technology or make and enforce new regulations for the field."). 
1 1 . As discussed fully infra at note 25, the clinical predictive value of these tests for 
determining whether an individual who has tested positive for the alleles will suffer breast 
cancer in her lifetime has not been determined, except for a very small percentage of the 
population. 
12. It is important to distinguish predictive genetic testing from reliable 
presymptomatic genetic testing, as the meaning of these terms is being muddled in the 
current genetic testing debate. The distinction between these terms is certainty, clinically 
known as "positive predictive value" (PPV), which is defined infra at note 25. 
Presymptomatic genetic testing refers to testing for genetic alterations causative of disorders 
and often controlled by a single genetic alteration, prior to the onset of symptoms. Such 
disorders include Huntington's Disease and Amyotrophic Lateral Sclerosis (ALS), 
commonly known as Lou Gehrig's disease. So-called "predictive" genetic testing is also 
testing for genetic alterations linked to health conditions and disorders. However, due to the 
influence of other genes and environmental factors over the target health conditions, 
predictive genetic testing at most offers the general public estimated chances of actually 
developing the health condition. 
13. Even years ago, leaders in the field of genetics were responding to "the very real 
possibility that the explosion of knowledge in the field of genetics will produce a windfall of 
diagnostic and therapeutic technologies." Philip J. Boyle, Sh aping Priorities in Genetic 
Medicine, HASTINGS CENTER REP., May-June 1995, supp. at l ;  see also Weiss, supra note 2, 
at Al ("New genetic tests are moving rapidly from research laboratories into doctors' 
offices, where they are being marketed as a way to predict people's chances of getting 
common diseases such as colon cancer, breast cancer and Alzheimer's disease."). The truth 
has become undeniable. "Scores of genetic tests have been developed for dozens of 
diseases. Some are used to diagnose existing conditions and others are used in healthy 
people to predict the odds that a disease will occur." Id. Representative genetic tests in 
various stages of development include the following: 
Medically useful: (a) APC gene, which is linked to familial adenomatous 
polyposisa condition that leads to colon cancer; (b) MEN gene, which is linked to 
multiple endocrine neoplasia and indicates a very high risk of cancer of the 
endocrine glands; and (c) RB gene, which is linked to retinoblastoma---<:hildhood 
eye cancer; 
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information about the technology, 14 and other commercial and 
academic laboratories are introducing their own tests for genetic­
influenced disorders that may help assess future disease risk.15 From a 
Id. 
More research needed: (a) BRCAI and BRCA2, which have been linked 
to breast and perhaps ovarian cancer; (b) MSH2 and MLHl, which have been 
linked to hereditary nonpolyposis colon cancer; and (c) p53, which has been 
linked to Li-Fraumeni syndrome, an elevated risk of many cancers; and 
Little clinical utility at present: (a) p 16, which has been linked to 
malignant melanoma, a serious skin cancer; and (b) APOE-4, which has been 
linked to Alzheimer's disease. 
14. As recognized by Professor Annas, 'The gene has become more than a piece of 
information; it has become 'a cultural icon, a symbol, almost a magical force."' George 
Annas, Genetic Prophecy and Genetic Privacy, TRIAL, Jan. 1 996, at 19, 24-25 (quoting 
DOROTHY NELKIN & M. SUSAN LINDEE, THE DNA MYSTIQUE: THE GENE AS A CULTURAL 
ICON 2 (1995)); see also Richard Saltus, Sounding the Alarm, BOSTON GLOBE, May 26, 
1 996, (Magazine), at 14 [hereinafter Saltus, Sounding the Alarm] ("No longer merely a 
scientific schematic, it is now a staple of pop culture. It appears time and again in op-ed 
pieces, newspaper and magazine articles, and books that tackle the thorny dilenunas of the 
genetic revolution."). Dr. Richard C. Lewontin, a Harvard scientist who is critical of present 
priorities in gene research and also affiliated with the C ouncil for Responsible Genetics, a 
consumer group based in Cambridge, Massachusetts, has coined the term "genomania," that 
is, "the idea that almost everything-a baby's chin or nose, someone's personality quirks, or 
a preponderance of men in positions of power-can be explained by genes." Id. But see 
Richard Saltus, Early Alzheimer's: Do You Want to Know?, BOSTON GLOBE, July 3, 1 995, at 
39 [hereinafter Saltus, Early Alzheimer's] ("Recently developed gene tests ... for inherited 
predispositions to breast cancer and other cancers have raised this issue for an increasing 
number of families. If any conclusion can be drawn thus far, it's that people are more 
hesitant and ambivalent about learning their genetic destiny than anyone expected."). It is 
important to emphasize that industry is attempting to facilitate consumer interest in and 
demand for genetic testing. For example, "Myriad is currently establishing a genetic testing 
and information business to identify individuals who have inherited gene mutations which 
increase their risk for specific illnesses." MYRIAD LABORATORIES, INC., supra note 7, at 2. 
The predominant force that drives consumer demand for a great deal of predictive genetic 
testing may be social pressure. See Daniel Callahan, The Genetic Revolution, in BIRTH TO 
DEATH: SCIENCE AND BIOETHICS 15 (David C. Thomasma & Thomasine Kushner eds., 1 996) 
("New medical technologies rarely remain discretionary for long. If they are not legally 
imposed on people, something hard to do in our western society, they can just as effectively 
be imposed by social pressure."). 
1 5 .  See ASSESSING GENETIC RISKS (Lori Andrews et al. eds., 1 994) (reporting on 
pervasive, informal genetic testing by research); ELSI TASK FORCE ON GENETIC TEsTING, 
supra note 1 ,  at 2; Paul H. Silverman, Commerce and Genetic Diagnostics Laboratories), 
HASTINGS CENTER REP., May-June 1995, supp. at S l5 ('The prospect of routine genetic 
diagnostics for a wide variety of diseases ranging from rare monogenetic afflictions (for 
example, Tay-Sachs) to conunon polygenic diseases (for example, many cancers) have 
attracted the attention of conunercial testing laboratories and venture capitalists."); Joan 
Stephenson, Questions on Genetic Testing Services, 274 JAMA 1661 (1995) ("As scientists 
pinpoint genes that underlie such diseases as cystic fibrosis and breast cancer, commercial 
and academic laboratories are scrambling to provide genetic testing services aimed at 
diagnosing gene-related disorders and assessing future disease risk."); Ronald Rosenberg, 
For Matritech, an Encouraging Prognosis, BOSTON GLOBE, Feb. 18, 1996, at 80 ("Matritech 
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business perspective, these laboratories are doing so ( 1) to generate 
immediate revenue streams to finance their scientific research and 
development (R&D); (2) to amass patient data to determine the extent 
to which their tests predict the onset of breast and ovarian cancer for 
the general population, thereby giving them the option to sell their tests 
as kits and charge market prices rather than simply recouping costs; 16 
(3) to obtain subject samples for gene sequencing and outpace their 
science competitors; (4) to accelerate the development of more 
marketable diagnostics, therapeutics, and maybe even gene therapies; 
and/or (5) to increase familiarity, acceptability, and demand for such 
tests among physicians and the public, and thereby perhaps achieve 
standard care acceptance and insurance coverage for their products. 17 
The precedent set by IVF, Myriad, and OncorMed (as well as 
academic research institutions) conceivably affects all Americans 
directly. More than five thousand genetic alterations have been 
identified,18 and estimates are that every person has four or five genetic 
alterations linked to serious health conditions.19 Now that a "critical 
mass" of the human genome has been mapped through the Human 
and other biopharmaceutical finns are developing a new generation of simple diagnostic 
tools, or exams, to track the progress of the cancer itself in recovering patients."). 
l 6. See infra note 64 and accompanying text. 
17. According to the ELSI Task Force, the four primary forces fueling expansion of 
the commercialization and availability of predictive genetic testing are: (1) the reward 
structure of science, which encourages immediate repor ting of findings; (2) public demand 
for progress in the fight of disease; (3) biotechnology companies' objective o f  developing 
markets large enough to make testing profitable; and (4) media coverage of genetic 
discoveries. See ELSI TASK FORCE ON GENETIC TEsTING, supra note I, at 4. For a general 
discussion of the inconsistency of insurance coverage in the United States for state of the art 
medical treatments, see Karen L. Illuzzi Gallinari, Commentary, The State of the Law on 
Insurance Coverage for State of the Art Medical Treatments, MEALEY's LIT. REP.: BAD 
FAITH, Oct. 18, 1995, at 16. 
18. A catalog of human genes and genetic disorders has been compiled by Dr. Victor 
A McKusick, doctor of medical genetics and professor at the National Center for Human 
Genome Research at John Hopkins University. This catalog, which is updated daily and 
available on the World Wide Web, lists more than 5,000 genes/genetic disorders. See Ellie 
McCormack, Sought-After Counselors Find It's All in the Genes, BOSTON Bus. J., Apr. 26-
May 2, 1996, at 3, 23; see also Do You Really Want to Know?, Nightline (ABC television 
broadcast, Apr. 26, 1996) (videotape on file with authors). Consider that, in 1966, this list 
consisted of just l ,500 entries. Id. 
19. "According to the British Medical Association, '[g]enetic and part-genetic 
diseases affect one in every twenty people by the age of 25 and perhaps as many as two in 
three people during their lifetime."' Sheila A.M. M clean, Genetic Screening of Children: 
The U.K. Position, 12 J. CONTEMP. HEALTH L. & PoL'Y 113, 114 (1995) (stating also that 
the proportion of childhood deaths attributable to genetic factors, wholly or partly, is 
approximately 50%) (citing BRITISH MEDICAL ASSOCIATION, OUR GENETIC FUTURE: THE 
SCIENCE AND ETHICS OF GENETIC TECHNOLOGY l (1992)). 
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Genome Project (HGP),20 linkages between genes and health 
conditions should increase exponentially.21 Technology also has made 
testing for genes associated with health cheaper and easier, and 
standard medical practice soon will include much more genetic 
testing.22 Kaiser Permanente, the nation's largest health maintenance 
organization, already has decided to allow its divisions to offer BRCA 
genetic testing to its members.23 
The danger is that, absent regulatory safeguards and quality 
controls, the forthcoming multitude of predictive genetic testing 
20. The HGP is a three-billion-dollar initiative launched by the federal government 
to map the entire human genome by the year 2005. For discussion of the HGP, see generally 
ROBERT M. COOK-DEEGAN, THE GENE WARS 169 (1994); Robert M. Cook-Deegan, Origins 
of the Human Genome Project, 5 RISK: HEALTH, SAFETY & ENV. 100 (1994). The impact of 
the HGP on the biotechnology industry is addressed in Michael J. Malinowski & Maureen 
A. O'Rourke, A False Start? The Impact of Federal Policy on the Genotechnology 
Industry, 13 YAIEJ. REG. 163, 190-91 (1996). 
21. See Detailed Human Physical Map Published by Whitehead-MIT: STS-Based 
Map Represents Halfway Point to JOO-kb Human Genome Project Goal, HUMAN GENOME 
NEWS, Jan.-Mar. 1996, at 5 [hereinafter Human Physical Map] ('The new map, which 
contains more than 15,000 STS DNA markers spaced an average of 199 kb apart, covers 
almost 95% of the entire genome . . . . Although originally slated for 1988, map completion 
by Whitehead-MIT and other groups is expected b y  the end of this year. "). The HGP is a 
"global attempt to identify the blueprint of every individual's genetic makeup." Mclean, 
supra note 19, at 114-15. For a full discussion of the HGP, see Malinowski & O' Rourke, 
supra note 20, at 190-93; Michael J. Malinowski, Coming into Being: Law, Ethics, and the 
Practice of Prenatal Genetic Screening, 45 HASTINGS L.J. 1435, 1441-45 (1994). See also 
infra Part II.A. One of the fundamental goals underlying HGP is "[t]he rapid transfer of 
technology to industries that can develop economically and medically useful applications 
.. . that affects us all." ROBIN J.R. BLATT, CONCEIVING THE FUTURE: THE X's AND Y's OF 
GENETIC TEsTING IN PREGNANCY (forthcoming 1997) (on file with the authors). 
22. See Dee Lord, Something in the Genes, ABA J., Apr. 1996, at 86; Richard 
Saltus, Curbs on Use of Genetic lnfonnation Studied, B OSTON GLOBE, Feb. 23, 1996, at 19. 
The capability to test for multiple mutations at one time is known as multiplex testing. See 
Lori B. Andrews, Prenatal Screening and the Culture of Motherhood, 47 HASTINGS L.J. 967 
(1996) (addressing multiplex testing in the context of prenatal screening). An advanced 
form of this technology, Multiple Allele Specific Diagnostic Assay (MASDA), developed by 
Genzyme Genetics in Framingham, Massachusetts, makes it possible to test over 500 patient 
samples for over I 00 known mutations simultaneously. See Private Communication 
between Robin Blatt and Judith King, Former Education and Corporate Communications 
Manager, Genzyme Genetics (July 1996). 
23. According to one report, Kaiser 
plans to offer genetic tests to show the predisposition to breast cancer among 
some of its 6.8 million members. Kaiser guidelines will lay out the process for 
getting the test, and will probably require any candidates to undergo 
comprehensive counseling in advance. Patients and their families will be 
included in a registry and will be followed afterward to monitor the consequences 
of the test. 
Robert B. Whitcomb, Our Genetically Evolving Future, PROVIDENCE JOURNAL-BUUETIN, 
Sept. 5, 1996, at 7B. 
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services will be overused. Even tests that are good predictors for some 
people may be overused and misinterpreted by patients, providers, 
insurance companies, and employers. 24 Biotechnology companies can 
sell their testing services outside major research centers and through 
the broad community of primary care physicians. This substantiates 
concern that genetic tests will become widely available to patients 
without adequate pretest counseling by providers who either 
"interpret" them without appreciation for the technologies' predictive 
limits or, worse, leave patients to make their own interpretations. In 
other words, genetic testing may be mainstreamed before the 
predictability of such testing is detennined with scientific accuracy. 
Such tests may become the equivalent of biological tarot cards, 
subject, like the Tarot, to misinterpretation and overreliance. 
This Article explores both the patient-care and public-health 
implications of commercialization of predictive genetic testing 
services under the existing regulatory scheme. A central premise is 
that regulatory safeguards must be introduced to ensure that genetic 
testing is made available only when it carries scientifically valid 
predictive value (positive predictive value, or PPV).25 Equally as 
24. See Stephenson, supra note 15,  at 1 66 1  (stating, 
[t]he problem with this development, according to a new survey, is that some of 
the laboratories offering genetic testing are bypassing the admittedly vague 
regulatory controls or other less formal measures that exist to help assure test 
validity. Some are also failing to make it clear to physicians and patients that 
many such procedures are still investigational in nature. 
); see also Proposed Recommendations of the Task Force on Genetic Testing, Meeting 
Notice, 62 Fed. Reg. 4539, 4539-44 (1997). This conclusion is supported by a recent study, 
conducted by Dr. Neil Holtzman, that sampled 594 commercial and 425 nonprofit 
laboratories (mostly academic institutions) and realized a response rate of approximately 
80%. See id.; see also Barbara Koenig, Gene Tests: What You Know Can Hurt You, N.Y. 
TIMES, Apr. 6, 1996, at A23 ("Unfortunately, nothing prevents laboratories from offering 
genetic tests, nor are there any regulations to insure the quality of the tests."). Although Dr. 
Holtzman has not yet published the results of his survey, according to one interpretation: 
The poll revealed that most commercial enterprises that currently market such 
tests are doing so without gaining clearance from the Food and Drug 
Administration (FDA), and thus there is no guarantee that the laboratory tests are 
performed properly or that they are even appropriate for the disease in question. 
The researchers also found that many testing organizations are failing to seek 
approval from institutional review boards-panels composed of physicians,  
scientists, ethicists, clergy, and representatives from the lay community-which 
hospitals often establish to discuss whether new procedl1res or technologies 
should be put into effect. 
The Hazards of Genetic Testing, HARV. WOMEN'S HEALTH WATCH, Dec. 1995, at 6. 
25. As explained by the ELSI Task Force, the penetrance of the genetic factor 
(genotype) is the probability that the related condition will appear in the physical makeup 
(phenotype) when the genetic factor is present. See ELSI TASK FORCE ON GENETIC TESTING, 
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important, providers and patients must be educated about both the 
technology's limitations and their respective legal rights and 
responsibilities. 
Part II presents an overview of genetic testing capabilities, 
existing regulations, and the dangers of premature use of genetic 
testing. Part ill employs legal storytelling to illustrate implications of 
the commercialization of genetic testing services. Part IV addresses 
these implications by presenting diverging theories on the appropriate 
regulatory response to the advent of commercialized genetic testing 
services. Part V sets forth proposals for the responsible 
commercialization of these technologies. 
II. TODAY'S TECHNOLOGY, YESIBRDAY'S REGULATIONS 
Expansive genetic testing capabilities have been a long time in 
coming.26 Such technology was foreseeable at the commencement of 
the HGP in 1990.27 Concern about the impact of such testing on 
supra note 1, at 9. 'The quantitative measurement of penetrance is [] 'positive predictive 
value (PPV) . . . . "' Id. The application of PPV to BRCA tests is illustrative of the concept. 
"The observed lifetime PPV for breast cancer due to inherited BRCAl mutations is 85%-
90% in women in high risk families, but some women with these mutations will develop 
breast cancer for other reasons." Id. at 9-10. To accurately detennine the PPV, it must be 
detennined through clinical research what percentage of women with the mutation will get 
the disease for other reasons. In other words, what percentage of women without the 
mutation will still get the disease? Further, the percentage of women with the mutation who 
do not develop the disease must also be determined. Several studies raise some doubts on 
inherited risk, suggesting that "environmental factors, such as age at first childbirth, diet, and 
exposure to hormones, can alter the effects of the BRCAl and BRCA2 genes, and other 
genes may have an impact as well." Richard Saltus, New Data Add to Confusion on Breast· 
Cancer Gene Issue, BOSTON GLOBE, Apr. 30, 1996, at 9. Due to the factors that must be 
considered and the potential importance of interaction between factors, "[ o ]btaining data for 
PPV may take years to accomplish, particularly for late-onset disorders." ELSI TASK FORCE 
ON GENETIC TEsTING, supra note 1, at 10. This BRCA example illustrates that presently the 
PPV and clinical sensitivity of genetic tests are intrinsically limited. For example, "[m]any 
different alleles in the same gene (allelic diversity) or alleles of different genes (locus 
heterogeneity) can lead to the same disease ... . Failure of a test to detect all disease-related 
mutations reduces its clinical sensitivity." Id. at 8. A test carries high clinical sensitivity 
when it is immune from being skewed by other substances (such as substances in food or 
drink) and high clinical specificity when it can determine the exact substance(s) linked with 
a condition. See id. at 5-12. 
26. Predictions by scientists that genetic technology would greatly improve human 
health date back at least 15 to 20 years. See Saltus, Sounding the Alann, supra note 14, at 
14. 
27. Strong concerns about the uses of genetic information by insurance companies 
were raised by public officials, such as Congressman Obey, during House appropriations 
hearings for the HGP back in 1990. See COOK-DEEGAN, supra note 20, at 169; see also 
DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, EDUCATION, AND RELATED 
AGENCIES APPROPRIATIONS FOR 1991 pt. 48, at 887-960. In fact, today's pressing genetic 
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society inspired James Watson, codiscoverer of the double-helix 
structure of DNA and the first head of the HGP, to insist at the outset 
of the HGP that a respectable percentage of the annual budget be 
committed to addressing the project's e.thical, legal, and social 
implications. 28 
Nevertheless, most public health officials and other regulators, 
both federal and state, are only beginning to become aware of the full 
implications of new genetic · technologies.29 Similarly, the 
testing issues were readily foreseeable as early as 1986. See Mame E. Brom, Note, Insurers 
and Genetic Testing: Shopping for that Perfect Pair of Genes, 40 DRAKE L. REV. 1 2 1 ,  1 28 
· (1991 )  ("In a 1986 survey of biotechnology companies, eight planned to offer genetic tests 
as a laboratory service for clinicians and researchers, and six predicted that diagnostic kits 
would be available for sale by 199 1 ."). 
28. See COOK-DEEGAN, supra note 20, at 237. 
29. This is true both domestically and abroad. Domestically, the National Institutes 
of Health (NIH) and Department of Energy (DOE), though their ELSI program, assembled 
the Task Force on Genetic Testing and charged it with completing a report by the end of 
1997. See generally ELSI TASK FORCE ON GENETIC TESTING, supra note 1 ,  at 2. Also, the 
Clinton Administration recently appointed a fifteen-member National Bioethics Advisory 
Commission (NBAC) whose initial studies will cover the appropriateness of patenting genes 
and the rights of patients who participate in genetic research. See Jeffrey L. Fox, US 
Bioethics Commission Meets, Outlines Agenda, 1 4  NATURE BIOTECHNOLOGY 1 533, 1 533 
(1996) (emphasizing importance placed on genetic privacy issues); Russ Hoy le, US 
National Bioethics Commission: Politics as Usual?, 14 NATURE BIOTECHNOLOGY 927, 927 
(1996) ("(A]n effective bioethics commission must take as its mission the review of difficult, 
or 'big time' research in public before it is done."); Eric Convey, Mass. Exec. Named to 
Bioethics Panel, BOSTON HERAID, July 25, 1996, at 29 (announcing appointment to 
presidential panel to explore ethical issues surrounding the biotech industry); Charles Craig, 
National Commission to Study Ethics of Genetic Medicine, 7 B10WORLD TODAY, July 25 , 
1996, at 1 ;  see also Office of Science and Technology Assessment, National B ioethics 
Advisory Comm. Proposed Charter, 59 Fed. Reg. 41 ,584, 41 ,584-86 (1 994) (announcing the 
establishment of such a commission); US Agencies Seek Rules on Human Testing, BOSTON 
GLOBE, Jan. 23, 1 997, at A l l  (reporting that five Cabinet departments and two agencies 
agreed to a formula to share the $1 .1  million operational cost). "In Europe, similar 
commissions are already well established, from B ritain's Nuffield Council o n  Bioethics 
(London) and UNESCO's International Bioethics Committee (Paris) to the European 
Commission's Group of Advisers on Ethical Implications of Biotechnology (Brussels)." 
Hoyle, supra, at 927. Also, in July 1996, the U .K. government announced the establishment 
of a Human Genetics Commission to serve as a strategic body to monitor medical genetics in 
response to parliamentary pressure for a unified group with a strategic overview. See UK 
Sets Up Human Genetics Commission, CLINICA, July 1996, at 1 (describing the commission 
as a nonstatutory body consisting of eminent, independent experts who will report to both 
health and industry ministers); Michael J. Malinowski, Globalization of Biotechnology and 
the Public Health Challenges Accompanying It, 60 ALB. L. REV. 1 19, 123-33 ( 1 996). In the 
United Kingdom, the Medical Research Council is deciding whether it will publicly fund a 
search for genes that influence IQ-test results. See David King, Editorial, Business Gets the 
Upper Hand; David King Calls for Democratic Decision-Making, GUARDIAN, May 23, 
1996, at 19. 
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genotechnology3° industry has just begun to recognize the need to 
address ethical concerns regarding the commercialization and 
responsible applications of its work.31 As a result, the regulatory 
infrastructure necessary for responsible commercialization of genetic 
technology is being developed in response to, rather than in 
anticipation of, its commercialization. The following is an overview 
of present genetic testing capabilities, existing regulations, and dangers 
arising from the premature commercialization of genetic testing. 
A. Overview of Genetic Testing Capabilities 
Today the scientific community is experiencing a nature 
movement as forceful as the nurture movement that took force in the 
1960s and that set the priorities in science for the decades to follow.32 
Behavioral genetics, the nature extreme in genetic medicine, is a 
burgeoning field grounded in the belief that molecular genetics even 
30. Genotechnology is the subset of biotechnology cons1stmg of scientific 
discoveries associated with human genetics and the HGP. See Malinowski & O'Rourke, 
supra note 20, at 1 9 1  & n. 1 65. "Genomics" is another descriptive term, used routinely by 
industry for this category of technology. See generally BIO '96, INTERNATIONAL 
BIOTECHNOLOGY MEETING & EXHIBITION, GENOMICS: IMPACT ON HEALTH CARE (1 996) 
[hereinafter Bio '96] (on file with authors) (discussing the impact of genomics on health 
care). 
3 1 .  The Biotechnology Industry Organization (BIO) recently formed an ethics 
committee to deal with privacy and research issues. See Kathleen Day, Genetics Research 
Begets Questions; Biotech Industry Seeks Ethics Advice to Deal with Complex Issues, 
WASH. POST, May 8, 1 996, at Al . This committee 
will focus on [the) issue of privacy and on what types of research should and 
should not be performed, said BIO President Carl Feldbaum. He said executives 
from American Home Products Corp., Genentech Inc. and Genzyme are heading 
committees on these and other topics and that the organization is trying to hire a 
PhD [sic] in philosophy to become its full-time staff member on ethics issues. 
Id. Perhaps even more impressive, Novartis, one of the world's largest life-sciences 
companies (formed through the merger of Ciba-Geigy and Sandoz in December 1996), will 
voluntarily label its genetically-engineered food products as part of a campaign to educate 
the public about the advantages of these products-e.g. , a significant reduction in the use of 
pesticides and pesticide residues. See Scott Allen, Genetically Altered Food to be Labeled, 
BOSTON GLOBE, Feb. 25, 1 997, at D2. 
32. See Saltus, Sounding the Alarm, supra note 1 4, at 14 (stating, 
If "nurture" was the rallying cry of the 1 960s, when changing the social 
environment through Great Society-style programs seemed the surest way to 
better lives, the pendulum has swung back i n  the last 25 years toward "nature" 
and the belief that genes are decisive components of what and who we are and 
how we behave. 
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"points the way to the future of psychiatry."33 Recent discoveries 
linking genes to complex behavior such as depression34 and nurturing35 
are reinforcing this belief. 36 
Generally, when a gene or biological marker linked to a physical 
or mental condition is discovered, the basic scientific capability to test 
for the presence of that marker is a given. Thousands of such linkages 
have been made subsequent to the commencement of the HGP,37 and 
at a rate accelerating with the passage of time, to the point that 
linkages are being identified almost on a weekly (if not daily) basis.38 
Now that a critical mass of the human genome map has been 
33. Erik Parens, Taking Behavioral Genetics Seriously, HASTINGS CENTER REP., 
July-Aug. 1996, at 1 3  (citing U.S. CONGRESS, OFFICE OF TEcHNOLOGY ASSESSMENT, 
MENTAL DISORDERS AND GENETICS: BRIDGING THE GAP BElWEEN REsEARCH AND SOCIETY 
(1994)) (although emphasizing the danger of straying away from appreciation for 
environmental factors, recognizing that "much research suggests that genetics may help to 
explain a partial but significant component of some fonns of, for example, schizophrenia, 
bipolar disorder, and depression"); see also Richard A. Knox, Study of Mice Links a Gene to 
Nurturing, BOSTON GLOBE, July 26, 1996, at Al  (reporting that the objective of scientists 
working in the field is to identify "molecular handle[s] to try to unravel some of the 
neuronal circuitry involved in mediating behavior"); Rick Weiss, Discovery May be Brewing 
in Search for Genetic Link to Alcoholism, WASH. POST, July 1 ,  1996, at A3 (reporting new 
breakthroughs in discovering genes relating to alcoholism); Anxiety Linked to Genetics, N.Y. 
TIMES NEWS SERVICE, Nov. 29, 1 996 (reporting that "[s]cientists have discovered a modest 
but measurable link between anxiety-related behavior and the gene that controls the brain's 
ability to use serotonin"); Parens, supra, at 1 3- 1 8  ("As information about the genetic 
component of human behavior increases, so, of course, does the number of opportunities for 
its abuse."). 
34. During the spring of 1996, scientists in Edinburgh, Scotland identified a gene 
linked to depression that could lead to much more effective treatment. See Nigel Hawkes, 
Scientists Identify Gene Linked to Depression; Discovery Prompts Study of Families, TIMES 
LoNDON, Mar. 15 ,  1996, available in Westlaw, 1996 WL 648 1 302. 
35. See Knox, supra note 33, at Al (reporting that a team consisting of researchers 
from Harvard Medical School and Tufts University, through manipulation of a gene called 
fosB, have created a strain of mice that seem normal in every way except that they ignore 
their newborn offspring). 
36. At the present time, "research suggests that genetics may help to explain a partial 
but significant component of some forms of, for example, schizophrenia, bipolar disorder, 
and depression." Parens, supra note 33, at 1 3 .  
37. For listings of such discoveries over the past several years, see Malinowski, 
supra note 21 ,  at 1443-44. See also Saltus, Sounding the Alann, supra note 1 4, at 1 4  ("In 
recent years, researchers have claimed that homosexuality, schizophrenia, alcoholism, risk 
taking, violent behavior, and even basic temperamental traits like shyness are governed by 
genetic variations."). 
38. Recent genetic-linkage discoveries have been made both for the tendency to 
nurture and the tendency to have strokes. See Peter J. Howe, Gains Reported Toward 
Identifying Stroke-Related Genes, BOSTON GLOBE, July 30, 1996, at A6 (reporting on Nature 
Genetics article and stating that the discovery may create novel opportunities for diagnosis 
of potential strokes); Knox, supra note 33, at A l  (noting a gene, FosB, which is linked to 
nurturing). 
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completed,39 the pace of such discoveries is likely to increase 
exponentially. In fact, although the impact of environmental factors on 
the function of genes and physical and mental health must not be 
underestimated, an age governed by molecular medicine, in which a 
patient's actual and future health can be diagnosed primarily through 
deciphering genes, is a conceivable possibility.40 
Biotech companies are using such discoveries to develop and 
commercialize predictive screening tests for an abundance of health 
conditions in addition to breast and ovarian cancer. Recent discoveries 
include genetic links to Alzheimer's,41 bladder cancer,42 cervical 
· 39. See Human Physical Map, supra note 2 1 ,  at 5 ('The new map, which contains 
more than 1 5,000 STS DNA markers spaced an average of 199 kb apart, covers almost 95% 
of the entire genome . . . . Although originally slated for 1998, map completion by 
Whitehead-MIT and other groups is expected by the end of this year."). 
40. See Annas, supra note 14, at 20 ("Molecular medicine, based on deciphering the 
genes of a patient instead of diagnosing the patient based on signs and symptoms, is said to 
be just around the comer."); Bio '96, supra note 30, at 5 C"lnhe study of genetic variation 
will enable the identification of patient sub-populations that may respond particularly well 
or poorly to currently-marketed drugs."); id. at 9 ("Drugs developed using genomics 
technology can be expected to offer advantages in  specificity that will result in therapeutics 
with fewer side effects."); id. at 16 ("The ability to eliminate ineffective therapies due to 
individual therapeutic response will be another way in which genomics will contribute to the 
reduction in healthcare costs. . . . Genomic diagnosis will provide physicians with a sound 
basis upon which to prescribe appropriate therapies."). 
4 1 .  See Eric M .  Reiman et al., Preclinical Evidence of Alzheimer's Disease in 
Persons Homozygous for the e4 Allele for Apolipoprotein E, 334 NEW ENG. J. MED. 752, 
752 ( 1996) (stating that variants of the apolipoprotein E allele appear to account for most 
cases of late-onset Alzheimer's disease, and that persons with two copies of one variation 
appear to have an especially high risk of dementia); Stephenson, supra note 1 5, at 1 661-62 
("One such test detects APOE-4 (also frequently denoted as APOE4), a form of the gene 
that directs the production of cholesterol-carrying protein called apolipoprotein E. 
Individuals who possess the APOE-4 gene have an elevated risk for developing Alzheimer's 
disease, particularly those who have two copies of the allele."). Athena Diagnostics, a 
biotech company located in Worcester, Massachusetts, developed the first specific laboratory 
test for Alzheimer's disease, a disorder which affects four million Americans. See Richard 
Saltus, Worcester Firm Touts First Lab Tests for A lzheimer 's, BOSTON GLOBE, Mar. 27, 
1996; at 47. According to Athena officials, the company is making the test available as a 
service under an investigatory protocol, meaning that, like OncorMed and Myriad, Athena 
will perform the test in-house for samples (blood and cerebrospinal fluid, obtained by a 
spinal tap) submitted by providers for a fee of $ 1 95.  See id. ; see also Jerry E. Bishop, Test 
Improves Detection of A lzheimer's, WALL ST. J., July 1 2, 1 996, at B3 (discussing genetic test 
that may improve the accuracy of diagnosing Alzheimer's disease). The clinical utility of 
the test, as defined by Athena, is that it  may be used to distinguish Alzheimer's from other 
forms of dementia, some of which can be treated. See id. ; see also Saltus, Early 
Alzheimer's, supra note 1 4, at 39 ("With the discovery last week of a gene that causes an 
aggressive inherited form of Alzheimer's disease, it will soon be possible to offer a test to 
people in at-risk families, where, on average, half the children of any affected parent will get 
the gene."); Saltus, supra, at 47. 
42. See Rosenberg, supra note 15, at 80. In comparison with the traditional bladder 
test now on the market, this test (1)  is performed on a simple urine sample, thereby avoiding 
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caricer,43 colon cancer,44 obesity,45 prostate cancer,46 and tumor growth 
associated with a spectrum of common cancers.47 Researchers are 
even developing an "Ides of March" genetic test to serve as a crude 
indicator of a person's life span.48 By conservative estimates, "some 
50,000 gene markers will be developed as a result of molecular 
biology and translated in not easy-to-employ biochemical assays, 
genetic tests, new drugs, and genetic therapies."49 
Unfortunately, the discovery of genetic alterations linked to many 
health conditions comes well before those discoveries can be turned 
into therapeutics and reliable predictors of disease in specific 
the painful cystoscopy-the insertion of a fiber-optic rod through the urethra and into the 
bladder-which is required for the current test; (2) costs $50 rather than $300; and (3) is 
much more accurate and, therefore, can detect the earliest signs of cancer. See id. 
43. Matritech ,  a biotech company located in Worcester, Massachusetts, i s  working 
on a test for cervical cancer that would be an improvement to the Pap smear procedure. See 
Ttna Cassidy, Matritech Says It Will Begin Trials on a More Accurate Colon Cancer Test, 
BOSTON GLOBE, Apr. 20, 1996, at 25. 
44. Trials are being conducted on a colon cancer test that allegedly is more than 
twice as sensitive (70% compared to 33%) as the current leading diagnostic test for early­
stage colorectal cancer. See Cassidy, supra note 43, at 25. 
45. A gene-signaling system has been discovered through the independent work of 
two biotech companies, Amgen and Millennium Phannaceuticals. Amgen discovered a 
gene that makes leptin, an enzyme linked to obesity in rats; Millennium has identified a 
genetic receptor for leptin. See Richard Saltus, Piece of Obesity Puzzle Found in 
Cambridge: Drug Researchers Locate Key Receptor, BOSTON GLOBE, Dec. 29, 1 995, at I .  
The work of these companies has pushed their competitors, and "researchers have now 
found five genes involved in regulating food intake and weight." Id. 
46. At least one biotech company is working on an improved test for prostate cancer. 
See Cassidy, supra note 43, at 25. 
47. Through research in an extended family with a high incidence of kidney cancer, 
scientists have discovered a gene known as FHIT. See Richard Saltus, Gene Eyed in Many 
Cancers, BosroN GLOBE, Feb. 25, 1996, at 9. This gene is believed to make a protein that 
helps to keep the body's cells dividing in an orderly, regulated way. Control over cell 
growth is lost when the gene is damaged by environmental pollutants, diet, or other factors. 
See id. The FHIT gene may prove to be an invaluable lead for understanding how normal 
cells become malignant in a variety of common cancers, including those of the esophagus, 
stomach, and colon; and possibly including ovarian, cervical, lung, and bone cancers. See 
id.; see also Cancer Research Yields 'Time Bomb' for Tumors, BOSTON GLOBE, Apr. 24, 
1996, at 8 ("Cancer researchers have engineered what they call the first genetic time bomb, 
set to go off inside tumor cells when they blow their cover by producing telltale proteins."). 
48. Research involving APOE variations indicates linkages to general susceptibility 
to diseases of aging. See Jerry E. Bishop, A Gene Gives a Hint of How Long a Person 
Might Hope to Live, WALL ST. J., Oct. 19, 1995, at A l  ("If some scientists are correct, the 
test may be the forerunner of what could be called the Ides of March tests, a panel of blood 
tests that might predict, as the onlooker foretold for Julius Caesar, when one might die-but 
not how."). The researchers responsible for this discovery admit that APOE is, for any one 
individual, a "sloppy indicator." Id. Nevertheless, there is the possibility that such a test 
could be used by insurers who engage in grouping. See infra note 1 1 3 and accompanying 
text. 
49. Boyle, supra note 13,  supp. at S2. 
1 226 TULANE IA W REVIEW [Vol . 7 1 : 1 2 1 1 
individuals.50 Although the availability of therapeutics to offset 
genetic predispositions will make genetic testing much less 
controversial, that time is years away for most conditions.51 Similarly, 
for families other than those with high occurrence of disease and well­
documented pedigrees, determining predictability is a laborious, 
subject-intensive process that may take more than a decade to 
complete. 52 
50. See Mclean, supra note 19, at 1 1 6. As recognized by the U.K. House of 
Commons Science and Technology Committee, "(w]hile a knowledge of how the gene 
works, when established, should, in time, lead to new drug development, through rational 
drug design, at present it can take 1 5  years to develop and gain approval for a new 
pharmaceutical product." Id. (citing 1 SCIENCE AND TEcHNOLOGY COMMrITEE, HOUSE OF 
COMMONS, HUMAN GENETICS: THE SCIENCE AND ITS CONSEQUENCES xxxvi ( l  995)); see also 
Boyle, supra note 1 3, supp. at S2 ( 
People will be tested for conditions that might never fully express themselves as a 
disease, or only express themselves in a mild form. For example, nearly 20 
percent of persons who carry the gene for fragile-X, the most common form of 
inherited mental retardation (affecting one in every 2,500 live births), will never 
express any fonn of mental retardation. Yet if parents knew their children's 
genetic status, they might treat unaffected children as if they were mentally 
disabled. 
); Saltus, Sounding the Alarm, supra note 1 4, at 1 4  ("But today, 15  or 20 years after the 
first predictions that gene technology would greatly improve health, scientists have been 
far more successful in finding defective genes than in fixing or replacing them."); infra 
Part 11.C. Examples of  the practical effect of this gap between the discovery of a genetic 
linkage to a health condition and treatment derived from that discovery are plentiful: 
Genetic researchers, in their quest to understand a terrifying disease, have 
once again delivered the means to predict a person's future, but not yet to alter it. 
With the discovery last week of a gene that causes an aggressive inherited 
form of Alzheimer's disease, it will soon be possible to offer a test to people in at­
risk families, where, on average, half the children of any affected parent will get 
the gene. 
Recently developed gene tests for Huntington's disease and for inherited 
predispositions to breast cancer and other cancers have raised this issue for an 
increasing number of families . . . .  
The test for familial, early-onset Alzheimer's might be relevant for 500,000 
or more Americans who are at risk for having the gene . . . .  
Unlike the more common type of Alzheimer's disease, which affects an 
estimated 4 million people in the United States and generally appears in the late 
60s, the 70s or 80s, the early-onset form can show up even among people in their 
30s. 
Saltus, Early Alzheimer's, supra note 14, at 39. 
5 1 .  See Malinowski & O' Rourke, supra note 20, at 174-77 (discussing status of 
gene therapy). Dr. Ruth Hubbard and Jonathan Beckwith recognize that, even for conditions 
such as Huntington's and multiple sclerosis, which are known to be caused by a single 
genetic variation that is responsible for the failure of the cell to make a single protein, 
science has not been successful in turning genetic discoveries into treatments. Multifactorial 
conditions multiply this complexity. See Saltus, Sounding the Alarm, supra note 14, at 14. 
52. See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1; infra Part II. C. 
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Nevertheless, a deluge of fully commercialized genetic testing 
services and kits is well within sight.53 Even by conservative 
estimates,54 expectations are that the DNA testing market ( 1) for 
neoplastic (tissue growth) diseases will reach $340 million in 1998� 
(2) for infectious diseases will exceed $300 million by 1 998; and 
(3) for genetic diseases will exceed $65 million by 1 998.55 This 
market could experience a several-fold increase with the availability of 
probes for polygenic (multifactorial) diseases.56 To build these 
markets, the developers and manufacturers of genetic tests need patient 
data both ( 1) to establish clinical predictability, and (2) to sequence 
and better understand the most fundamental intricacies of specific 
genes. The latter will enhance the predictive capabilities of resulting 
tests and perhaps lead to other products, including therapeutics and 
even gene therapies. The commercial possibilities, including patient­
care possibilities, create a powerful incentive to make research-stage 
genetic tests available to the public. 
Many developers and manufacturers of genetic tests now are 
making investigatory, predictive genetic testing available to the public. 
53. The commercial interests developing genetic technologies are nearly as diverse 
and plentiful as the underlying discoveries: 
Major diagnostic companies (Abbots, Boehringer Mannheim, Miles, Baxter, 
Beckman, Becton Dickenson, Ciba-Geigy, Johnson & Johnson, Eastman Kodak, 
Bio Rad, etc.) are developing a variety of technologies by inhouse invention and 
through alliances and acquisitions . . . .  
In addition to the established major commercial players, hundreds o f  start­
up companies have been formed to exploit various niche diagnostic capabilities 
generated in academic research laboratories. 
Silverman, supra note 1 5, supp. at SIS; see id. supp. at S 1 7  ("Regardless of the numerous 
unknowns in the development of DNA diagnostics, the potential demand for these services 
will continue to grow. Attractive financial rewards assure that DNA diagnostics will become 
a significant commercial enterprise."). 
54. These estimates, generated during the Spring/Summer of 1995, are conservative 
because they predate ( 1 )  the precedent for commercialization of genetic testing services 
without FDA oversight now being set by OncorMed and Myriad, (2) the advancement of 
pending FDA reforms to streamline the FDA review process for biotechnology products, 
(3) growth in consumer demand for genetic tests due to both increased media coverage and 
marketing efforts o n  the part of biotechnology companies, and (4) a globalization of 
biotechnology and expansion of worldwide markets. See Malinowski, supra note 29, at 
123-33. 
55. See Silverman, supra note 15, supp. at S l6 ;  see also BLATT, s upra note 2 1  
(noting that the revenues presently being generated are from biogenetic analysis for prenatal 
testing of chromosome conditions). But see Vicki Glaser, Myriad Pulls /PO from 
Inhospitable Market, 1 5  NATURE BIOTECHNOLOGY 14 (1 997) (reporting that Myriad pulled 
its follow-on public offering, and speculating that lack of investor interest may have been 
attributable to below lower-than-anticipated sales figures for its BRCAl and BRCA2 tests). 
56. See Silverman, supra note 15,  supp. at S16. 
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Although IVF, Myriad, and OncorMed are commercializing their tests, 
other companies and research laboratories are making research-stage 
genetic tests available in a more discreet manner. In 1 994, the 
Committee on Assessing Genetic Risks assembled by the Institutes of 
Medicine documented pervasive informal genetic testing by research 
laboratories,57 and the ELSI Task Force on Genetic Testing has reached 
similar conclusions regarding both research and commercial 
laboratories that report results to patients. 58 
The emergence of predictive genetic tests with implications for 
broad segments of the population, such as the APOE-4 (Alzheimer's) 
test, is raising c oncern among public health officials and providers 
57. See generally ASSESSING GENETIC RISKS, supra note 15. 
58. See ELSI TASK FORCE ON GENETIC TESTING, supra note 1 ,  at 2-4; see also 
Richard Saltus, Survey of Labs New Tests Concerns Genetics Specialists, BOSTON GLOBE, 
Oct. 28, 1995, at 14 ("Commercial and academic labs are moving so quickly to offer gene 
tests predicting future health risks that some are bypassing regulatory and ethical quality 
controls, specialists in genetics say."). According to a survey conducted by Dr. Neil 
Holtzman's office at John Hopkins University: 
Although any lab perfonning clinical genetic tests must register with HCFA under 
the Clinical Laboratory Improvement Amendments of 1 988 (CLIA) [ 42 C.F.R. 
§ 493. 1  ( 1 996) ] ,  the study found that about 10% of responding labs failed to do 
so. Several labs (8%) did not use external review (including proficiency testing) 
to help assure quality. Many labs intended to market genetic tests to non­
geneticist providers, even though most respondents were of the opinion that such 
providers knew little about these tests. Responding labs also tended to view the 
current regulatory scheme as inappropriate. 
Dr. Stephen Hilgartner described the highlights of his follow-up interviews 
of selected respondents to Holtzman's survey. He found a variety of commercial 
genetic testing activity, ranging from large companies seeking to offer 
comprehensive test services to smaller firms developing specific tests for 
particular market niches. 
Meeting Minutes, supra note 1 ,  at 1 -2. Other studies, including a study undertaken by the 
Genetic Screening Study Group in the spring of 1 992, have reached similar conclusions 
about the pervasiveness of genetic discrimination. See, e.g. , Carol I .  Barash & Joseph S. 
Alper, A Study on Genetic Discrimination, 8 GENETIC RESOURCE 43, 43 ( 1 994) ('The study 
found that a wide variety of social institutions engage in genetic discrimination. People 
reported discriminatory practices by insurance companies (life, health, disability, and 
mortgage), in employment (hiring and promotion), by the military, schools and universities, 
adoption agencies, and health care providers."); Lisa N. Geller et al., Individual, Family, and 
Societal Dimensions of Genetic Discrimination: A Case Study Analysis, 2 SCIENCE & 
ENGINEERING Ennes 7 1 ,  75 ( 1 996) (concluding that, of the 9 1 7  questionnaire respondents, 
455 indicated instances of genetic information discrimination). For anecdotes of genetic 
information discrimination, see generally id. 
In contrast with the United States's incremental approach to protection against genetic 
discrimination by insurers, see, e.g., Health Care Portability and Accountability Act, Pub. L. 
No. 104-191 ,  1 1 0  Stat. 1 936 ( 1 996), European countries are considering an outright ban on 
the use of genetic testing information by insurance in the absence of comprehensive self­
regulation. See Insurers Risk Ban, supra note 8. 
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who understand the limitations of this technology and are sensitive to 
its potential impact on the lives of patients and their families.59 
However, with such understanding comes appreciation for the 
difficulty of introducing a satisfactory regulatory response to the 
multitude of genetic technologies approaching and entering 
cornmerce.60 
B. Existing Regulations 
Predictive genetic testing services, perfonned in-house by the 
tests' developers and manufacturers, are square pegs in the rubric of 
federal regulation. The FDA regulates the production of reagents, 
probes, or test kits manufactured for use by others in laboratories and, 
therefore, genetic tests manufactured and sold for others to perform.61 
59. See Stephenson, supra note 15,  at 1661-62 ("Concerns about genetic testing 
have escalated with the recent emergence of tests that may have implications for large 
segments of the population."). 
60. See Boyle, supra note 13, supp. at S2 ("Genetic technologies are by no means a 
homogenous lot; they have varied medical and social effects, and are intended for diverse 
populations with distinct severity of illnesses, both actual and potential."). 
6 1 .  Such tests constitute "diagnostic kits" subject to regulation under the Medical 
Device Amendments of 1 976 (MDA), 2 1  U.S.C. § 360k(a) (1 994), and the FDA has 
exercised some considerable discretion in the area of home testing. See, e.g.,  Daniel J. 
Murphy, FDA Ridiculed for Blocking At-Home Drug Testing, INVESTORS Bus. DAILY, Oct. 
1, 1994, at A4 (reporting FDA's prohibition of the sale of drug-testing kits to parents). 
Pursuant to the MDA, the FDA regulates medical devices in the context of a classification 
scheme that distinguishes among devices based upon the concerns they raise about safety 
and effectiveness. The FDA is required to classify each medical device intended for human 
use into Class I, II,  or III. See 21 U.S.C. § 360(C)(a)( l ). Class I devices pose no 
unreasonable health risk (general controls that ensure, among other things, safe labeling and 
that the produce is safe when used as directed), while Class II devices carry special controls, 
such as performance standards necessary to ensure safety and effectiveness. See id. Class 
III devices are those represented to be life-sustaining or life-supporting and those presenting 
potentially unreasonable risk of illness or injury, and they require premarket approval to 
assure safety and effectiveness. The premarket-approval process requires submission of a 
premarket-approval application (PMA), which the FDA must review before it authorizes 
marketing. However, there is an exception for diagnostics that are the substantial equivalent 
of others already approved. See id. § 360k. Still, additional review is required for any 
change in a device's design. See 21 C.F.R. § 807.8 l (a)(3)(i) ( 1996). There also are 
regulations for device construction and manufacture, known as good manufacturing practice 
(GMP) requirements, that establish detailed requirements for all stages of the manufacturing 
process. To monitor compliance, the MDA require factory inspections at least once every 
two years for Class III products and post-marketing reporting. See 2 1  U.S.C. § 360(h); 2 1  
C.F.R. § 803. 1-.58. 
Because of their complexity, when genetics-based diagnostics are subjected to review, 
they generally are labeled Class III devices. See Malinowski & O'Rourke, supra note 20, at 
206. Before developers make these products available to the public, they must apply for an 
Investigational Device Exemption (IDE), which is analogous to the Investigational New 
Drug Application (IND) required for new drugs. See id. Device manufacturers can 
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However, manufacturers and private laboratories may avoid the 
routine FDA review process for diagnostics and comply with 
applicable federal regulations by manufacturing and using their own 
reagents in-house and selling testing services through primary care 
physicians.62 Such reagents are called "home brews" because they are 
manufactured and used within the same facility, and a number of such 
tests are being developed and made available to the public.63 
Home brews may be marketed as e stablished products or, to limit 
product liability where clinical efficacy is not yet established, labeled 
investigatory.64 Although the developers of investigatory tests are 
circumvent the IDE requirement by establishing that there is an independent means by 
which to confirm the validity of their test. 
This may be accomplished ( 1 )  through the 5 IO(k) clearance process, by establishing 
that the product is the substantial equivalence of a previously marketed product or (2) by 
obtaining premarket approval (PMA), which requires a full documentation of safety and 
effectiveness and an advisory conunittee review. However, the general absence of approved 
genetic diagnostics on the market makes these exceptions unlikely for predictive genetic 
tests. In fact, the manufacturers of such kits should expect added requirements, such as a 
requirement that counseling accompany test results. The FDA imposed such a requirement 
when approving a home AIDS test in May of 1 996. See Weiss, supra note 2, at A I .  
62. See Medical Devices, Classification/Reclassification; Restricted Devices; 
Analyte Specific Reagents, 6 1  Fed. Reg. 1 0,484 ( 1996) (to be codified at 21 C.F.R. pts. 809 
& 864) (proposed Mar. 1 4, 1996) ("FDA currently regulates the safety and effectiveness of 
diagnostic tests that are traditionally manufactured and commercially marketed as finished 
products. However, in-house developed tests have not been actively regulated by the 
Agency and the ingredients used in them generally are not produced under FDA assured 
manufacturing quality control."); see also OncorMed BRCA J  Testing Service, supra note 8, 
at 7 (reporting on the FDA statement that it has the authority to regulate but not the needed 
resources and expertise to actually do so). 
63. See FDA Needs to Regulate Genetic "Home Brews," 1 4  NATURE 
BIOTECHNOLOGY 1 627 (1996) [hereinafter FDA Needs to Regulate]; Stephenson, supra note 
15, at 1662. The ELSI Task Force, in its investigation of genetic testing practices, found 
that "at least some companies appear to be circumventing this process by offering genetic 
testing services themselves-using the very probes and other products that would be subject 
to FDA regulation i f  these products were sold to others as part of a kit for the purpose of 
genetic testing." Stephenson, supra note 15, at 1 662. The distinction is that, if a developer 
performs an assay in its own laboratory, that laboratory may be designated a reference 
laboratory, and uncertainty regarding how reliably a third party will perform the test is 
removed. See id. ; see also ELSI TASK FORCE ON GENETIC TESTING, supra note 1 ,  at 1 2  
("Often [laboratories developing new tests] use home brews as well as reagents purchased 
'for research use only' in clinical tests, although neither have been approved for clinical 
use."). Still , as discussed in Part II.C., the results of predictive genetic tests are prone to 
misinterpretation by both providers and patients and, therefore, may be misused clinically. 
64. As discussed above, a BRCA test is being marketed without self-restraint by 
IVF, while OncorMed is  limiting its potential liability by restricting access to its testing 
service. See Weiss, supra note 2, at Al .  There are two main labeling options for products 
without established clinical efficacy: 
For research use only and not for use in diagnostic procedures. The 
manufacturers of such tests are not permitted to make claims regarding the test 
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allowed to charge consumers only enough to recapture costs, 
commercialization of these tests enables them to generate a revenue 
stream, gather needed patient data, and build standard-care acceptance 
of their technologies. Standard-care acceptance means enhanced 
acceptability among physicians and the public, limits on product 
liability, and perhaps insurance coverage.65 Also, the costs of 
investigatory tests may be considerable, depending upon the stated 
research objective.66 
Private laboratories performing genetic testing services also are 
essentially immune to federal laboratory-quality assurances imposed 
by the Health Care Finance Administration (HCFA) through the 
Clinical Laboratory Improvement Amendments (CLIA).67 Under 
beyond statements that identify and explain its research purpose, and such tests 
are not supposed to be used clinically (the results are not supposed to be reported 
to subjects); and 
For investigational use only. Infonned consent must be obtained before 
the test is perfonned, and those tested must be apprised of the facts that 
performance characteristics are not yet established and data is being collected (the 
test is being offered) for that purpose. 
See id. ; see also BLATT, supra note 21 .  However, off-label uses of tests, where a test 
approved by the FDA for one purpose is used for another, are commonplace. See ELSI 
TASK FORCE ON GENETIC TE.sTING, supra note I ,  at 1 1  ('The Task Force opposes off label 
use of genetic tests without independent validation and is exploring new policies to deal 
with this problem."). A prime example of widespread, off-label testing is the use of the 
maternal serum alphafetoprotein (MSAFP) screening for the presence of Down's syndrome. 
Although the test was initially designed to screen for the presence of neural tube disorders in 
the unborn, researchers and labs noticed a correlation between low MSAFP results and 
Down's syndrome, thereby creating a new application for its use. See BLATT, supra note 2 1 .  
The shortcomings o f  this labeling system include the following: ( 1 )  despite these 
requirements, it is not uncommon for laboratories to offer testing labeled "for research 
purposes only" to patients and report the results to them; (2) off-label uses are common; 
(3) the FDA, although aware of compliance problems in laboratory genetic medicine, lacks 
the resources to bring laboratories into compliance and is hesitant about removing products 
from the marketplace out of fear of causing disruption and arousing public and political 
opposition; (4) compounding this problem, the FDA is presently in a state of flux and there 
is a moratorium on new regulations; and (5) although laboratories are required to be aware 
of the regulatory status of the products they use and are expected to use them appropriately, 
consumers and medical practitioners are frequently unaware of the regulatory status of the 
laboratory tests being performed. See id. 
65. See The First BRCAJ Test Hits the Market; Are Oncologists, Patients Ready?, 
CANCER LETIER, Jan. 26, 1 996, at 1, 1-5 [hereinafter First BR CAI Test Hits the Market]. 
66. For example, if the stated objective of providing a genetic testing service is gene 
sequencing, the cost may increase tenfold. See id. at 2. 
67. See 42 C.F.R § 493. l (1996); Proposed Recommendations of the Task Force on 
Genetic Testing, Meeting Notice, 62 Fed. Reg. 4545 (Nat'! Insts. Health 1997) ("Many tests 
currently on the market have not been systematically validated nor subject to external 
review. . . . The Task Force is concerned about the lack of Federal law or regulation 
covering genetic tests . . . .  "). As enacted, CLIA prescribed general regulations for medical 
laboratories, but it applied only to ( I )  laboratories involved in testing specimens originating 
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CLIA, a laboratory must demonstrate analytical validity of its tests and 
their components, but there is no clinical validity requirement.68 In 
other words, the CLIA validity requirement is satisfied when a genetic 
test to detennine the presence of a specific genetic alteration does so 
accurately, even though the test may offer no clinical predictability.69 
There is no required express showing that the alteration tested for has 
any bearing on the subject's health. The only CLIA patient-care 
safeguard on clinical quality is the requirement that the proposed 
clinical protocol receive institutional review board (IRB) approval 
when an investigatory test enters the human-trial phase.70 Academic 
laboratories are required to report to their standing IRBs, but "[t]he 
situation with respect to IRBs is murkier for biotechnology companies 
and commercial laboratories. They also may consult an IRB of an 
academic institution with whom they have ties, or they may form their 
own IRB-a practice that has the potential for a conflict of interest."71 
out-of-state and (2) laboratories processing specimens from individuals on Medicare and 
Medicaid. CUA 88 set forth revised regulations that more unifonnly govern laboratory 
testing involving human samples by establishing general laboratory standards for personnel, 
proficiency testing, quality control, and quality assurance. See generally Summary of 
United States Product Liability Law (May 24, 1 996) (research memorandum prepared by 
Kirkpatrick & Lockhart LLP, Boston, MA) (on file with authors). 
68. See ELSI TASK FORCE ON GENETIC TESTING, supra note 1, at 14-15.  
69. The ELSI Task Force's Subcommittee on Laboratory Quality's "main theme [is] 
that genetic testing is unique and better assurance of its quality is needed." Meeting 
Minutes, supra note 1, at 5; see also id. at 6-7, 8 (stating that even the "high complexity" 
category under CUA does not adequately address the unique nature of genetic tests). The 
failure of CLIA to address the impact of genetic tests on patient care is addressed in Boyle, 
supra note 13,  supp. at S7 ("[T]he FDA's standards would consider a test to screen infants 
for a genetic anomaly 'effective' if it yields an accurate diagnosis, even if no treatment exists 
. . . . Accepting such narrow judgments of effectiveness may . . .  create substantial harm by 
providing information that can cause anxiety, stigmatize, and promote invidious 
discrimination."). 
70. See Stephenson, supra note 15 ,  at 1 662. An organization planning clinical 
validation studies is supposed to file its protocol with a properly constituted IRB competent 
to review clinical validation protocols. See Joseph Palca, Institutional Review Boards: A 
Net Too Thin, HASTINGS CENTER REP., May-June 1 996, at 4. This requirement reflects the 
original purpose of IRBs, to protect the autonomy of human subjects participating in 
research. See id. For discussion of the increased dependence on IRBs to resolve genetics 
issues due to proposed disbandment of the Recombinant DNA Advisory Committee (RAC), 
see infra note 257 and accompanying text. 
7 1 .  Stephenson, supra note 15,  at 1662; see infra notes 245-247 and accompanying 
text (proposing national IRB standards); Proposed Recommendations of the Task Force on 
Genetic Testing, Meetin g  Notice, 62 Fed. Reg. at 4544 ("The Task Force is concerned that 
the high workload of IRBs, their variability i n  community representation, in evaluating 
protocols, and in expertise germane to the review of genetic tests, as well as the conflicts of 
interest that can arise i n  local review, impairs current review of genetic tests that warrant 
stringent scrutiny."). See generally JOHN ABRAHAM, SCIENCE, Pouncs AND THE 
PHARMACEUTICAL INDUSTRY: CONTROVERSY AND B IAS IN DRUG REGULATION ( 1995) 
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The general lack of regulatory quality control on genetic tests, 
which raises questions about their fundamental reliability,72 is 
exacerbated by the fact that very few specific guidelines for these tests 
have been formally developed and introduced by the medical 
profession.73 "[L]ack of consensus about what type of screening 
should be offered means that there is also no clear guidance for state 
policy makers adopting mandatory screening plans" even on issues 
such as the testing of fetuses for BRCA 1 and BRCA2 variations.74 
Also, reliance on state regulation to monitor (in the ongoing manner 
necessitated by the research nature of the technology) the quality of 
genetic testing services is misplaced for, there too, "the field of 
laboratory licensure and monitoring remains in a state of flux."75 
(exploring the capture theory in the context of IRBs, and suggesting that those from the 
medical profession who serve on IRBs reap tremendous financial rewards and, due to 
revolving-door staffing of IRBs, may even receive R&D funding from the manufacturer 
whose products they are reviewing); ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 ,  
at 1 1  ("The Task Force recognizes that IRBs differ widely in their approach to clinical 
protocols and in their policies regarding what constitutes research in their purview."); 
Advisory Committee on Human Radiation Experiments, Research Ethics and the Medical 
Profession, 276 JAMA 403, 403-09 (1996) (callin g  for alterations in the IRB component of 
the federal system to protect human subjects). 
72. See Medical Devices; Classification/Reclassification; Restricted Devices; 
Analyte Specific Reagents , 61 Fed. Reg. 10,484 ( 1 996) (to be codified at 2 1  C.F.R. pts. 809 
& 864) (proposed Mar. 14,  1996); FDA Needs to Regulate, " supra note 63, at 1 627 ( 
As a resul t ,  neither patients nor practitioners have assurance that all ingredients in 
the laboratory developed tests are of high quality and capable of producing 
consistent results. 
[The] FDA is concerned that the present situation with respect to in-house 
developed tests, in which these ingredients are essentially unregulated and 
therefore of unpredictable quality, may create a risk to the public health. 
); see also The Hazards of Genetic Testing, supra note 24, at 6 (reporting on Dr. Holtzman's 
survey). 
73 . But see infra notes 245-246 and accompanying text (addressing how 
professional opposition to BRCA testing outside research centers is resulting in initiatives to 
develop such guidelines). 
74. Andrews, supra note 22, at 99 1 .  
75. Bl.Arr, supra note 2 1 (  
While almost every state public health department has a laboratory licensing 
bureau that is supposed to monitor the quality of laboratory services, many do not 
have standards designed specifically for genetic laboratory studies (i.e., DNA 
analysis) and performance requirements are not always enforced. Some 
laboratories have gone for years without an on-site visit. 
). An
.
exception
_ 
is the State of New York , which has some meaningful laboratory quality 
authonty that 1s enforceable and has regulatory language addressing the use of 
investigational genetic testing. See Meeting Minutes, supra note 1 ,  at 7 ( 
New York cannot impose "cease and desist" orders on labs failing to meet 
voluntary PT [proficiency testing] standards , and for this reason the state does not 
recognize the voluntary lab standards promulgated by the College of American 
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Perhaps most importantly, circumvention of the FDA review 
process also may avoid the FDA's tight control on advertising.76 
Advertising carte blanche is a troubling proposition in the context of 
providers dealing directly with b iotechnology companies and 
Pathologists [CAP]. However, New York is  empowered to revoke a lab's license 
for ignoring the reconunendations of lab surveyors. 
); see also Proposed Reconunendations of the Task Force on Genetic Testing, Meeting 
Notice, 62 Fed. Reg. at 4545 (discussing how New York requires certification of all 
laboratories performing clinical genetic tests on state residents). 
76. According to some accounts, FDA officials have all the power and discretion of 
tax collectors----discretion enhanced by the ambiguity of the regulations they enforce. See, 
e.g., James G. Dickinson, Will Anybody Sue FDA?, MED. MARKETING & MEDIA, Oct. 1993, 
at 1 00, 102 ('The Food, Drug and Cosmetic Act's failure to address pharmaceutical 
marketing activities that are neither 'advertisements' nor 'labeling' created the gray zone in 
which both industry and FDA take liberties. Congress simply failed to foresee the 
innovations that modem communication technologies [advertising] could spawn."). As 
explained by Dr. Dickinson: 
Advertising alone is defined as "commercial speech" and is thus subject to 
less First Amendment protection than labeling or non-commercial speech. But 
FDA has been able to tie advertising's statutory dependence on the content of 
approved labeling to a broad array of "labeling" materials in such a way that 
companies "have no freedom of speech rights when it comes to advertising 
prescription drugs, compared to the way in which those rights are conunonly 
understood and i nterpreted by the courts for other industries." 
Id. (quoting Richard T. Kaplar, Vice President of the Washington-based Media Institute). 
Dr. Dickinson alleges that, "[b]ecause FDA has excessive coercive power in its ability to 
approve an advertiser's products for market, and Congress has shown no interest in 
balancing FDA's First Amendment incursions, the regulation of drug advertising and 
promotion should be handed over to the Federal Trade Conunission." Id. at 103-04. Dr. 
Dickinson, citing other authority, contends that the FDA's definition of "deception" is '"the 
basis for the mischief created by the FDA's regulation of advertising'" because the FDA 
declares ads or promotional materials "deceptive" unless they contain a "fair balance." Id. at 
104 (quoting Kaplar). In practice, according to Dr. Dickinson, '"any message promoting 
some pharmaceutical must also present virtually all negative information about the 
product. "' Id. (quoting Kaplar). Citing a book by Paul H. Rubin, an Emory University 
economics professor, Dickinson sets forth the following proposals for reform: 
FDA should ( l )  cancel all recent initiatives restricting promotion of off-label uses; 
(2) allow manufacturers to advertise any reasonable claim for which reliable 
scientific evidence exists; (3) abolish the "brief sununary" requirement for 
consumer advertising; and (4) allow unrestricted advertising of drugs, subject only 
to regulation for "falsity" but not for "deception" as currently defined. 
Id. Nevertheless, the hyping of health-care product features by their manufacturers is a 
pervasive problem: 
So endemic is the practice of hyping product features the facts clearly don't 
support that FDA deputy commissioner Mary K. Pendergast, speaking in October 
1994 before the House Subcornmittee on Regulation, Business Opportunities, and 
Technology, was moved to uncharacteristically straightforward language. 
"Promotion of unapproved uses by company sales representatives," she stated, "is 
a major problem." 
Greg Critser, Oh, How Happy We Will Be, HARPER'S MAG., June 1996, at 39, 47. 
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institutional laboratories to run extraordinarily novel tests on patient 
samples. These are tests that, without predictability defined through 
scientifically reliable clinical data, are highly subject to 
misinterpretation. The dependence of both providers and their patients 
on the developers of genetic tests for information-information test 
developers are compiling on an ongoing basis from patient data­
could not be greater. Ironically, because test developers are the entities 
with the most information about their evolving technology, advertising 
restrictions that are too intrusive could exacerbate rather than lessen 
misinterpretation by cutting providers and their patients off from the 
most up-to-date data. 77 
The FDA, in response to the actions taken by IVF, Myriad, and 
OncorMed, has proposed regulations to bring genetic testing services 
(and home brews in general) more directly within its purview.78 
Specifically, the FDA would like to regulate the active ingredients 
used in genetic tests. The FDA's proposal is to classify "active 
ingredients," chemicals or antibodies that are useful only in testing for 
one specific disease or condition, as analyte specific reagents (ASRs), 
which are subject to controls.79 This l abeling would require suppliers 
77. Historically, advertising of health products accompanied the spread of 
journalism during the Civil War and was targeted to reach consumers. See ABRAHAM, supra 
note 7 1 ,  at 42. However, this was followed very quickly by dependence by doctors on the 
"pharmacopoeias" for knowledge about specific drugs and their measured doses. Soon, 
drug manufacturers began to make standard preparations available, and 
a close relationship based on mutual interest evolved between the big 
pharmaceutical companies in the U.S. and American physicians; the latter could 
extend their professional power since only they had the knowledge to prescribe 
the new science-based drugs, while the large high technology finns create a 
unique prescription market, in which they had a clear advantage over other 
medicine makers. 
Id. In an age of burgeoning medical science, of a deluge of genetics products, and of 
competition to attract and retain patients under managed care (by, among other things, 
offering them the latest treatments), providers' need for infonnation could not be greater. 
Where products are being made available under investigatory protocols, their developers and 
manufacturers may be the only entities with such information. 
78. See Medical Devices; Classification/Reclassification; Restricted Devices; 
Analyte Specific Reagents, 61 Fed. Reg. 10,484 ( 1 996) (to be codified at 21 C.F.R pts. 809 
& 864) (proposed Mar. 14 ,  1996). But see Weiss, supra note 2, at Al ('The Food and Drug 
Administration, already on the defensive amid corporate claims of over-regulation, has 
declared it has the authority to regulate genetic tests but hastens to add that i t  has no plans to 
do so."); ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 ,  at 15 ('The Task Force has 
requested a legal opinion from FDA as to whether, if it has the authority to regulate the 
development of genetic test services, it can limit the duration of the investigational stage."). 
79. Although ASRs generally are subjected to general Class I controls, those 
detennined to carry a high risk may be designated for Class III controls, which i nclude a 
premarket approval requirement, or they may be regulated by the Center for Biologics 
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of such active ingredients to register with the FDA and provide lists of 
the ASRs they are supplying to laboratories for use in developing tests. 
These suppliers then would be held to good manufacturing standards, 
which require FDA reporting of all adverse events possibly 
attributable to products.80 The FDA also has left open the possibility 
of directly regulating in-house genetic testing services at a later date.81 
Ironically, h owever, the advent of commercialization of genetic 
testing by OncorMed and Myriad is juxtaposed against weighty 
political and public pressures on the FDA to streamline, expedite, and 
privatize its review process.82 Despite recent self-reforms,83 this 
Evaluation and Research (CBER) because their use presents particularly high risks. See 
Medical Devices; Classification/Reclassification; Restricted Devices; Analyte Specific 
Reagents, 61 Fed. Reg. at 1 0,484-86. 
80. See id. ; 2 1  C.F.R §§ 803 . 1 -.58, 820. 1 -. 1 98 ( 1996). 
8 1 .  In the Proposed Rules, the FDA states: 
However, at a future date, the agency may reevaluate whether additional controls 
. . . .  may be especially relevant as testing for the presence of genes associated 
with cancer or dementing diseases becomes more widely available. Additional 
controls might include a broad array of approaches, ranging from full premarket 
review by FDA to use of third parties to evaluate analytical or clinical 
performance of the tests. 
Medical Devices; Classification/Reclassification; Restricted Devices; Analyte Specific 
Reagents, 61 Fed. Reg. at 10,486. 
82. See John Schwartz, FDA Often Blamed for Problems that Aren 't Agencys Fault, 
WASH. PosT. , July 1 5 , 1 996, at Al 7 (reporting how the pharmaceutical industry's trade 
organization brought 1 40 disease victims to Washington to lobby for reform); cf. Matthew 
Rees, What Makes David Kessler Run?, WKLY STANDARD, June 3, 1996, at 25 (stating that, 
rather than a political victim, "the Commissioner of the [FDA] is an amazingly resourceful 
political animal"). The most dramatic features of the proposed FDA reform legislation are 
privatization of the review process (using private companies to help review clinical data) 
and a six-month ( 1 80-day) time limit on the review of all drugs by 1998-a dramatic 
reduction compared to the average of 12 months. See The Food and Drug Administration 
and Accountability Act of 1995, S. 1477, 1 04th Cong. ( 1 995) (bill introduced by Sen. 
Nancy Kassebaum); Malinowski & O'Rourke, supra note 20, at 210-23 ; Robert Pear, 
LLlwyers and Lobbyists Help Guide Ef ort by Republicans to Speed Drug Approvals, N.Y. 
TIMES, Mar. 4, 1 996, at A l 5  ("Republicans on the Senate Committee on Labor and Human 
Resources and the House Commerce Committee, joined by some Democrats, have 
concluded that Congress must revise the F.D.A. laws to give patients swifter access to new 
drugs and devices."); Ronald Rosenberg, Biotech Group Hits Kennedys FDA Stance, 
BOSTON GLOBE, Apr. 26,  1 996, at 90 ("Citing scientific advances over the past 50 years, the 
biotech industry wants to abolish the two-track approval process for biology-based drugs. 
That process now requires separate approvals for a biological drug, its manufacturing 
process and for every lot or batch produced."); see also Jeffrey L. Fox, "Nitty-Gritty " FDA 
Guidelines Wanted Sooner Not LLlter, 14 NATURE B IOTECHNOLOGY 698, 698 ( 1996) (stating 
that reforms are expected by late summer which will lessen the burdens on biologics 
manufacturing). Other proposed reforms include: ( 1 )  mandatory review of all 
"breakthrough" drugs for killer or untreatable diseases in four months. two months faster 
than today; (2) a requirement that the FDA farm out its work to private companies if it does 
not meet the proposed review deadlines by 1 998;  and (3) the opportunity for companies to 
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pressure has been mounting, especially for cancer and AIDS-<liseases 
that affect millions of people and, not coincidentally, major research 
and development (R&D) areas for biotechnology companies.84 
petition for automatic approval for sale in the United States of any therapy that is approved 
in certain foreign countries if the FDA misses its deadline (the FDA then would have 30 
days to block the sale, by declaring the treatment unsafe or unproven). See Lauran 
Neergaard, FDA Resists Claiming Potential for Dangerous Errors, BOSTON GLOBE, Feb. 22, 
1996, at 3. The public pressures on the FDA also have been profound. See, e.g., Editorial, 
The FDA and Shannon McDermott, BOSTON GLOBE, Apr. 15, 1996, at 1 0  ("Janet 
McDennott[, who was brought to Washington by pharmaceutical trade groups,] is waging a 
valiant struggle to get medication that will prevent the seizures suffered by her daughter 
Shannon. But Shannon's plight should not encourage support for a bill in Congress that 
would force the [FDA] to speed up the approval process for new drugs."). These forces 
have joined, for drug companies have learned the power of teaming up with patients. See 
Pear, supra ("Drug companies contribute substantial sums of money to patient-advocacy 
groups, but those groups insist that they are not unduly influenced by the money."). The 
FDA reform movement is the culmination of a general trend to deregulate the 
commercialization of pharmaceuticals. See Critser, supra note 76, at 40 ('Today, the 
American patient is inexorably being transformed into his own pharmacist. The trend is 
most apparent in the pages of magazines, with their weirdly text-heavy ads. Less obvious 
are the marketing fests taking place in the nation's doctors' offices and emergency rooms."). 
83. See BILL CLINTON & AL GoRE, REINVENTING DRUG AND MEDICAL DEVICE 
REGULATIONS 4-5 ( 1 995) (executive branch/FDA proposals for self-reform); KENNETH B.  
LEE, JR. & G. STEVEN BURRILL, BIOTECH 97: ALIGNMENT , THE ELEVENTH INDUSTRY 
ANNUAL REPORT 34-36 ( 1 996); For Biotech Firms, FDA Rules Have Much to Please, 
BOSTON GLOBE, Nov. 23, 1996, at 90 ("[B]iotechnology executives are breathing a lot easier 
these days about such big up-front investments now that the [FDA] has revamped a host of 
regulations governing the industry."). These proposed reforms, many of which now are in 
the process of allegedly being implemented, were referred to by some in the industry as "the 
most significant and sweeping in 50 years." CLINTON & GORE, supra, at 4-5. The reforms 
included proposals to ( l )  eliminate requirements that each company seek a separate license 
for each facility where it plans to manufacture a drug, (2) eliminate the requirement that each 
batch of a biotech-developed drug be sent to the FDA to test, and (3) impose a 30-day 
deadline for the FDA to respond to a company that has submitted additional information 
requested after the FDA has put a clinical trial on hold. See id. Many of these proposals 
have been incorporated into Senator Kassebaum's FDA reform bill. See supra note 82 and 
accompanying text; see also Pear, supra note 82, at A l 5  (reporting that industry experts 
helped write an FDA bill regarding speeding up approval for new drugs). 
84. See generally Elizabeth C. Price, Teaching the Elephant to Dance: P rivatizing 
the FDA Review Process, 5 1  FOOD & DRUG L.J. 65 1 (1 996); Cancer Diagnostics , MED. 
TECH. STOCK LETTER (Piedmont Venture Group, Berkeley, CA), Apr. 18,  1 996. "Within 
days after the Republicans won control of Congress in 1 994, some gay rights groups saw an 
opportunity to win speedier access to new, unapproved treatments for AIDS by rewriting 
Federal drug Jaws." Pear, supra note 82, at AI5 (discussing new FDA regulations regarding 
new drug approval process); see also Tanya E. Karwaki, Note & Comment, The FDA and 
the Biotechnology Industry: A Symbiotic Relationship?, 7 1  WASH. L. REV. 821 , 8 2 1 -22, 
834-37 (1996) (addressing reform). This strategy appears to be working, for in response to 
the political and public pressure, the FDA already has expedited approval of drugs that fight 
AIDS and cancer. See Pear, supra note 82, at Al5;  Laurie McGinley, FDA to Quickly Clear 
Merck AIDS Drug, after Approving Abbott's Treatment, WALL ST. J., Mar. 4, 1 996, at B3 
("On �riday . . .  the [FDA) approved Norvir, known generically as ritonavir. That approval 
came JUSt 72 days after Abbott filed its application-the fastest drug approval in the 
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Moreover, the manufacturers of medical devices and diagnostics are 
pressuring the FDA by organizing and calling for reforms favorable to 
their products.85 The drive to reform the FDA does, however, have its 
agency's modem history. And it came just one day after the advisory panel backed its 
approval."). It i s  important to note, however, that many consumer advocacy groups oppose 
the "premature" commercialization of genetic testing: 
The National Breast Cancer Coalition, for example, a patients' rights group, 
opposes open marketing of a test for the so-called breast cancer gene, BRCA 1 .  At 
the risk of sounding as paternalistic as the doctors they often fight against, 
members said the test's general ambiguous results may trigger unnecessary panic 
in many women while reassuring others who should remain vigilant. 
Weiss, supra note 2, at A l .  
85. According to the General Accounting Office (Congress's investigator), the 
average time required for the approval of new drugs has fallen in the last decade from 33 to 
1 9  months. However, acceleration of FDA review of drugs has not been matched for 
diagnostics. See 1 42 CONG. REC. S3203 (daily ed. Mar. 29, 1996) (statement of Sen. 
Edward Kennedy acknowledging that the review process is slower for medical devices and 
various animal vaccines); Neergaard, supra note 82, at 3 ("Today, the FDA spends six 
months reviewing breakthrough drugs and 1 6  months reviewing nonessential medicines. 
Medical devices take much longer."); Pear, supra note 82, at Al5 ('The agency has 
accelerated the process of reviewing AIDS drugs, but patients with other life-threatening 
conditions contend that those drugs receive preferential treatment," and the FDA has not had 
similar success in accelerating approval of devices and food additives.). See, e.g., FDA 
Delays Approval of New Test for Diabetics, BOSTON GLOBE, Feb. 27, 1996, at 1 2  ("Diabetics 
pleaded with the government yesterday to approve the first pain-free way to measure blood 
sugar, but a panel of specialists said there was no proof the machine works well enough to 
keep their disease at bay."); id. ('"I can't tell you how frustrating it is to know this device 
exists but is just out of reach of Bonnie,' said Glenn Sklar of Columbia, Md., who draws 
blood from his 3-year-old's finger six times a day."). Some argue that the FDA's approval of 
Olestra, a fat substitute, reflects organization of the Grocery Manufacturers of America, see 
Pear, supra note 82, at A l  5, and that the FD A's recent approval of Intemeuron's antiobesity 
drug, the first obesity drug approval in over 20 years, reflects the FDA's responsiveness to 
biotechnology. See Ronald Rosenberg, Antiobesity Drug Cleared by FDA; Available Soon, 
BOSTON GLOBE, Apr. 30, 1 996, at 3 (reporting that Redux, developed by Intemeuron 
Pharmaceuticals Inc., was the first new obesity drug approved in 22 years). To create a 
counterpart to BIO and the Pharmaceutical Research and Manufacturers of America 
(PHARMA) and a voice for device manufacturers in the FDA refonn movement, the device 
manufacturers are organizing. Specifically, 
[a)fter years of being lumped with the biotechnology industry, Massachusetts' 
medical device companies yesterday announced the formation of their own trade 
association. Known as the Massachusetts Medical Device Industry Council, or 
MassMEDIC, the group intends to have a voice in pending reforms at the Food 
and Drug Administration and in local business and government issues that affect 
the industry. 
Ronald Rosenberg, Medical Device Firms Form Trade Association, BOSTON GLOBE, May 7, 
1 996, at 43 (defining the industry as 200 member companies that employ more than 1 5 ,000 
people in Massachusetts, create more than three percent of all manufacturing jobs, and 
generate collective revenues of $3.5 billion). The formation of MassMEDJC coincides with 
enhanced FDA responsiveness to the manufacturers' industry. According to former 
Commissioner Kessler, the FDA has shortened the time it takes to review a device from 1 34 
days in 1 994 to 90 days. See id. Presently, the FDA is modifying rules that govern export 
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opponents, most notably fonner Commissioner David Kessler86 and 
Senator Edward Kennedy. 87 
licenses for medical device products that have not been approved by the agency, that govern 
pilot testing private-industry review of some low-risk medical devices, and modification of 
safety and inspection procedures for devices. See id. ; see also Kate C. Beardsley, Medical 
Devices·Regulation and Refonn, in ALl·ABA COURSE OF STUDY MATERIALS: BIOTECH '95 
BUSINESS, !Aw, AND REGULATION, Nov. 2-3, 1995, at 255; FDA lays Out Plan to Reduce 
Delays, Costs in Approval Procedures, BOSTON GLOBE, Apr. 4, 1996, at 6 (reporting that 
FDA has launched a pilot test to determine if outside groups could assume some of the 
reviews of routine medical devices now handled by FDA scientists for low and moderate 
risk devices like electronic thermometers and surgical gloves). More specifically, the 
manufacturers' industry supports proposals that include: (I) exempting (by moving from 
Class II to Class I) an additional 1 25 medical device categories from premarket notification 
requirements, thereby exempting a total of 570 categories (about one-third) from this 
requirement; (2) allowing the export of devices without an IND exemption; and (3) adopting 
"an approach similar to that used in the European Community in which device firms have 
their device applications reviewed by a third-party scientific organization accredited by the 
government." Id. ; see also Malinowski, supra note 29, at 1 34-42. Under this approach, "a 
manufacturer pays a third-party organization for its review, the third-party organization 
notifies the government of the results, the device i s  marketed without government review, 
and the government monitors the device after it is on the market for subsequent safety 
problems." Beardsley, supra, at 280. FDA responsiveness to the device manufacturers' 
industry has, however, accompanied new reporting requirements: 
The FDA has issued final regulations specifying new requirements for reporting 
serious problems with medical devices, as required under the Safe Medical 
Devices Act of 1 990. . . . It will also provide the necessary assurance of product 
safety to enable the FDA to clear innovative devices for marketing more quickly. 
Under the new requirements, medical facilities must report all serious 
device-related injuries or illnesses within 10 days . . . .  
Manufacturers have been given 5 days to report to the FDA any device­
related incident that requires immediate action to protect the public health. The 
time limit for the rest of the manufacturers' reports to FDA on device-related 
deaths and serious injuries or illness is 30 days. This gives manufacturers time to 
investigate incidents and provide the FDA with detailed information on adverse 
events. 
Stuart L. Nightingale, From the Food and Drug Administration, 275 JAMA 585, 585 
( 1996). 
86. According to former Commissioner Kessler, the proposed reforms could 
endanger the health o f  Americans. See Neergaard, supra note 82, at 3; Legislation Puts 
Public Health at Risk, FDA Chief Tells Panel, BOSTON GLOBE, May 2, 1996, at 9.  For a 
detailed discussion of former Commissioner Kessler's position on this issue see 
Malinowski, supra note 29. 
' 
87. See 142 CONG. REC. S3203 (daily ed. Mar. 29, 1 996) (statement of Sen. Edward 
Kennedy regarding the FDA Reform Markup); Rosenberg, supra note 82, at 90. In the 
words of Senator Kennedy: 
Most recently, we reduced the delays in approving prescription drugs with 
user fees. As a result, we are now approving drugs faster than the United 
�ngdom. We have fixed the drug lag. In fact, the United States approves more 
important new drugs faster than any other country in the world. 
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The FDA review process significantly impacts the economy of 
the United States, for "[t]he products regulated by the ED.A. account 
for 25 percent of the nation's economic output."88 Nevertheless, the 
biotechnology aspect of the FDA reform movement is grounded in 
more than the profit motives of biotech companies. With the 
exception of predictive genetic testing services, biotechnology 
products have been more highly regulated than traditional 
pharmaceuticals. 89 Biotech drugs and therapeutics generally are 
classified as biologics and, as such, are subject to requirements 
imposed by both the Federal Food, Drug, and Cosmetic Act (FDCA)90 
and the Public Health and Services Act (PHSA).91 Because of 
fundamental differences in the regulatory approaches taken under 
these statutes,  an entire dimension of added regulation is imposed 
upon biologics. Specifically, "[t]he primary objective of the FDCA is 
to ensure the safety and effectiveness of the final product, with 
controlling the manufacturing process a secondary concern. In 
contrast, biologics regulation under the PHSA is focused on 'rigid 
control of the manufacturing process . . . .  "'92 The practical effect on 
biologics has been that, to reach the market, developers and 
manufacturers have had to negotiate an entanglement of licensing and 
other requirements that front-load their financial investment.93 Self-
. . .  The [proposed] legislation says you have to examine all of them, a11 of 
the drugs within the 6 months . . . .  
So now instead of bringing focus and attention of the gifted and able 
scientists out at FDA on those drugs that could be breakthrough drugs in cancer, 
in AIDS, in hepatitis, in all kinds of diseases, we are going to divert their attention 
to looking after the "me-too" drugs that can make extra bucks for the 
pharmaceutical companies. 
142 CONG. REC. S3203-04 (daily ed. Mar. 29, 1 996). 
88. Pear, supra note 82, at A15. 
89. See JAMES T. O'REILLY, FOOD AND DRUG ADMINISTRATION §§ 13- 1 5  (2d ed. 
1993) (detailing drug regulation, specifically the approval process, safety and qua1ity issues, 
and economic and labeling issues); Gary E. Gammennan, Regulation of Biologics 
Manufacturing: Questioning the Premise, 49 FOOD & DRUG L.J. 213,  2 1 3  ( 1 994) (arguing 
that, in retrospect, the divergent regulatory emphasis of the Biologics Act and the FDCA 
were appropriate when biologics were crude mixtures or biological extracts); Malinowski & 
O'Rourke, supra note 20, at 205. 
90. 21 U.S.C. § 360k(a) (1994). 
9 1 .  42 u.s.c. § 262. 
92. Malinowski & O' Rourke, supra note 20, at 205-06 (quoting Gammerman, supra 
note 89, at 213); see also Gammerman, supra note 89, at 220-26 (analyzing the utility of the 
Biologics Act). 
93. See Gammerman, supra note 89, at 230-33; Malinowski & O' Rourke, supra 
note 20, at 205- 13 ,  21 5-24. Establishment licensure requirements have mandated that 
products used in Phase III trials produced in the intended commercial-scale manufacturing 
facility and that only the company that manufactures the biologic may obtain and hold the 
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refonns by the FDA to eliminate some of the most unduly burdensome 
licensing and other requirements imposed upon biologics have come 
too late to quell the organization of the biotechnology industry and 
frustrated consumers awaiting products. International competition 
stemming from the establishment of the European Medicines 
Evaluation Agency (EMEA) should inspire more self-reform by the 
FDA and perhaps produce a new commitment to international 
collaboration in drug review and approval.94 
The impact of regulatory uncertainty on the biotech industry has 
provided an incentive to "Coase around"95 and reform the existing 
FDA review process.96 Moreover, the reform movement is fueled by 
genuine concern that, "'[i]n this increasingly complex scientific world, 
where the half-life of knowledge is growing shorter and shorter every 
day, it's going to be impossible for the ED.A. to maintain in-house the 
full range of expertise and experience that will be needed.' "97 Despite 
marketing licenses. Accordingly, in comparison with traditional drug developers, CBER has 
forced biotech developers to commit more financial resources to manufacturing before they 
know if they have an approvable product. See Gammerman, supra note 89, at 230-3 1 .  
94. See generally John Ashworth, Development of the European Biotechnology 
Industry, 33 CAL. W.L. REv. 83 (1996); Malinowski, supra note 29. 
95. See Ronald H. Coase, The Problem of Social Cost, in THE FIRM, THE MARKET 
AND THE LAW 95, 99 ( 1 988) (arguing that parties will be driven to overcome market 
interferences, whether caused by regulations or contractual provisions, to reach maximum 
efficiencies). 
96. FDA actions have had, and continue to have, a profound impact on the market 
appeal of biotechnology. See Malinowski & O'Rourke, supra note 20, at 2 1 5-24. This is 
true even for relatively "mature" biotech companies with diverse technology, such as 
Genzyme Corp., an established biotechnology company located in Cambridge, 
Massachusetts. See Steve Bailey & Steven Syre, After the Fall, BOSTON GLOBE, Mar. 28, 
1996, at 41 (reporting that vote by FDA advisory committee reconunending approval for 
limited uses of Seprafilm, a membrane product designed to prevent the adhesion of organs 
and tissue after some operations, caused a two-day fall  in Genzyme stock). 
97. Pear, supra note 82, at Al5 (quoting Sen. Bill Frist, who is a heart surgeon). A 
prime example of the innovative products at issue is Olestra, a fat-based substitute for 
conventional fats manufactured by Procter & Gamble. See Nightingale, supra note 85, at 
585. In a flourish of controversy, the FDA approved this drug but imposed enhanced post­
mariceting obligations. See Henry Blackbum, Sounding Board: Olestra and the FDA,  334 
NEW ENG. J. MED. 984, 984 (1996) ("Procter & Gamble will be required to conduct studies 
that monitor consumption and examine Olestra's long-term effects. The FDA's Food 
Advisory Committee will review these studies in a public meeting within 30 months."). 
This decision may be an indication that the FDA is beginning to recognize that truly 
innovative products may require more than the FDA's limited resources: 
Clearly, the FDA is becoming more aware of the need for epiderniologic 
studies and clinical trials with adequate statistical power to detect effects and 
monitor human safety. The agency apparently also has the fortitude to stick to its 
guns, as it has done, for example, in the cigarette controversy by maintaining that 
nicotine is an addictive drug. But the FDA does not have the statutory authority, 
the staff, or the funding to examine adequately the benefit and safety of food 
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the short "half-life" of its underlying science, the work necessary to 
fully assess clinical applications takes years. These problems are 
exacerbated by the FDA's resistance to accept scientific evaluations of 
technology by the rest of the industrialized first world, a resistance 
presumably due to a belief in the superiority of United States science 
and scientific capability.98 The success of the HGP, the globalization 
of the science community responsible for the biotechnology 
revolution, and the realization of meaningful global 
telecommunications support the introduction of uniform, international 
scientific standards for compiling and evaluating clinical data.99 
The strength of the FDA reform movement reduces, but does not 
make impossible, 100 the likelihood that a comprehensive regulatory 
response to the commercialization of genetic testing services will be 
introduced in the immediate future. Without such FDA reform, other 
biotechnology companies will follow the precedent set by IVF, 
Myriad, and OncorMed. Dangers arising from the widespread 
availability of investigatory, predictive genetic testing services must, 
additives generated by the powerful food industry and its sophisticated 
technology. Moreover, there are now serious political pressures on the FDA, 
including informal proposals that it become a rubber-stamp certifying body for 
industry. There are even threats to abolish the agency. In this climate, it is 
understandable, if  unfortunate, that the FDA has to set priorities and choose 
carefully where to do battle. 
Id. at 986. 
98. In the words of Senator Barbara Mikulski, a Maryland Democrat, '"If we can 
use NATO weapons, why can't we use drugs from NAm countries?"' Neergaard, supra 
note 82, at 3. Despite former Commissioner Kessler's assertions to the contrary, gaps in 
approval between the United States and Europe do exist and, at times, are extreme. For 
example, although the FDA only recently approved dexfenfluramine, "in Europe, where it 
has been used for l 0 years, an estimated 1 0  million patients have been treated with no 
epidemiological signal indicating any behavioral problem in clinical usage." Ronald 
Rosenberg, "Take a Pill, " Lose Some Weight, BOSTON GLOBE, Apr. 15, 1 996, at 91  (noting 
that three fat-fighting drugs are entering the United States market: dexfenfluramine by 
Interneuron Pharmaceuticals, Inc., known as Redux; sibutramine, with the trade name 
Meridia, by Knoll Pharmaceutical, Inc., a unit of BASF Corp; and orlistat, with the trade 
name Xenical , by Hoffmann-La Roche, Inc.). 
99. See generally Malinowski, supra note 29. See also Malinowski & O'Rourke, 
supra note 20, at 2 1 8  (noting that the FDA standards should be harmonized with 
international medical standards). 
I 00. A personal observation is that the ongoing work of the ELSI Task Force and 
consumer groups such as the National Breast Cancer Coalition and the Jewish Women's 
Coalition on Breast Cancer could make this issue a priority on Congress's agenda. See 
Richard Saltus, Jewish Women s Group Warns of Risks of Cancer-Gene Testing, BOSTON 
GLOBE, Jan. 17 ,  1997, at B2 (reporting on formation of a coalition that includes the 
Combined Jewish Philanthropies, National Council of Jewish Women, Beth Israel 
Deaconness Medical Center, and Jewish Community Centers of Greater Boston to challenge 
testing for inherited breast cancer genes). 
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therefore, be identified, thoughtfully considered, and addressed 
without further delay. 
C. Dangers Arising from the Premature Use of Genetic Testing 
Predictive genetic testing services are, in the aggregate, biological 
tarot cards subject to misinterpretation by both patients and their 
physicians.101 The predictive capability of many genetic tests remains 
scientifically undefined for the general population.102 This type of 
testing must be conclusively distinguished from presymptomatic 
genetic testing. The latter constitutes a reliable and meaningful 
predictor only for a small number of conditions-conditions usually 
caused by a single genetic mutation. 1 03 Only these few conditions, 
such as Huntington's and Tay Sachs disease, can be diagnosed 
conclusively through genetic testing.104 Even when such conditions 
101 . See ELSI TASK FoRCE ON GENETIC TESTING, supra note 1, at 14 (reporting that a 
test is ready for routine use only when it has been carefully assessed for ( l )  sensitivity, 
(2) positive PPV, and (3) clinical utility). The ELSI Task Force has identified the following 
aspects of genetic testing as bases for special consideration by public health officials and 
other policy makers: 
predictability seldom approaches certainty; often no independent test is available 
to confirm the prediction of a genetic test (only appearance confirms the 
prediction); no interventions are yet available; those tested may be subject to 
psychological distress, discrimination, and stigmatization; ethnicity may influence 
genetic makeup ;  [and] most health providers have received little training in 
genetics. 
Id. at 3; see also Weiss, supra note 2, at Al ("Genetic tests differ from many medical tests 
because they often provide very vague answers, such as, 'You have a gene that gives you a 
70 percent chance of getting breast cancer in the next 20 years."'). 
102. See supra note 25 and accompanying text. 
103. See supra note 25; see also ELSI TASK FORCE ON GENETIC TESTING, supra note 
1 ,  at 8 ("In only a small proportion of patients with common disorders, such as breast cancer 
or malignant melanoma, do inherited mutations at a single gene locus contribute 
significantly to the occurrence of the disease."). Examples of the clinical limitations of 
modern genetic science are almost as plentiful as the genetic linkage discoveries that so 
captivate the media and the public. Consider the APOE-4 discovery: 
Two-thirds of people who develop Alzheimer's later in life have ApoE4. 
Having just one copy confers three times the average risk of developing the 
disease; having two copies raises the risk to beyond 90% (The risk of developing 
Alzheimer's disease is 2% at age 65, but about 1 0% at age 85.) However, many 
people with Alzheimer's do not carry even one copy of ApoE4, and some who 
have two copies of ApoE4 do not develop the disease. 
The Hazards of Genetic Testing, supra note 24, at 6; see Bishop, supra note 48, at Al 
(describing blood tests identifying the gene Apoe, which will eventually help determine how 
long a person lives). 
104. See Stephenson, supra note 15 , at 1 66 1  ( 
The Task Force investigators discovered that while academic laboratories were 
more likely than the biotechnology companies to offer tests for single gene 
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can be diagnosed through genetic testing, the rate of expression may 
vary; with many genetic conditions, severity remains an open 
question. 105 Most often there is no available treatment,106 or treatment 
exists but is price-prohibitive. 107 In addition, in the absence of unifonn 
federal regulatory oversight, the quality of laboratory performance is 
questionable. 108 
disorders, such as cystic fibrosis, fragile X syndrome, and muscular dystrophy, the 
latter are far likelier to be engaged in developing or offering tests for complex 
genetic disorders, such as Alzheimer's disease, breast cancer, and hereditary 
nonpolyposis colon cancer, and in conducting population testing for such 
disorders. 
105. See, e.g. , COOK-DEEGAN, supra note 20, at 242 (discussing clinical 
heterogeneity i n  the context of cystic fibrosis). 
1 06. In the absence of therapeutics and gene therapies, most predictive genetic tests 
offer few options: 
For example, the only options now available to a woman who learns that 
she is predisposed to breast cancer are prophylactic mastectomy (in hopes that 
cancer would not develop in the residual amount of breast tissue) or frequent 
clinical breast exams and mammograms. Physicians have little to offer in terms of 
preventive strategies to patients who discover that they have a markedly increased 
risk of developing Alzheimer's disease by virtue of having two copies of the 
APOE-4 allele. 
Stephenson, supra note 1 5, at 1 662; see Hilzenrath, supra note 4, at D 1 4  ("Should the 
patient have her breasts or ovaries removed as purely preventive measures, when there is no 
guarantee that the surgery would prevent the disease, and no assurance that cancer would 
develop in the absence of the surgery?"); Richard Saltus, Genetic Clairvoyance, BOSTON 
GWBE, Jan. 8, 1 995, (Magazine), at 14 ("One of the lessons patients and counselors have 
learned from this experience is that knowing one's genetic fate is not for everyone­
especially when, as is the case with Huntington's, knowing what's ahead doesn't help one to 
avoid it."). 
1 07. A prime example is the treatment for Gaucher Disease. See Gaucher Disease: 
Current Issues in Diagnosis and Treatment, 275 JAMA 548, 548 ( 1996) ( 
Despite the success of enzyme therapy, treatment is limited by the cost of 
the agent. 
[This) makes it imperative to determine the lowest effective initial and 
maintenance dosages and the most cost-effective dosage for clinical response, to 
define the appropriate clinical indications for treatment, and to establish uniform 
methods to optimize outcome assessment. 
108. See Proposed Recommendations of the Task Force on Genetic Testing, Meeting 
Notice, 62 Fed. Reg. 4539, 4545-46 ( 1 997) (expressing concern over the absence of federal 
law and regulation to ensure the laboratory quality o f  genetic tests). Due to the novelty of 
widespread commercialization of predictive genetic testing services, those scrutinizing them 
tend to rely heavily on anecdotal evidence. According to one account: 
Citing case studies reported to the Task Force, Dr. Holtzman pointed out other 
problems: I) laboratory error in performing and interpreting genetic tests; 
2) ordering of genetic tests for inappropriate reasons; 3) restriction by managed 
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More troubling, due to the absence of adequate clinical data, 
health care providers cannot interpret the results of predictive genetic 
tests for most of their patients with any reliability even when they are 
knowledgeable about genetics.109 This interpretation problem is 
exacerbated because the current generation of health care providers 
does not possess such knowledge. 1 10 Their lack of genetics education 
care organizations of the labs in which tests o n  their subscribers can be perfonned; 
and 4) maintaining confidentiality of genetic test results. 
Meeting Minutes, supra note 1 ,  at 2. 
109. See Stephenson, supra note 15, at 1 66 1  ("Interpreting the results of such tests is 
difficult, in part because the rate of false negatives is unknown."); Brom, supra note 27, at 
1 26. Fully assessing the PPV of existing genetic testing capability for individual patients 
could take a decade or more. Moreover, it may be that, in the aggregate, environmental 
factors control approximately 50% of physical characteristics, and that each of us carries 
multiple genetic predispositions for disease. See id. ; cf ELSI TASK FORCE ON GENETIC 
TESTING, supra note 1 .  
1 10. See The First BCAJ Test Hits the Market, supra note 65, at 2 ('"Available data 
suggest that many primary care providers lack the knowledge about genetics that's necessary 
to educate their patients and ensure informed consent for genetic testing . . . .  "' (quoting 
Caryn Lennan, associate professor of medicine and psychiatry at the Georgetown University 
Lombardi Cancer Center)); Proposed Recommendations of the Task Force on Genetic 
Testing, Meeting Notice, 62 Fed. Reg. at 4546 ("A provider's need for knowledge is 
particularly keen when tests are in transition from research to clinical use and when clinical 
utility is still under i nvestigation and there are no established practice guidelines."); see also 
William C. Felch & Donald M .  Scanlon, Bridging the Gap Between Research and Practice, 
277 JAMA 1 55 ( 1 997) (arguing that the research and provider communities must work 
together to bring medical technology into patient care). At the meeting of the National Task 
Force on Genetic Testing held in April 1996, representatives of the biotechnology industry 
placed the responsibility of informed consumption of genetic testing services o n  physicians. 
In response, "Doctors said they were still getting up to speed in genetics and would be 
unable to stem the tide of patient demand if testing were not subject to regulatory 
restrictions." Weiss, supra note 2, at Al5;  see also ELSI TASK FORCE ON GENETIC TESTING, 
supra note 1 ,  at 24 ( 
Several studies have documented the deficiencies in health care providers' level of 
knowledge about genetics and genetic tests. As opposed to the results of a serum 
sodium or a complete blood count, which the referring physician is competent to 
interpret and convey to the patient, genetic test results raise unfamiliar problems 
about probabilities, psychological impact, and reproductive implications. 
). Concern about the ability of physicians to interpret such tests for their p atients is well 
founded: 
Even though both commercial and academic laboratories are marketing the 
tests to physicians who lack any expertise in medical genetics, including 
obstetricians and primary care providers, only a minority of the laboratory 
directors who responded to the survey said they felt that most physicians can 
interpret genetic tests adequately for their patients. 
Stephenson, supra note 1 5, at 1661 (confirming by study of 4,210 Ohio family physicians). 
As reported in The Boston Globe, based upon a survey of laboratories: 
"A lot of people are getting into genetic testing now who haven' t  been 
through human genetics training," said Dr. Michael S. Watson of Washington 
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and the novelty of the technology makes providers dependent upon the 
developers and manufacturers of these tests (both commercial and 
academic laboratories) for information. This dependency suggests that 
neither consumers nor their health care providers can reasonably 
evaluate the technology. Accordingly, until this informational 
asymmetry between providers/patients and biotechnology companies 
is decreased through the compilation of clinical data and education, 
heavy reliance upon market forces like consumer and provider demand 
is misplaced. In fact, the premature commercialization of genetic 
testing services may create a general climate of uncertainty that skews 
incentives for all market participants: 
Biotech companies ' decisions about what technologies to 
develop are subject to being inflated by dependence upon them 
for information, consumer demand, and the influence of 
consumer advocacy groups;1 1 1  
public demand is  subject to being bloated by the aggressive 
marketing efforts of biotechnology companies that play off of the 
cultural icon status of DNA, 1 1 2  the fact that the public is 
accustomed to undergoing testing for reliable health evaluation 
and diagnosis, and providers' lack of adequate genetic 
education; 1 1 3  and 
University in St. Louis [an official of the American College of Medical Genetics]. 
'This used to be an unprofitable and esoteric field" when the only genes scientists 
had identified were those that caused rare disorders. "Now that we are getting 
into common diseases" influenced by genes-including cancer, heart disease and 
diabetes- "people are jumping into it." 
Saltus, supra note 58,  at 14. This problem will be exacerbated with the proliferation of 
genetic testing services. See ELSI TASK FORCE ON GENETIC TEsrING, supra note 1 ,  at 23 
("As the number of genetic tests proliferate and their usage expands, primary health care 
providers and other non-genetics specialists (e.g., [sic] oncologists, neurologists) will play a 
major role in the provision of genetic tests."). 
1 1 1 . Advocacy groups (e.g. , for those afflicted by breast cancer and AIDS) may 
influence what products are brought to market based upon what they treat rather than their 
relative quality. See Boyle, supra note 13,  supp. at S5. 
1 1 2. See Annas, supra note 14, at 25. 
1 1 3. FDA enforcement of its advertising restrictions has had a profound impact on 
the availability of genetic testing within the United States: 
While a number of blood tests have been used in other countries, they have been 
much less common in the United States. P art  of this is the result of Centocor's 
experience with their test for CA 1 5.3, a marker for breast cancer. In 1 99 1 ,  the 
FDA forced Centocor to stop selling this test as a research product in the United 
States and the rest of the world. 
Cancer Diagnostics, supra note 84, at 2. As explained above, the precedent set by 
OncorMed and Myriad is revitalizing this industry. FDA controls on advertising are 
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providers ' decisions to make the technology available may be 
skewed by fears of legal liability, the desire to appear 
knowledgeable about and receptive to health care technology, 
pressure from consumers anned with newspaper and magazine 
stories on genetic discoveries, and care managers who place 
severe limits on physicians' time and pressure to maintain patient 
enrollment. 1 14 
Many of the concerns about the commercialization of genetic 
testing services are familiar and apply to other medical technologies. 
Nevertheless, (I) the fact that research-stage genetic testing available 
to the general public is being conducted by private companies rather 
than by major research institutions, (2) the absence of reliable quality 
controls on in-house testing services, and (3) perceptions and 
uncertainties about the predictive capabilities of genetic testing make 
circumvented when laboratories and biotech companies sell investigatory services rather 
than kits. See supra note 76 and accompanying text. The relationship between providers 
and the entities perfonning these testing services i s  one-on-one enough to be difficult to 
regulate. See Boyle, supra note 13, supp. at SS. Moreover, at least one study has 
challenged the accuracy of the information provided by genetic laboratories and biotech 
companies about their tests. According to Dr. Holtzman' s study, as interpreted b y  one of his 
colleagues who reached preliminary conclusions based upon a sampling of consent forms 
collected, 
several grossly overstate the test's accuracy or represent it in a way that is likely to 
be misleading. For example, some tests for a single gene did not specify that they 
only detected a few of the known mutations and therefore would yield an 
underestimate of the false negative rate. . . . (O]nly  half the materials mentioned 
the availability of genetic counseling to accompany test results. Victoria Odesina 
and Nancy Press questioned whether recipients even understood the information 
they did receive. 
Meeting Minutes, supra note 1 ,  at 2. Some public health officials are also monitoring 
and documenting the marketing efforts of biotech companies. According to one such 
account, "[p]rivate companies are performing sophisticated market research studies in order 
to determine what kinds of new genetic technologies will sell and reap large profits . . . .  
There are numerous reports being issued to generate investment in prenatal genetic tests." 
BLATI, supra note 2 1 .  
1 1 4. .Providers are especially prone to overuse genetic testing technology in the 
prenatal context in states recognizing the common-law doctrines of wrongful birth and 
wrongful life. See generally Belinda L. Kimble, Wrongful Birth: A Practitioner s Guide to 
a New Arrival, 55 ALA. L. REV. 84 ( 1994) (recognizing a cause of action for wrongful 
birth); Malinowski, supra note 21 ,  at 1497- 1 5 1 3  (demonstrating the need for minimum 
bioethics standards); Timothy J. Dawe, Note, Wrongful Life: Time of a "Day in Court" ,  5 1  
OHIO Sr. L.J. 473 ( l  990) (discussing the elements for these causes of action, their 
application, and relevant state statutes, and providing case citations); see also CooK­
DEEGAN, supra note 20, at 243 (addressing this potential problem in the context of cystic 
fibrosis screening); Ellen Wright Clayton, The Dispersion of Genetic Technologies and the 
law, HASTINGS CENTER REP., May-June 1995, supp. at s 1 3- 1 4. 
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these concerns profound enough to stand alone. 1 15 Specifically, lack of 
regulatory quality control and the perceived ability of predictive 
genetic tests to penetrate well into the future despite the absence of 
PPV makes this testing different. Many consumers and providers are 
more in awe of the "miracles of modem genetics" than appreciative of 
its clinical limitations. The demand for predictive genetic testing 
services may reflect this faith in genetic medicine, a tendency to equate 
investigational genetic tests with reliable, standard-care diagnostic 
tests, and the influence of entrepreneurial and academic interests. 1 16 It 
also may reflect intolerance for health conditions that deviate from the 
majority.1 17 
The information generated by predictive genetic tests, regardless 
of its clinical reliability, will deeply impact people's lives. 1 1 8  Some of 
1 1 5. See Silverman, supra note 1 5, supp. at S 1 7  ("While the concerns about 
developing new medical technologies are not unique to DNA diagnostics, genetic analysis 
has the potential for particularly potent impact on society because of its predictive 
capacities."). 
1 16. See BLATT, supra note 21 .  
1 17. Advocates for the disabled who challenge the availability of  genetic testing 
argue that the concept of "disease" is a social construct. See Marsha Saxton, Cost­
Benefit/Cost-Effectiveness Analysis in Genetics, Presentation at the Whitehead Inst. for 
Biomolecular Research (Mar. 30, 1996) (on file with authors). There is concern that 
genetics testing capabilities could result in less tolerance for deviation from the majority, less 
appreciation for life, and a general submission to the prejudices of society. Society could be 
cheated of all that can be learned from those born with disabilities, and genetic testing 
capabilities will reduce the freedom of choice of prospective parents by putting more 
pressure on them to abort. See id. ; see also John Seabrook, All in the Genes, NEW YORKER, 
Feb. 12, 1996, at 80 (reviewing PIIDJP KITCHER, THE LIVES TO COME (1 996)) ("Eugenics is 
to the science of biology what the A-bomb was to physics."); Malinowski, supra note 21 ,  at 
1478-89 (describing how prenatal genetic testing may cause some parents to abort anything 
less than a "perfect" baby). 
1 1 8. See generally Andrews, supra note 22,  at 974-91 (discussing how genetic 
infonnation, including carrier status, may have a multifaceted impact on people's lives). As 
stated by one observer: 
Knowing your genetic makeup can also create profound emotional and 
financial problems. For example, a spouse might use this information in a 
custody dispute. Or a woman might decide not to have children, for fear of 
passing on the gene. But if she decides to adopt, will she be approved by an 
agency? And should a 9-year old girl be tested for the mutation? 
Koenig, supra note 24, at A23. Similarly, another stated: 
The ability to predict late-onset diseases, both common (for example, cancer) and 
unusual (for example, Huntington's) can result in dramatic changes in life-style. 
Premarital genetic analysis can affect the selection of prospective marriage 
partners, or even whether one will choose to marry. Genetic analysis is already 
being used for decisions on childbearing or adoption. And in prenatal genetic 
analysis the prospect of pregnancy termination is confronted directly. 
Silverman, supra note 1 5 ,  supp. at S l  7. 
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those who have opted to undergo the presymptomatic test for 
Huntington's, a clinically valid test that conclusively determines future 
onset, have experienced detrimental psychological reactions to the 
results even when they are negative. 1 19 For those whose results are 
positive, the suicide rate is approximately thirty-five percent higher 
than among the general population. 12° Further, it appears that genetic 
infonnation already is disrupting the lives of individuals and their 
families by subjecting them to discrimination from employers and 
insurers.121 
Although adequate genetic counseling could, perhaps, enable 
people to cope better with genetic information, genetic counseling is 
1 19. See Andrews, supra note 22, at 976; Silverman, supra note 1 5, supp. at S17 
(discussing market influences on genetic testing); Koenig, supra note 24, at  A23; Saltus, 
supra note 106, at 1 4  ("[P]eople who receive good news from a genetic test can be as 
seriously troubled as those who discover the worst."); see also COOK-DEEGAN, supra note 
20, at 235-36 (discussing the experience of Dr. Nancy Wexler, codiscoverer of the allele 
responsible for Huntington's, and her family). Although reliable figures are unavailable, in 
January 1995 it was estimated that several hundred people in the United States and more 
than 500 in Canada had been tested for the genetic predisposition to Huntington's. 
Although the psychological angst condition following testing experienced by those who test 
positive has not yet been adequately researched, it appears to include the following: 
(I)  "[l]ike lottery winners, people who receive the gift of unexpected genetic health face the 
quandary of what to do with it"; (2) the results completely disturb conscious and 
subconscious views of the future which have shaped their lives; (3) though each sibling has 
an equal chance of carrying a parent's genetic susceptibility to Huntington 's, people 
misinterpret their good fortune as their sibling's doom, and vice versa; (4) having lived their 
lives anticipating the worst, individuals may experience an identity crisis and mourn 
opportunities they did not pursue; and (5) all emotional problems blamed on the disease 
now must be dealt with and family members and friends no longer will make special 
allowances. See Saltus, supra note 106, at 14. As stated by one who underwent this testing: 
I don't know who I am or what my goals are . . . . The whole world is open to me 
now. Before, I lived a year at a time; I always had short-range goals. I got my 
associate's degree, then my bachelor's, then a master's, and I switched careers so I 
would be working for an employer where I would have good benefits and be 
protected by federal laws. Now, I don't know what I am going to do-I just know 
that I'm restless. 
Id. To decide whether to take the Huntington's test, Dr. Nancy Wexler asked herself: 
"Would I change my job? No, I love what I ' m  doing. Would I work any less? 
No. Would I work any more? I am not sure I can. Would I be any less frantic 
and obsessional? Probably not. Would it change personal relationships and 
friendships? No. There's an awful lot it wouldn't  change . . . .  I'm already h appy, 
how much happier am I going to be? Part of me realized how happy I am, being 
part of this whole research process that's going to make a difference in the future." 
COOK-DEEGAN, supra note 20, at 236. 
1 20. See Communication between Robin J.R. Blatt and Dr. Patricia Murphy), 
(January 1997); see also Andrews, supra note 22, at 976 (stating rate is four times higher). 
1 2 1 .  See Andrews, supra note 20, at 984-9 1 ;  Barash & Alper, supra note 58,  at 43; 
Geller et al., supra note 58, at 72. 
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expensive and not necessarily covered by insurance;1 22 the United 
States does not have enough certified, practicing genetic counselors;123 
and health care providers are not knowledgeable enough about 
genetics to help stretch these limited resources. 124 Because of poor 
insurance coverage, costs for investigatory genetic testing are likely to 
be paid out of the pockets of consumers, and adequate counseling 
could increase the costs of testing tenfold. 125 But without mandatory 
provisions for pre- and post-genetic counseling, the United States is in 
danger of repeating its sickle-cell screening mistake, multiplied for a 
whole spectrum of conditions. 126 
Moreover, absent a legal infrastructure to comprehensively 
protect the public from discrimination by insurers, people may be 
paying out of their pockets for tests to generate genetic inf orrnation 
that gets into their medical records and damages their insurability. 127 
122. Even when counseling is covered, the time constraints placed on genetic 
counselors under managed care may be responsible for the profession's high rate of burnout. 
1 23. See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 ,  at 4 ('The number of 
medical geneticists and genetic counselors to whom patients can be referred is likely to 
remain too small to cope with the potential volume of testing."). At the present time, the 
National Society of Genetic Counselors has an enrollment of only 1 ,450 members. See 
McCormack, supra note 1 8, at 3. Note, however, that some biotech companies are 
employing counselors to act as a resource for providers. For example, Genzyme Genetics, 
which has 1 6  testing labs across the country, employs three counselors. See id. 
124. See supra note 1 1 0  and accompanying text. 
1 25. See Michael J. Malinowski , Capitation, Advances in Medical Technology, and 
the Advent of a New Era in Medical Ethics, 22 AM. J.L. & MED. 335, 35 1 & n. 1 06 ( 1996). 
126. The United States's sick.le cell screening program was launched in the early 
1970s with good intentions and lots of shortsightedness: 
[ G]enetic counseling of the individuals tested, and restrictions on the use of 
the genetic information obtained from the tests, were not made priorities. As a 
result, the screening generated confusion and anxiety among the population. 
Many identified as carriers of sickle cell mistakenly thought they were afflicted 
with the disease. Often, confidentiality was breached, and in some instances, 
carriers, not actually possessing the disease, were denied health insurance. In 
addition, because no prenatal test was available, some carriers were told the only 
prevention for the disease was to avoid having children. 
Brom, supra note 27, at 1 29 (footnotes omitted). 
127. The EEOC has issued a comment in its Enforcement Manual that prohibits 
employers from discriminating on the basis of genetic information. See EEOC COMPLIANCE 
MANUAL § 902.8 ( 1 995); see also infra note 263. President Clinton recently signed into law 
legislation that includes a prohibition against denying a person, previously insured, coverage 
on the basis of genetic information during a change in insurance. See Health Insurance 
Portability and Accountability Act, Pub. L. No. I 04-191 ,  1 10 Stat. 1 936 (1996) 
(nonetheless, not protecting those presently without insurance against genetic discrimination 
and denial of coverage based upon preexisting conditions); see also Senate Passes Bill on 
Portable Health Insurance, BOSTON GLOBE, Aug. 3 ,  1 996, at A4. Moreover, approximately 
1 1  states have enacted protective legislation, and there presently is a flurry of activity at the 
state level. See Neil A. Lewis, 2 Marines Who Refused to Comply with Genetic-Testing 
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Investigatory predictive genetic tests also may endanger the physical 
health of patients by creating the possibility of over-treatment. 128 The 
Order Face a Court-Martial, N.Y. TIMES, Apr. 13, 1996, at 7 (reporting that "[o]nly 1 1  
states forbid discrimination based on a person's genetic makeup" and mentioning that bills 
are pending in 20 other states). Nevertheless, the danger of genetic discrimination is 
expanding with the generation of genetic infonnation from the availability of genetic testing. 
See Genetic Screening by Insurance Carriers, 267 JAMA 1 207, 1207-09 (1992) ("Insurers 
may apply genetic information inappropriately. Individual risk will be overestimated if the 
concepts of penetrance and variable expressivity are not considered."); Susan O' Hara, 
Comment, The Use of Genetic Testing in the Health Insurance Industry: The C reation of a 
"Biologic Underclass ", 22 Sw. U. L. REV. 12 1 1 ,  1 219-24 ( 1993) (exploring the potential 
for discrimination by the health insurance industry arising from genetic testing); Geneticist 
Calls for Privacy in Test Results , BOSTON GLOBE, Sept. 30, 1995, at 3 ("One study found 
1 00  people who were denied insurance benefits because of genetic risks, and a survey of 
families with inherited diseases found 31 percent had been denied coverage even if they 
weren't actually ill . . . .  "); Koenig, supra note 24. 
In April 1996, representatives of the insurance industry stated publicly at a meeting of 
the National Task Force on Genetic Testing that they "would go out of business if they were 
restricted from having access to genetic information." Weiss, supra note 2. According to 
some accounts, 'Though insurance industry representatives often state that their companies 
are not likely to use genetic screening now or in the foreseeable future, they demand access 
to this information concerning their applicants if it is available at professionals' offices, 
employment settings, or governmental agencies." O'Hara, supra, at 1220. The insurance 
industry already has organized to maximize its access to underwriting i nformation. 
"Currently, seven hundred insurance companies have formed an organization called the 
Medical Information Bureau (MIB), sharing information about policy holders in an effort to 
prevent concealment of underwriting information." Id. at 122 1 .  Insurance companies may 
already be demanding genetic testing. See generally Geller et al., supra note 58, at 72 
(discussing reports of genetic discrimination); Lee Bowman, Genetic Inheritance Seen as 
Privacy Issue, WASH. TIMES, Apr. 15, 1996, at A 10 (According to Dr. Paul Billings of 
Stanford Medical School, co-author of a study on genetic discrimination, 
[m]ore than 900 people known to have a genetic predisposition for certain 
diseases but without any symptoms themselves said they had experienced some 
form of discrimin ation on the job or from insurers, according to the study . . . .  
Many more people also have been denied life or health insurance for refusing to 
submit tissue for genetic testing . . . .  
One response is to flatly exclude genetic information from the insurance process, see 
Genetic Screening by Insurance Carriers, supra, at 1 207-08, a position supported by the 
biotechnology industry. See Lisa Piercey, Kennedy Alleges HIAA Seeks to Undennine 
Genetic "Nondiscrimination " Provision, B10WORLD TODAY, May 15, 1996, at I .  The 
industry perceives fear of genetic discrimination as an impediment to consumption.  See id. 
Such an approach is prudent in the context of health insurance for predictive conditions. We 
all carry genetic predispositions for disease and, i n  light of the frequency of which 
individuals change jobs and health insurance coverage, the genetic predisposition factor is  
"a wash" for all practical purposes. However, such an approach in the context of l ife and 
disability policies (life-long contracts) could price those policies off of the market due to the 
problem of adverse selection-individuals with genetic information may use it to "cheat" the 
health insurance market by buying added coverage. Genetic Screening by Insurance 
Carriers , supra, at 1 208. 
128. The importance of specificity (this term is defined at supra note 25) in the 
context of genetic screening tests for cancers is underscored by the fact that the human body 
can be thought of as "one giant precancer": 
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United Kingdom has explored the impact of predictive genetic testing 
information on the lives of children and concluded that children should 
not have genetic diagnoses for late-onset disorders. 129 
The precedent set by IVF, Myriad, and OncorMed could carry 
significant implications for the commercialization of predictive genetic 
testing services, including widespread commercialization of 
investigatory genetic testing services. The BRCA testing services 
offered by these companies may shape standards used to evaluate this 
technology. If a test has no predecessor, it becomes the governing 
standard; the most definitive method or test in existence becomes the 
"gold standard" against which analytical validation is measured. 1 30 
The availability of BRCA testing services should enable IVF, 
Myriad, OncorMed, and their research allies to compile enough 
clinical data to determine predictability in a greatly accelerated 
fashion. These advantages will pressure other biotechnology 
companies to make genetic testing available to the public. All of the 
related science, including sequencing, could be pushed forward, 
thereby making more therapeutics and treatments a viable possibility. 
Although such benefits to public health may be considerable, the 
financial and emotional costs to those who undergo predictive genetic 
As it turns out, virtually all of us have precancerous lesions in our bodies. 
Autopsy studies of women who died of something other than cancer reveal that 39 
percent of women between the ages of 40 and 50 have hidden precancer lesions in 
their breasts-but only 1 percent of women in this age group are clinically 
diagnosed with breast cancer. Likewise, more than 40 percent of men between 60 
and 70 have cellular evidence of prostate cancer that can be found when their 
tissue is scrutinized under a microscope, though only 1 percent are actually 
diagnosed with the disease. 
Madeline Drexler, Malignant Predictions, BOSTON GLOBE, Feb. 18, 1 996, (Magazine), at 9. 
1 29. This conclusion was reached by the Science and Technology Committee of the 
House of Commons and the U.K. Working Party of the Clinical Genetics Society. See 
Mclean, supra note 1 9, at 1 20 (discussing recent report of the U.K. Working Party of the 
Clinical Genetics Society) (citing 1 SCIENCE AND TECHNOLOGY CoMMTITEE, supra note 50, 
at xxxviii). The findings of these entities have been summarized as follows: 
Id. 
Where the diagnosis has no direct impact on the health of the child, they suggest 
that testing, and knowledge of test results, have a number of negative 
implications. For example, they may lead to the loss of self-esteem, affect the way 
in which the child is treated in the family or the wider community, prevent a later 
exercise of autonomy by taking the decision about testing out of the hands of the 
potential adult, and breach current U.K. policies on the need for counseling before 
or in the tandem with screening. 
1 30. See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 ,  at 4-6. 
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testing during the interim will be significant. At what point does this 
cost become too high? 
The four cornerstone principles of health care are "autonomy, 
beneficence, nonmalfeasance, and justice or equity."131  These are 
inherently individualized concepts, meaning that they lead providers to 
"focus on the specific patient to the exclusion of other actual or 
potential patients."132 Applying these principles to widespread 
investigatory, predictive genetic testing raises many questions. One of 
the most fundamental is, what should patients be told before they 
decide to undergo such testing? The danger is that the answer to this 
question is left to the provider and to the protocol established by the 
test's developer, who has every incentive to encourage use to gather 
both patient data and revenue to cover the costs of research. 
The following is a more comprehensive analysis ·  of the 
commercialization of testing services for BRCA mutations linked to 
breast and ovarian cancers. First, the prevalence of breast cancer and 
the approaches taken by the companies marketing these tests are 
addressed in more detail. Next, the regulatory and general health­
policy implications of BRCA testing services are explored through the 
technique of legal storytelling, which is applied to identify important 
public health issues ("issue spot"). The varying stories presented 
embody the perspectives-cancer survivor, genetic counselor, health 
consumer advocate, and corporate representative-of individuals with 
personal experiences dealing with breast cancer, BRCA genetic 
testing, and the R&D, marketing, and regulation of medical products. 
ill. THE SEMINAL CASE: BRCA TEsTING SERVICES 
As stated by Dr. Francis Collins, head of the HGP, "[b ] reast 
cancer is the most common cancer among women in the Western 
world, with a cumulative lifetime risk of 1 in 8."133 This year alone, 
1 84,300 women will be diagnosed as having breast cancer. 134 Some 
1 3 1 .  Mclean, supra note 1 9, at 1 17. 
1 32. Id. ; see also Malinowski, supra note 1 25, at 334-47 (discussing the 
deontological tradition of medical ethics). 
133. Collins, supra note 2, at 186; see also Hon Fong Louie Mark et al., Clinical and 
Research Issues in Breast Cancer Genetics, 26 ANNALS CLINICAL & LABORATORY SCI. 396, 
396 (1996) ("Breast Cancer is the most common form of cancer in women in the U.S."). 
1 34. See From the CDC: Breast Cancer Incidence and Mortality-United States, 276 
JAMA 1293, 1 293-94 (1 996) [hereinafter Breast Cancer Incidence] ;  David Plotkin, Good 
News and Bad News About Breast Cancer, ATLANTIC MONTHLY, June 1996, at 53, 55-58 
(relying upon data provided by the American Cancer Society); see also Dolores Kong, 
Mammogram Wars, BOSTON GLOBE, May 27, 1996, at 34 (stating that, overall, 1 80,000 
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44,300 women will die from the disease. 135 Of the women in whom 
cancer is diagnosed, 9 ,200 will not have reached their fortieth birthday, 
nearly twice the number of women under forty who were found to 
have breast cancer in 1970, 136 and another 33,000 will be in their 
forties.137 Breast cancer "is now the leading cause of death for 
American women aged forty to fifty-five, and causes women to lose 
more years of productive life than any other disease."138 
BRCA testing is available through three schemes, two of which 
reflect the labeling options under present regulations. 1 39 The third 
entails direct marketing without FDA oversight and restrictions: 
For research use only and not for use in diagnostic procedures. 
NIH is conducting a BRCA testing study in the Washin�on-Baltimore 
area that involves 5,000 Ashkenazi Jewish volunteers. 1 Pursuant to 
this labeling, 141 those participating in the study are not given their test 
results. 142 
For investigational use only. OncorMed has labeled its genetic 
testing service accordingly. To comply with the accompanying federal 
restrictions: ( 1 )  women must be referred for counseling before and 
after the test is performed; (2) results must be given by the physician in 
person; (3) the physician must follow up with the patient about three 
months later; (4) the test developer must compile data on an ongoing 
basis to determine which aspects of the gene-testing process need 
cases of breast cancer are diagnosed in the United States each year); Richard Saltus, Breast 
Cancer Testing: Do You Want to Know?, BOSTON GLOBE, Mar. 1 1 ,  1996, at 25 ("Each year, 
about 185,000 new cases (4,600 in Massachusetts), and 44,000 deaths are reported."). For 
more information, contact the National Cancer Institute, Cancer Information Service, 9000 
Rockville Pike, EPN 300, Bethesda, MD 20892. The Institute may be reached by telephone 
at (800) 4-CANCER (422-6237). 
135. See Plotkin,  supra note 1 34, at 55, 58 (relying upon data provided by the 
American Cancer Society); see also Kong, supra note 1 34, at 34; Saltus, supra note 134, at 
25. 
136. See Plotkin, supra note 134, at 55, 5 8 .  The significance of these numbers is 
underscored by the fact that malignancy generally grows faster in younger women. Kong, 
supra note 134, at 34. Despite advances in detection through mammography, surgical 
technique, radiation therapy, and chemotherapy, these advances have not lessened the 
likelihood that women will die of breast cancer. See Plotkin, supra note 1 34, at 76. "In 
1935, 26.2 out of every 1 00,000 women died of breast cancer . . . .  In 1 992, the latest year 
for which figures are available, the adjusted rate of mortality was 26.2 women per 
1 00,000--the same as 1 935." Id. 
1 37. See Kong, supra note 134, at 34. 
138. Plotkin, supra note 134, at 58. 
1 39. See supra note 64. 
1 40. The recruitment target of 5,000 volunteers was surpassed in just two months. 
See Wadman, supra note 5. 
141 .  See supra note 64 (addressing "research" labeling). 
142. See Wadman, supra note 5, at C3; Weiss, supra note 2, at A l .  
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improvement� and (5) the developer only may charge an amount 
necessary to recapture the costs incurred for the stated research 
objective. 143 Many of these restrictions were developed through an 
IRB assembled by OncorMed. The IRB was staffed with experts paid 
consulting fees 1 44 to develop a protocol for investigational marketing in 
compliance with CLIA. 145 The sum effect of the work of OncorMed's 
IRB is that physicians are given a well-developed protocol for their 
interactions with patients regarding the test, and they are instructed to 
make the testing service available only to patients with breast cancer or 
at a high risk of getting the disease. 146 The costs charged for the test 
fluctuate significantly according to the stated research objective and 
the testing undertaken. If the company is attempting to locate a 
specific mutation, the cost may be as low as $150; if the data is used 
for sequencing, that cost may reach $1 ,650. 147 
Independent of FDA Regulations. A BRCA test also is being made 
available entirely independent of FDA oversight by IVF Institute. IVF 
Institute offers its BRCA test and the results to any woman willing to 
pay $295 .148 Similarly, two of Canada's most respected universities­
McGill University and the University of Toronto-are offering open 
access to BRCA testing. 149 
143. See Weiss, supra note 2, at A2. OncorMed continues to revisit and revise its 
protocol. As of January 1997, OncorMed also requires physicians to call in or fax patients' 
family histories to the company before testing. See OncorMed, Hereditary Breast Cancer 
Education and Testing Packet (Jan. 15, 1997). 
144. See First BRCAJ Test Hits the Market, supra note 65, at 1-5. 
145. See id. at 3-5. A summary of the OncorMed protocol is attached as Appendix I. 
146. OncorMed is instructing physicians that its BRCA test is available only to 
certain at-risk patients. See App. I. 
147. See id. OncorMed offers testing in stages I to III for BRCAI alterations and 
stages I and II for BRCA2 mutations. Each stage tests for different BRCA alterations and 
carries a separate cost-from $420 for a Stage I BRCA 1 test to $800 for a Stage III BRCA 1 
test, and $800 for a Stage II BRCAI and BRCA2 multiplex test (the tests are done together). 
See Hereditary Breast Cancer: Questions and Answers for Patients 3, in OncorMed, supra 
note 143 .  
148. See Wadman, supra note 5 ,  at C3 (discussing a genetic test for breast and 
ovarian cancer); Weiss, supra note 2, at A2. Dr. Schulman, who is working in  conjunction 
with IVF Institute, is making the test available to all Jewish women who have been referred 
by a physician. See Wadman, supra note 5, at C3. One of Dr. Schulman's first clients was 
his wife, who underwent the test at the age of 38, tested positive and had both of her breasts 
removed. See id. 
149. See Wadman, supra note 5, at C3 ("In last week's New England Journal of 
Medicine, they report that they are offering on-demand testing for the Jewish mutation."); 
David S. Rosenblatt et al., Genetic Screening for Breast Cancer, 334 NEW ENG. J. MED. 
1 199, 1199-1200 (1996) (testing for 185delAG is being offered at the University of Toronto 
and McGill University). 
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Although the occurrence of breast cancer is epidemic, 1 50 the fear 
of breast cancer and the potential market for genetic testing services is 
exponentially larger.15 1  Even according to Myriad's own marketing 
materials, current data suggests that, of all the women with breast or 
ovarian cancer, only approximately five percent carry a BRCAl 
mutation.152 Of the approximately 1 85,000 people diagnosed with 
breast cancer annually, only five to ten percent inherit the disease.153 
Nevertheless, OncorMed, IVF, and Myriad envision multimillion­
dollar markets for their BRCA tests, and their expectations are well 
grounded. The market for cancer diagnostics is big business, that 
business is growing quickly, 154 and "surveys of women have revealed 
150. See AMERICAN CANCER SOCIETY, CANCER FACTS AND FIGURES ( 1995). Women 
in the United States have an estimated 1 0% lifetime risk of getting the disease, and the 
median onset age is 64. 
1 5 1 .  See Koenig, supra note 24, at A23 (after the discovery that l % of Ashkenazi 
Jewish women carry genetic predisposition to breast and ovarian cancer, "a surgeon who 
operates on women with breast cancer told me that a day rarely passes when a patient does 
not ask about 'the gene test"'); Weiss, supra note 2, at Al ("Most important, many women 
seem not to realize that it is only if a woman has a clear family history of breast cancer­
usually identified as two or more close relatives with the disease-that the BRCAI mutation 
confers 85% odds of getting breast cancer."). But see Alison Bass, Ethnicity Called Factor 
in Patients' Decisions, BOSTON GLOBE, Sept. 14, 1995, at 3 ("For example, a majority of 
elderly people of Korean and Mexican descent would prefer not to be told that they suffer 
from metastatic cancer, while European-Americans and African-Americans would rather 
know the bad news, the study of 800 nursing home residents found."); Saltus, supra note 
106, at 14 ("Before the HD test became available, people who were at risk showed strong 
interest in a predictive test. But when the test appeared, fewer people than expected actually 
stepped forward."). 
152. See MYRIAD LABORATORIES, INC., supra note 7, at 2; Saltus, supra note 134, at 
25 (stating that inherited mutant genes probably account for 5 to I 0 percent of breast cancer 
cases, but this inherited type "seems to be more aggressive; it may also appear earlier than in 
noninherited cases, sometimes when the woman i s  in her 20s or 30s"). "About I in 200 
women in the United States are thought to carry a mutant BRCAI gene. BRCAI accounts 
for about 50 percent of inherited breast cancers, BRCA2, may cause 35 percent, and the 
remainder are due to undiscovered genes." Id. 
153. See The Scientific Questions, supra note 4, at 4 (stating that it is estimated that 
10% of breast cancers are due to gennline mutations); Hilzenrath, supra note 4, at D24 
(discussing a news service to detect predisposition to breast and ovarian cancer); Saltus, 
supra note 2, at A18 .  
154. "Today, the cancer diagnostic business alone i s  a $1 billion industry attracting 
some major corporate players and small companies," and the demand for more reliable ways 
of detecting and monitoring cancer is growing with an aging American population. See 
Rosenberg, supra note 15 ,  at 80. As stated by a market analyst: 
Genetic tests for susceptibility to cancer are a hot area currently, as there 
have been many announcements of the discovery of genes which predispose some 
people to specific types of cancer. While genetic tests are done using blood, they 
are more expensive and difficult than traditional blood tests. Myriad Genetics, 
one of the genomic companies, has made a decision to enter this business. They 
are one of the discoveries of the BRCAI gene, which identifies one form of the 
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an overwhelming interest in being tested to learn their gene status."155 
As stated by the National Cancer Coalition, "ready or not, genetic tests 
are on the threshold of entering everyday practice of medicine."156 
A. Meaningfu,l Assessment of the Commercialization of BRCA 
Testing Services 
Understanding the full implications of commercialization of 
predictive BRCA testing services is a necessary prerequisite for 
defining resulting health-policy issues and constructing a regulatory 
response that maximizes public health benefits. Especially in light of 
the novelty of this technology, there must be meaningful assessment­
in other words, appreciation of innumerable issues and perspectives, 
many of them contradictory. The potential impact of such law on 
individual lives, society in general, and the commercial sector 
responsible for producing health care technology mandates such an 
approach. 
"Legal storytelling" has been defined by some scholars as a 
license to describe personal experiences without the constraints of 
traditional legal scholarship, which include an objective tone, 
extensive footnoting, and reliance upon empirical research.157 
Extremists contend that only those excluded by the legal academy, 
hereditary risk of breast cancer. OncorMed is a genetic testing company which 
also sees an opportunity in cancer testing, and is acquiring diagnostic rights to 
discoveries made by others. Additional cancer genes will be discovered over the 
next few years, but the acceptance of such tests will be controversial. Unless the 
patient will gain some benefit from the knowledge, there is no justification for an 
expensive test. In some cases, the knowledge that a patient has a high risk of 
cancer could be devastating. 
Cancer Diagnostics, supra note 84, at 3. 
155.  Saltus, supra note 1 34, at 25. 
1 56. First BRCAJ Test Hits the Market, supra note 65, at 4. 
1 57. See Arthur Austin, Evaluating Storytelling as a Type of Nontraditional 
Scholarship, 74 NEB. L. REv. 479, 485-88, 521 (1995) (stating that feminists and members 
of the racial critique theory movement profess to speak in a different voice derived from 
their gender and race experiences, and that they make no pretense of balance or objectivity); 
Mary I. Coombs, Outsider Scholarship: The lAw Review Stories, 63 U. COLO. L. REV. 683, 
685 (l  992) (discussing the rejection of dispassionate objectivity in favor of narrative 
discourse). For a general and thoughtful discussion of the deontological aspect of the legal 
storytelling technique, see Toni M. Massaro, Empathy, Legal Storytelling, and the Rule of 
lAw: New Words, Old Wounds?, 87 MICH. L. REV. 2099 ( 1989). See also Anne M .  
Coughlin, Regulating the Self: Autobiographical Perfonnances in Outsider Scholarship, 8 1  
VA. L. REV. 1229, 1 23 1  ( 1995) (applying autobiographical narrative to legal discourse); 
Angela P. Harris, Foreword: The Jurisprudence of Reconstruction, 82 CAL. L. REV. 741 , 
750-54 (1 994) (discussing how critical race theory utilizes modem narratives in its 
optimistic moments). 
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such as people of color and women, have stories to tell . 158 They also 
argue that reversion to elements of traditional scholarship, such as 
extensive footnoting, weakens resulting scholarship.159 Critics of this 
genre of legal storytelling (the extremist perimeter of "outsider 
jurisprudence"160) dismiss such scholarship as anecdotal self­
absorption. 161 Many pages have been consumed debating whether this 
scholarship is more or less "real" and meaningful than its more 
traditional counterparts.162 
In this Article, the technique of legal storytelling is used to 
complement traditional-style scholarship. Absent the extensive 
clinical data necessary to comprehensively evaluate the impact of 
genetic testing capability on the lives of those who undergo it, legal 
storytelling is a technique used to thoughtfully assess both the need for 
and the potential impact of changes in regulatory law. These stories 
are offered to illustrate the practical effects of the commercialization of 
predictive genetic testing services. The objective is to engage in legal 
analysis that is more responsive to the underlying facts and, therefore, 
more intellectually rigorous and meaningful. Accordingly, rather than 
a substitute for comprehensive empirical data and with full recognition 
that its utility is l imited by the perspectives of the stories presented, the 
158. See Austin, supra note 157, at 487 (stating that both feminists and Racial 
Critique Theory people "claim to get special insights from status as victims or outsiders"). 
1 59. See id. at 5 2 1  ('The presence of footnotes should not distract from the plot or 
create static in the flow of the narrative."). 
160. See Mari J. Matsuda, looking to the Bottom: Critical Legal Studies and 
Reparations, 22 HARV. C.R.-C.L. L. REV. 323,  325 (1 987) (recommending a "new 
epistemological source for critical scholars: the actual experience, history, culture, and 
intellectual tradition of people of color in America"); Deborah L. Rhode, Feminist Critical 
Theories, 42 STAN. L. REV. 6 17, 622 ( 1990) (discussing the experience of women's actual 
circumstances, such as being dominated, as a way of understanding feminism). The 
"outsider" group "encompass[ es] various outgroups, including women, people of color, poor 
people, gays and lesbians, indigenous Americans, and other oppressed people who have 
suffered historical under-representation and silencing in the law schools." Mari Matsuda, 
Affinnative Action and Legal Knowledge: Planting Seeds in Plowed-Up Ground, 1 1  HARV. 
WOMEN's L.J. 1 ,  1 n.2 ( 1988). 
1 6 1 .  See Austin, supra note 157, at 49 1 ("Serious scholars revere analysis and 
objectivity. To them, subjective advocacy posturing is best left to the National Enquirer. 
Bias is a form of fraud." (footnote omitted)); see also Daniel A Farber & Suzanna Sherry, 
Telling Stories Out of School: An Essay on Legal Narratives, 45 STAN. L. REV. 807, 853-54 
( 1 993) (discussing the importance of reason and analysis in legal scholarship). 
162. See, e.g., Kathryn Abrams, Hearing the Call of Stories, 79 CAL. L. REV. 97 1,  
1021-27 (199 1 ); Austin, supra note 157, at 523-27; Richard Delgado, On Telling Stories in 
School: A Reply to Farber and Sherry, 46 V AND. L. REV. 665, 668-75 ( 1993); Farber & 
Sherry, supra note 1 6 1 ,  at 832-38; Daniel J. Solove, Book Note, Fictions About Fictions, 
105 YALE L.J. 1 439, 1 439-40 (1996) (reviewing L.H. LARUE, CONSTITU TIONAL LAW AS 
FICTION: NARRATIVE IN THE RHETORJC OF AtrrHORITY ( 1995)). 
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technique of legal storytelling is used as a means to illustrate 
underlying facts, identify issues, and analyze public health 
implications and regulatory considerations.163 
B. Some Stories 
The effectiveness of the legal storytelling technique is dependent 
upon the selection of stories and the manner in which they are 
presented. The following narratives are in the words of the subjects 
who relayed them. They illustrate many of the patient, provider, and 
regulatory issues identified above in more objective prose. Varying 
perspectives, both complementary and contradictory, are juxtaposed to 
stimulate issue identification. 
Many prospective subjects were considered, and representative 
subjects were selected. Interviews with these subjects were 
audiotaped, transcribed, edited, reviewed by the subjects for accuracy, 
and revised accordingly. In content, we have selected perspectives 
resulting from first-hand experience with the issue of BRCA genetic 
testing. We also have selected arguably contradictory perspectives, 
such as those of a consumer advocate and a corporate executive from 
the biotechnology industry. The overall objective was to solicit 
opinions, based upon personal and professional experiences, on the 
adequacy or inadequacy of the existing regulatory scheme for 
predictive genetic testing, with a particular focus on BRCA testing 
services. 
1 .  A Cancer Survivor's Story164 
In January 1 993, at age forty-eight, I was diagnosed with breast 
cancer. I had a routine mammogram that had a density on it. A six­
month follow-up visit was recommended. I elected to ask for a second 
opinion because I was on honnone replacement therapy, and I knew 
that this therapy could potentially affect the growth of a tumor if one 
was there. I went ahead and had a biopsy, and it was positive. So I 
had a lumpectomy, auxiliary dissection, and radiation therapy. 
Meanwhile, a decision was made to biopsy the other side. I had some 
163. The use of legal storytelling in this Article parallels the storytelling of outsiders. 
See Austin, supra note 1 57, at 505 ("Descriptions by people like Derrick Bell, Richard 
Delgado, and Patricia Williams convey the common theme that stories raise consciousness 
and serve as a vehicle to educate insiders." (footnotes omitted)). 
164. This story is based upon an interview with a breast and colon cancer survivor 
who also is a health care professional. 
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calcifications which normally wouldn't be of concern but, because I 
had a primary tumor on the left, a biopsy of my right breast was 
suggested. In fact, I had a precancer on that side. This was treated 
with a wide excision. Seven weeks after I finished radiation, I had a 
colonoscopy and was diagnosed with advanced colon cancer. I had 
four positive lymph nodes, so I went on to do a year of chemotherapy 
after that. 
I have a very strong history of cancer on my father's side of the 
family. My father, aunt, uncle, and grandfather had multiple cancers. I 
have three first cousins who have had cancer, and my brother also has 
had two primaries. Having grown up with cancer in my family, I have 
always thought about what's at work in our genetic background. I 
guess it was always an expectation that some day, eventually, I would 
probably get cancer. I just never thought I'd get it as young as I did. I 
certainly never thought I would get two at once. You do think about 
this when you grow up and are surrounded by it. In a way, it gives you 
a chance to sort things through and ask yourself, "What would I do if 
this type of scenario happens to me?" 
One of the reasons I remain optimistic despite the likelihood of 
my having a genetic predisposition is that I believe we are more than 
our genetic inheritance-lifestyle, diet, and environment all come into 
play in varying degrees . If you looked at my family pedigree, you 
would see that all the family members who had cancer lived in or near 
a paper mill town. Those who lived on the coast were cancer-free. 
There are also large quartz deposits and, consequently, high radon 
levels in the paper mill area . . . another carcinogen, along with the 
dioxin and other byproducts of the paper-making process. So I guess I 
believe that the bottom-line isn't in yet and that, while genetics are 
important, there is more to the story. 
I had really never thought to myself, "I wish there were a genetic 
test available so I could find out whether I' m going to get cancer." But 
I will say that, back in 1989, I became much more aware of genetic 
testing. I remember saying to my colleagues, "You know this is what 
my family history looks like . . . don't you think this is a lot of 
cancer?" 
Since my breast cancer diagnosis, I have thought about whether I 
would want BRCA 1 testing-if I would want to know whether I carry 
the alterations in the gene linked to cancer. I don't know that I would 
want to be tested for BRCAl,  and the reason is that my daughter is 
twenty-five and my son is twenty-four. As far as I'm concerned, for 
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me personally, the die is cast. I've had cancer twice. This is clearly 
my heritage. I know I could possibly have it again. I am probably also 
at elevated risk for both ovarian and uterine cancer. But I don't know 
what I would gain if I found out I have an altered BRCA I gene 
because I know I would not have a prophylactic mastectomy. I've had 
my children, and I don't know that my daughter would gain anything 
by knowing either. Her awareness i s  already heightened. She will 
certainly go through pretty rigorous surveillance, seeing the doctor 
frequently for breast exams, and there's not a lot else she can do in 
terms of prevention. 
Both my kids have asked whether it's possible that they have 
inherited a gene for cancer. We talk about it a lot. We tend to discuss 
the colon cancer more than the breast cancer. We have talked about it 
and, again, I think BRCAI for my family is probably not as big an 
issue as the colon cancer gene. I do think I would feel differently 
about genetic testing for the colon cancer gene for several reasons. If I 
do have that particular gene, I would then have the option to think 
about taking an action-such as having a hysterectomy. If I actually 
had the gene, once again, I don't know that anybody can put numbers 
on this, but I would be at elevated risk for ovarian and uterine cancers. 
So for me, personally, that would be something I could do with that 
infonnation. I can't think of anything I could do with the breast cancer 
infonnation that would be any different from what I'm doing now. 
I think risk is a lot like beauty. It is in the eyes of the beholder. 
Perhaps because I've grown up in a family with various, multiple 
cancers, and my family members have dealt with it and gotten on with 
their lives, my perception of risk is maybe a little different than 
someone else's might be. I don't know that I could say how I would 
feel if I had a strong family history of breast cancer. If my mom or 
sister had breast cancer, I suspect I' d feel a lot more threatened than I 
do now. I would probably also feel more threatened in terms of my 
daughter. In my opinion, undergoing this type of testing is a very 
personal decision. 
I think the whole area of predictive genetic testing is something 
that we need to address, because we're going to have a lot more genes 
coming down the pike. There are going to be many people who are 
going to be affected by earlier diagnosis, and all these discoveries that 
are coming . . .  it just means that there are that many more people at 
risk who are going to face these issues and be anxious. I also think 
one of the unfortunate down sides of genetic testing is that, for the 
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average person, it is extremely difficult to sort out where you fit into 
. this picture . . . if you fit in at all. While there are high-risk cancer 
clinics at some major teaching hospitals and research institutions, not 
everybody has access to these kinds of services. Not everybody lives 
in a metropolitan area. 
It's interesting that, although the BRCAl testing is still relatively 
new, independent labs are giving out results. I think it's potentially 
dangerous to offer predictive genetic tests without stringent quality 
control and regulation. Giving out results that aren't accurate isn't the 
whole problem. Based on my experience working with researchers 
who are extremely careful, even when they set up programs with many 
safeguards, the issues that arise for people are still traumatic. This type 
of genetic testing is not something to be taken lightly. My personal 
bias is that this kind of testing must be set up by the medical 
profession, ordered by the medical profession, and that members of the 
medical profession should be the ones responsible for giving out the 
results-not independent labs or companies developing the tests. I 
mean, if you go to your physician and you have your annual physical 
exam, and you have a chest x-ray or a blood test, the lab doesn't call 
you and give you your results. I really feel that there should be the 
same kind of oversight and development of medical standards for 
genetic tests that there are for other types of medical tests, perhaps 
even more so. A lab shouldn't  be doing genetic testing if it hasn't 
gone through an approval process for that particular test. 
There are so many things that one needs to know before 
undergoing genetic testing. I think one of the biggest challenges of the 
genetic revolution is the dissemination of infonnation and education of 
both the primary care providers and the patients themselves. It's very 
tough to sort out all this infonnation. I think it has created a great deal 
of concern and a lot of anguish for women who probably aren't even at 
risk for the inherited fonn of breast cancer. Women almost always 
overestimate their risk. 
From a cancer patient's perspective, what I believe is most 
needed for an individual prior to this type of genetic testing is time, 
especially time for genetic counseling. There also needs to be 
coordinated peer support so that when an individual is diagnosed with 
cancer, no matter what type it is, they can, through their physician, 
nurse, or social worker, say, "I would really like to speak with 
someone who has been through this decision-making process." The 
other issue that concerns me is the point in time that genetic testing is 
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discussed. If it's close to diagnosis, you are concentrating on how you 
are going to get through the surgery, whether you are going to live 
through the treatment, who's going to take care of your kids for five 
days a week during seven weeks of radiation, and what's going to 
happen with your job. That's enough for the average person. There's 
a limit to how much you can deal with at one time. We need to think 
more about when people are mentally ready to hear the information on 
genetic testing and its implications. 
I have spoken with many people with cancer .over the last few 
years. I also have had the advantage, if you want to call it an 
advantage, of not only talking with people and growing up in a family 
with a lot of cancer, but also working in this research area. And even 
having dealt with this every day, the decision to undergo genetic 
testing still takes a lot of thought. You have to know what the 
ramifications of that decision are and, let's face it, there are a lot of 
potential ramifications. How one perceives the risk of the 
ramifications i s  as important as how you perceive your risk of the 
disease. For example, the thought of being without health insurance, 
particularly if you have children, or the thought of being denied 
employment because of something like this is frightening to most 
people, and right now these are very real potential ramifications. 
One of the issues I came up against when I visited my 
gynecologist for my annual exam after I'd been through both 
diagnoses was insurance coverage. We discussed the fact that I might 
be at elevated risk for both uterine and ovarian cancer, and what 
strategy we would take on this. He suggested my having a baseline 
transvaginal ultrasound. I agreed that I would have the baseline 
ultrasound and the other baseline test recommended, which was a 
blood test called CA125. My insurance carrier refused to pay for the 
blood test. Just on general principles, I decided I was going to argue 
about it. So I called my doctor and told him what the insurance 
company said. Essentially, they said it would not affect patient care, 
and that's why they wouldn't cover it. So my doctor wrote a blistering 
letter saying it absolutely would affect patient care, explaining how I 
was at risk and that very positive action would be taken if this value 
was elevated. They covered it but made it clear that they were going to 
pay for this once and only once. Since then, I do go for a visit every 
six months and have a pelvic exam, but I'm not doing routine 
ultrasounds or blood tests. I could do it if I wanted to, and pay for it 
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out of pocket, but I just don't feel that is  something I choose to do right 
now. 
What it boils down to for me is, "Am I going to go and ask for a 
hysterectomy if I have this colon c ancer gene?" I don't know about 
that answer today. I've had a long time to think about this. I know a 
lot, and it's still very difficult for me. So can you imagine the 
confusion for the average person who, out of the blue, develops cancer 
or learns someone in their family has it? Right now, the colon cancer 
gene testing is at a stage where they' re verifying their results to be sure 
that they have completely reproducible results. Results are not yet 
being reported to patients. I have had my blood drawn and provided 
tissue samples as well .  I will be notified when a clinical testing 
program for colon cancer is available, and I will make a decision about 
testing at that time. 
In general, I support all the research taking place on gene 
susceptibility testing. I think that the quality of most of the research is 
good, and those researchers working in the area don't take any of these 
issues lightly. But I do think that this type of testing must initially take 
place in a research setting, to see what the ramifications are, to work 
out the kinks, before opening it up to the general public. It will be 
interesting to see who hops on this particular bandwagon. I've heard 
about the marketing of predictive genetic testing for breast cancer 
second-han�, and I think that's pretty unconscionable. I know how 
volatile it is for people to think about genetic testing. If it takes place 
outside a setting with a lot of education and counseling, well, I just 
think it's unconscionable to do the test and give out the results. I don't 
know that there will be any way to keep track of what the results and 
the outcome will be. I think that's the other very bad part about 
genetic testing for breast cancer. Are companies going to keep any 
kind of records? Are they going to do any kind of reporting? What 
about doing further testing on samples? Who will have access to the 
test results? Who will be there to help individuals deal with the 
information they receive? There is no doubt that safeguards need to be 
put in place, immediately, before it's too late. 
2. A Genetic Counselor's Story165 
Our center is involved in a number of clinical research projects to 
offer general predictive genetic testing to anybody in the local area 
165. This source is a genetic counselor at a major medical research institution. 
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who may have a mutation in a cancer susceptibility gene, BRCAl .  
One is a general research protocol that allows us to draw blood on 
anybody who has cancer to look for an inherited factor. We consider it 
a fishing expedition, and it has a pretty low yield. In another program, 
one of our predictive genetic testing programs for breast cancer, we 
only test people who already have a known mutation in their family, so 
we're starting with knowing exactly where in their genome to focus. 
In this program, we use a three-visit model with extensive counseling 
because it is too much to give all of the infonnation necessary in one 
visit. We do not do counseling by phone, so individuals who are out 
of state are referred elsewhere for counseling and testing. We use a 
networked group of counselors that are trained and specialize in cancer 
genetics. 
I'm not aware of any of our researchers having financial ties with 
the laboratories performing BRCA 1 testing. I really do not think there 
are any financial incentives among the researchers within our 
institution. However, since our laboratory does not have CLIA 
approval to perform testing at this time, we have agreements with 
other laboratories that are certified to c onfirm all results independently. 
So everyone who comes to our program has two independent tests 
done on their samples. Two samples of blood are drawn, and one tube 
is immediately sent out to the other laboratory. This offsets concern 
about a coding error or contamination at the beginning of the process. 
In addition, in a separate testing protocol, we have an agreement 
with a specific biotechnology company. They will perform the entire 
sequence of BRCAl free of charge and we will provide the pre- and 
post-counseling. We are one of nine centers with whom this 
laboratory is collaborating on this proj ect. It is with the understanding 
that they will be allowed to use that data to determine the sensitivity 
and specificity of their test assay. Before a lab can offer a test for 
clinical use and charge for it, and before developers can do clinical 
marketing, they have to prove that their analyses reach a level of 
specificity and sensitivity that's acceptable. And so we' re helping 
them do that, basically. This is a time-limited study. Right now, all the 
people who undergo BRCAl testing through our program receive it 
free of charge since it is part of a research protocol. Very soon, the 
commercial labs will be offering testing, and there will be a charge for 
the laboratory costs. 
The women who come to our BRCA 1 program are either 
concerned about getting breast cancer or actually have breast cancer. 
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A lot of those concerned have a family history of the disease. As a 
result of the publicity about BRCAI testing in lay press j ournals or 
. newspaper articles, we have recently received a flurry of phone calls. 
We also have a cancer risk and prevention clinic at our hospital that 
attracts a lot of inquiries. Many of the women who decide to be tested 
do so because this is an area of uncertainty that they've been living 
under. A lot of these women see this as a way of getting control-they 
really want to know, and that's a lot of what it comes down to. We 
also see people for second opinions. 
The majority of patient referrals come from outside providers, 
such as doctors and genetic counselors. Although we have the ability 
to search medical records here at the hospital to find people who might 
be at risk, we don't. In fact, even for people who come into the cancer 
risk and prevention clinic or who are at the hospital, special permission 
is necessary for us to obtain their records. The oncologists at the 
hospital know about us so, if they have a breast cancer patient who 
says, "Yes, my sister also had breast cancer at the age of forty," then 
it's very common that the oncologist will suggest to the patient that 
they contact us. Whether an individual with breast cancer follows 
through on this depends on the person themselves. Some people want 
to talk soon after diagnosis, others really have no interest in doing that 
at that point. 
The people who are eligible for genetic testing are those with 
significant histories of breast or ovarian cancer, meaning that they have 
three or more people in their family with the disease. It is important 
for the family history to include more than one generation and 
premenopausal cases of breast cancer. And they need to have a living 
affected family member that we can test first because, following the 
classic genetic model, we need to start with somebody who we assume 
has the disease. Otherwise, if the results are negative in the healthy 
person you're testing, you don't know if you've even looked at the 
right gene or the right place on the right gene. So we make a very big 
deal about needing to first test somebody who is affected with the 
disease and has had their diagnosis confirmed with medical records. 
The only exception to that now are Jewish women who have 
significant histories of breast or ovarian cancer. For these women, we 
offer testing for the three known mutations without testing an affected 
relative first. Part of what we are currently doing is mutation testing 
for the three common mutations in the BRCA gene that occur within 
the Ashkenazi Jewish population. I am familiar with the controversy 
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surrounding the notion of a "Jewish gene for breast cancer." I think 
that, if there is malice in targeting a racial group, it's very wrong. But I 
don't think that's the case with BRCA 1 .  This is not the first time that 
ethnic backgrounds have been important to think about in genetic 
research. 
What has struck me most in thinking about our predictive testing 
program is that we're starting with people who themselves have had 
cancer . . . they are the entry point into the family. These people 
understand that, really, their daughters and sisters are the ones who 
potentially have the most to benefit from this. These are people who 
have already had their cancer. We began offering testing with the 
assumption that an important reason why people who had the disease 
would want to be tested would be to get the explanation of why they 
got cancer, and that they already would be assuming that they carry an 
altered gene. What we found is that cancer patients we have seen are 
really much more tortured about the possibility of being a gene carrier 
and the possibility that they might in fact have higher chances of 
getting a second cancer. I've talked with several people now that have 
ultimately made the decision not to go forward with testing because 
the idea was so distressing to them that, despite the fact that their sister 
was really pushing them and wanted to know. When this happens, I 
tell the person "Look, you're the one that has to decide because it has 
direct implications for you. It's okay to make the decision that is best 
for you." So this has been eye-opening. BRCAl testing does not 
provide benign information even for somebody who's had cancer. It is 
not an easy decision to make. 
You can appreciate then that getting other family members to 
provide samples for BRCA 1 testing can be complicated. When you 
deal with families, you encounter all kinds of different situations. 
There have been situations where the person in front of you says, 
"There's no way that my aunt with cancer will agree to do this . . . I 
can't even ask her." In this case, you are really stuck. You can't offer 
anything. So there are certain instances where a person is the 
gatekeeper for the family, and, if that person does not want to 
participate at any time, we can't offer anything further. There have 
been other situations where somebody will initially be interested in 
participating but then change her mind. We honor that. There's 
another situation that doesn't come up as often, but it has happened. 
The person sitting in front of you says, "My cousin has had cancer," 
we're put in touch with that person and she becomes very enthusiastic 
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about participating, and then the person you have been directly dealing 
with says, "I don't want to hear any more about this." But, by that 
time, we're already working with other people in the family and will 
continue to work with them. 
Incidentally, we don't tend to see many husbands or fathers 
coming to the counseling sessions with the women considering 
BRCAl testing. We see a lot of friends, sometimes family members, 
but that gets complicated because family members may also be at risk. 
You wonder how much they are acting as a companion and how much 
they are focusing on their own stuff. Mainly, women come by 
themselves. We do encourage women to try to bring somebody when 
the results are given. 
All participants receive a patient information sheet that we've put 
together about the genetic testing program itself and another just about 
the BRCA I gene and what we know about it. Because our program is 
a research program, there are three consent forms: one to enroll in the 
program, a second to have blood drawn and analyzed, and a third to 
receive results. The initial consent form is mailed to patients before 
they come in for their first visit, and they are asked to bring it with 
them. There's a lot of information in the consent form that can be 
looked at beforehand. Women are asked to sign the first consent form 
during the first visit, and then at the end of the first visit we'll show 
them the blood drawing and analysis consent form. They can either 
sign it that day, or they can take it home and think about it. The 
informed consent process is integral to our research. All patients that 
participate in our testing program are told that this is part of a research 
protocol, and that they must sign an informed consent document. 
Much of the same information is reiterated for all three of the 
consent forms. We talk about the implications of results. We talk 
about the fact that, if there is no mutation, the person's risk is  lowered 
down to that of the general population. Having a gene alteration 
would substantially increase the risks of cancer. We also mention the 
pros and cons of testing, including the possible stigmatization of 
knowing that you have an altered gene. fusurance concerns are 
something that are heavily emphasized. We discuss the possible strain 
on family relationships, and we talk about the fact that there is no 
known medical benefit to being tested. 
For some people, there are other definite benefits. It may be that 
the person needs this extra information to put them into gear to have 
surveillance done. People have told us that they think knowing they 
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have an alteration would motivate them to plan better, to take better 
care of themselves. Now we're looking at the outcome in terms of 
behavior. I'm not sure anything changes human behavior, but there are 
people who think it will motivate them. Also, a lot of the women who 
want testing have daughters-that is a big reason for wanting to be 
tested. They say "For myself, I don't really care, but I really am so 
anxious about my daughters. I really want to know for their sake." If 
the woman has the altered gene, then her daughters have the option of 
being tested. If the woman doesn't have it, then her daughters are not 
at risk for inheriting it. 
Providing the results of BRCA 1 testing is one of the most 
difficult aspects of my job. It is very powerful infonnation. There has 
to be a lot of thought put into it beforehand, and a lot of follow-up and 
TLC (tender, loving care) afterwards. Giving the results can really be 
very involved, depending, of course, on the person being tested. For 
some people, it takes twenty minutes. That's all the time they want to 
give us. They just want to go home and let it sink in. Some people are 
very private and, whether they are devastatingly sad or 
overwhelmingly happy, they don't choose to share that with us.  That's 
why there is a third follow-up visit. Other people have a million and 
one questions or they want and need to express their emotions and, for 
them, it can be an hour-and-a-half to a two-hour session. We have set 
up our protocol to call in a couple days after giving the test results. If 
we're really worried, we'll call them that night. If we are not so 
worried, we' ll wait a couple days and then we'll check on them. There 
have been instances where a husband or other companion has come in 
with the woman when it is time to receive results. Some are very 
supportive, others are not as helpful. 
The results are given to the person verbally along with a letter 
that addresses all the things that we mentioned-the implications of 
the results, what it means and doesn't mean, what the concerns are, 
and the letter stresses that they can always contact us again. Even if 
they can't remember what we told them, they have the letter to refer to. 
And I tell them that they can either throw it away if they are worried 
about having something with their name and results on it, or show it to 
their health care provider, or stick it in a file somewhere in their house. 
The control is up to them. We don't document results in medical 
records. The results will be told to the other providers in our high risk 
clinic who know not to write it anywhere. Outside our little close-knit 
group, the providers are not told. We are more than happy to disclose 
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the results if we get written permission to do so, but otherwise it 
doesn't go anywhere. It is unlikely that an insurance company would 
learn about the result because it is completely done in a research 
setting. 
Because this is powerful information, we have to consider 
whether someone will be suicidal after hearing the news. We had one 
case where the woman was very upset that she got a normal result (not 
in the BRCA l gene, but in a different cancer gene). She was hoping 
for abnormal results as her way out of her horrible life-being able to 
get cancer and just die. Us telling her, "No, that's not going to 
happen," was not good news for her, so for her we were worried. But I 
think, in general , we are more concerned about the people who get an 
altered gene result. They have filled out some psychiatric assessments 
and had a lengthy discussion before the day results are given. So 
hopefully we have an idea of their stability and emotional well being 
before they even get to this point. It is  an important reason why we 
have a clinical psychologist working on the project. 
I generally do feel comfortable giving out the predictions of 
breast cancer risk because of the way that we do it. We're deliberately 
vague. I am amazed when I hear that somebody says, "Okay you' re 
forty. By age forty-five, you will have this risk, and at age fifty your 
risk will be that." We just don't know that for certain.  We' ll give 
ranges, but often we downplay the numbers. Remember, for most 
people, numbers don't mean anything. You could give the same 
number to four people and they wil l  all perceive it in a very different 
way. For many women in the breast cancer clinic, they are living with 
so much feeling of doom and fear that they already know they have a 
higher risk of cancer. In fact, for a lot of people, they' ve over­
estimated what their lifetime cancer risk is. So I'm not sure that they 
even hear me when I say, "Look, your highest risk is fifty percent." 
Now, for me or you, that sounds like an incredibly high risk, but for 
these people, that's quite a drop in what they already think their risks 
are. 
Sometimes I think that being part of this research is a scary place 
to be because there are not a lot of models for what we're doing. We 
see other institutions doing things in ways that we don't agree with so 
we can see what it is we don't want to do, but it's very hard to know 
how best to do things. For example,  I hear from other centers that 
have just gone ahead and started doing this type of testing more freely. 
I know that there are a few labs that are offering predictive genetic 
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testing for breast cancer without a required counseling component. 
There are a few labs where you can just send money and a blood 
sample and the test will be done. There's  at least one site that will take 
anyone's blood, regardless of whether they have cancer or a striking 
family history. A couple of these sites strongly encourage counseling, 
but I don't know if it's required. 
Whenever you work with families, what works for one family 
doesn't always work for another, and so you are constantly 
reevaluating how you're doing things. The first step in our testing 
program is to send an invitation letter to families saying "You know, 
this altered gene may be in your family. Do you want to know about 
it?" Well, one person is going to call and be upset that we didn't give 
more infonnation i n  the letter-"As you know, I've been seen in your 
center for five years. This is all you can tell me? What do you mean 
that I have to have another blood test? You already have my blood." 
And then a second person will get the letter and be devastated by what 
they are reading into it. So it's hard to know how much information 
people really want, and it's hard to be able to predict that. If there's 
one thing we've learned, it is that you can't predict how people are 
going to react to this information or what people are going to want to 
hear. 
I have confidence in our approach to predictive genetic testing for 
breast cancer because we do everything within a group process.  We 
have people with specialties in oncology, psychology, and genetic 
counseling. We also have set up an outside ethics group for our 
research protocol composed of people not affiliated with the hospital 
so that, when we really get stuck or we've done something and we 
want reassurance that it was okay, we can go to them. We meet a few 
times a year and go over the case histories and how we've resolved it, 
or how we plan to resolve it, and they give us their feedback. I think 
it's really useful, because we do a lot of obsessing about things. Also, 
you can get to a point where you're convinced that you' re doing the 
right thing, and sometimes it's really important for an outside group to 
look at it and say, "Well, what about doing it like this instead?" This is 
important because people do tend to think alike after working together 
for a while. 
From a laboratory standpoint, I think there has to be some sort of 
standard to ensure accuracy of the results. Still, it worries me 
whenever the word "regulation" is raised. Are we going to make it 
difficult, actually i mpede our ability, to do genetic testing? I think 
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there is a fine line sometimes when it  comes to regulations. Do we 
regulate each genetic test that comes along? Do we just regulate the 
labs? There are a lot of things to consider . . . .  
3. A Consumer Advocate's Story166 
As a statewide consumer advocacy organization, our mission is 
to increase breast cancer research funding, improve access to breast 
cancer care and treatment, and foster consumer participation in 
research decisions. Although we are always pleased to see that 
researchers are looking for the causes of breast cancer, we are seriously 
concerned with the trends in genetic research. There has always been 
some concern in our organization about the genetic factors at play in 
high-risk families. However, only five to ten percent of women who 
get breast cancer have a strong family history; most have no 
identifiable risk factors. The way in which Jewish women are being 
recruited for predictive genetic testing is alarming. BRCA 1 is now 
being referred to as the "Jewish gene," and this incredible focus on one 
particular ethnic group, especially without education and the support 
of the community, is appalling. 
The way in which genetic research is being portrayed is very 
distorted. There seems to be this implication that if you have a test, 
and it shows that you have an altered BRCA 1 gene, you can do 
something about it. That is not the case; there is still no known proven 
intervention for breast cancer. Our organization has received many 
calls about breast cancer genetic testing over the past year. There have 
been many people who are initially very excited about it, and say that 
they want to go out and get tested. But when they learn a little more 
about what this type of testing can and cannot tell them, they realize it 
may not be so great. First of all, it may not tell them anything that 
would be actually useful to them. And, psychologically, it can be 
extremely distressing to them and their families. Furthermore, there is 
no protection from discrimination. I think, these days, everybody 
understands how precarious health insurance is and that if you were to 
be diagnosed with breast cancer, or found to carry an altered BRCAI 
gene, you run the risk of losing your insurance, even your job. There 
are many people in our group who make serious life decisions based 
166. This story is based upon an interview with Jan Platner, J.D., who is the 
Executive Director of the Massachusetts Breast Cancer Coalition (MBC). MBC is located 
at 85 Merrimac St., Boston, MA 021 14. Ms. Platner may be contacted by telephone at 800-
649-6222 or 6 1 7-624-01 80, or by facsimile at 6 1 7-624-01 76. 
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on the fear of discrimination. The other concern is that most causes of 
breast cancer are not inherited, but occur sporadically, possibly as a 
result of environmental influences. We are very concerned about the 
focus shifting from the environment almost entirely to genes. 
All that really exists now is data. I think that we are in an age 
where people place a high value on information. I'm not sure it's 
knowledge; it's just information. We are a culture that reveres 
knowledge and that thinks that science has far more answers than it 
probably does. 
It is our position that predictive genetic testing for breast cancer is 
still experimental and academic. Whether a woman wants to have 
such testing is an extremely complex decision that needs to be made 
by the woman herself and her family. It's a very personal decision. 
But we believe that no one should even contemplate this unless they 
have up-to-date information and appropriate counseling. Also, 
nondiscrimination and confidentiality protections are needed for 
people who decide to be tested. It is our position that no genetic 
testing should take place whether in clinical trials or commercially 
without these protections in place. But this is not happening. Right 
now, for example, anyone could walk into some of the local hospitals 
and get tested for BRCA I .  All they need is to be able to pay for the 
test. It concerns me that this type of testing is being offered in some 
settings without professional counseling.  Very soon, wide-scale 
testing will be made available. The majority of health care 
professionals have little knowledge about the research status and 
ramifications of this type of testing and little, if any, experience in 
genetic counseling. 
It also concerns me that, through commercially available testing, 
people are getting information from the companies who administer the 
tests. There have been some pretty aggressive marketing campaigns 
and literature sent out to recruit people in a way that is problematic. 
For example, there is marketing to encourage all Jewish women to get 
tested. You can even do it by mail order-by sending in a blood 
sample and $295 to one lab in the country. The bottom line is that the 
companies have a tremendous financial interest in creating a new 
market for this product. And some researchers involved in this area 
have personal financial interests in the companies. Because I'm a 
lawyer, I may be more sensitive to the notion of conflict of interest. At 
the very least, there should be some rules regarding disclosure. We 
also know that one of the companies is marketing its testing service to 
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disease management facilities and insurance companies that would 
benefit from information about a person's risk for breast cancer. With 
the facilitation of computerized access to medical records and the lack 
of consumer protections, this is incredibly problematic. 
The other major concern of our organization is that gene testing 
for BRCA I seems to not be regulated at all. We have met with the 
State Attorney General 's Office and their Consumer Protection 
Division and Civil Rights Division to talk about these issues. It's 
problematic, because the resolution of this kind of issue usually occurs 
at the federal level. It is my understanding that the FDA could regulate 
this, but they don't since it's not a pharmaceutical and not a medical 
device. Although the FDA is not a perfect agency and its regulatory 
powers are being cut back, I think it is critical that they have strong 
jurisdiction over this. I don't think industries should ever regulate 
themselves. This information has the potential to impact individual 
· lives in so many ways. Inadequate regulation is a serious public health 
issue that needs to be addressed. 
The issue of informed consent for participating in these studies 
also is a great concern. I have reviewed a number of informed consent 
documents that are being given to women. The majority of these 
documents are inadequate, even the ones developed for clinical trials 
in large, well-respected institutions with people who are sensitive and 
knowledgeable about these issues. We have no idea what happens to 
people when they get test results, be they positive or negative results, 
or if they have any understanding of what this means to them or for 
their family members. We have talked with a few people who have 
been tested who entered the process understanding the issues and who 
were surprised at how they were emotionally impacted by the test. 
They thought they were prepared but later admitted they really were 
not. And the family issues created by this type of testing are 
overwhelming. One woman was tested within a clinical protocol and 
wanted the test to be blind; she didn' t  want to know the results. But 
after she was tested she received a letter from the facility basically 
saying, "We have some bad news for you . . .  you are at high risk." 
She was strictly doing this because she thought it would be a 
contribution to science. Then she was faced with the decision of 
whether to tell her daughter. Although some of the research programs 
have a psychologist and psychiatrist on board and apparently make an 
attempt to help sort through the issues, it sounds like it's just an 
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attempt. Many women considering testing feel that these programs 
still have a long way to go. 
Ruth Hubbard167 has a great analogy-she says that if you want 
to build a skyscraper you tum that task over to architects. But if you 
want to decide whether to build the skyscraper, those are not the 
people who should make the decision because you will get the 
skyscraper no matter what. Consumers really need to be part of the 
dialogue before genetic tests are developed. 
4. A Corporate Representative's Story168 
I work as the education and corporate communications manager 
for a national genetic testing company with a very large research and 
development arm, genomics group, and clinical trials lab. At our 
company we do prenatal testing as well as molecular and biochemical 
testing. We also do cancer cytogenetics and provide a number of other 
genetic laboratory services. 
Within our clinical trials lab, we are currently working with a 
number of collaborators in the area of BRCA testing. We were not 
involved in the cloning of the BRCAl gene. However, we do develop 
tests for certain genetically inherited diseases, and we have the 
capability with some new technology that we developed to run c linical 
trials for academic partners. We also are very much involved in the 
development of protocols for the delivery of this type of predictive 
genetic testing service, including genetic counseling, which has to be 
part of BRCA testing. Although protocols for testing are generally 
developed by professional medical organizations, we believe that we 
have the experience and the data to help these organizations as the 
BRCA test becomes available. We develop the protocols for use in 
conjunction with our academic collaborators who will be the ones who 
actually make them available within the physician community. 
There's a lot of information that comes forward during a clinical trial 
. . .  it's not just the mechanics of putting something through the testing 
process. We address the many ethical and social implications that 
arise from the testing process itself prior to introducing a new genetic 
test. 
Our laboratory does not accept specimens from physicians or 
consumers interested in BRCA testing. The specimens that come 
1 67. Ruth Hubbard is Professor Emerita of B iology at Harvard University. 
1 68.  This story is based upon an interview with an executive at a major biotechnology 
company. 
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through our lab come only from our collaborators, and they are all 
research studies. We have chosen not to make this test commercially 
available at this time because there are too many unanswered 
questions. The protocols for the use of this test have not yet been 
established, and we believe that its entry must be done carefully. The 
development of a predictive genetic test is a very touchy issue, one that 
needs a lot of examination and care in the thought process prior to its 
entry into the market. 
As an example, an important part of any genetic test is the 
protocol for providing test results. The findings and report process 
have to be explained very carefully to a physician. We do not just 
provide physicians with a written report that states that the patient has 
tested negatively or positively. With genetic disease, there can be 
familial and psychological impact, and a lab cannot just print out a 
report and send it off. The interpretive process is one of the most 
important things on any report that comes out of a genetic diagnostics 
laboratory. As part of our work, we are examining the way in which 
BRCA test results ought to be provided and the type of counseling that 
may be necessary to deal with the impact of the information. 
An illustration of how well the genetic diagnostics community 
works together i s  what happened when the genetic test, by linkage 
analysis, for Huntington Disease (HD) first became available in the 
early 1980s. A consortium was formed of academic and commercial 
geneticists and others who got together expressly to carefully map out 
the process for the manner in which testing should be offered. When 
the gene was uncovered in 1 993, these guidelines were only 
intensified. HD still is not offered to anyone except through a 
carefully controlled clinical protocol. All of our patient samples, for 
all genetic tests, come from referring physicians-not directly from 
consumers. 
I have seen one package of marketing literature on BRCA testing 
from one company offering the test. The materials do not appear to be 
very unusual. In fact, I was delighted to see how responsibly and 
sensitively they have been handled. The companies that are 
announcing and marketing this test, I believe, are now working 
through IRBs that have been established within their own companies. 
There is still much to be determined before this test is made widely 
available. 
I think, as a whole, the genetics diagnostic industry is very 
cautious about what tests it offers and how they are offered. In my 
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view, the commercial industry is equally as cautious and conscientious 
as the academic centers. I think the genetic testing industry does a 
very good job of regulating itself. We have a number of organizations 
that inspect and license our laboratories. These inspection and 
licensing procedures involve a wide range of quality control and 
assurance issues and standards that we are required to meet. CLIA, the 
College of American Pathologists (CAP), the Association of Certified 
Medical Geneticists (ACMG), and state licensing agencies have 
stringent rules and regulations, and our labs are licensed by all of these 
organizations. I do not think it is necessary for the genetic diagnostics 
industry to be regulated by the FDA. 
To my knowledge, no genetic test has to be approved by the 
FDA, and there are no FDA guidelines or approval processes on any 
genetic diagnostic test. The labs that develop these tests have very 
rigorous programs of their own. We would not offer any kind of 
genetic test without a large amount of data showing efficacy, 
sensitivity, and specificity. I don't think there is a need for any 
additional external review. Any genetic testing company would be 
foolish to introduce a test that wasn't technically sound. Think of the 
potential for harm, the liability issues, the damage to a lab's reputation, 
and so on. 
Our president presented testimony to the Senate Cancer 
Committee on the issue of regulation in late 1995. The Executive 
Summary states our position on external regulation: 
The dawn of a new era of testing for genetically-based disease is 
both exciting and challenging. The prospect of being able to identify 
individuals at increased risk of cancer and other devastating diseases­
and thereby facilitate prevention and earlier, more effective 
treatment--could reduce human suffering to an extent that is 
unprecedented in medical history. 
Our collective efforts towards this goal must be conducted with 
great care. The evolution of genetic diagnostics is an interactive 
process that needs a high level of flexibility to cope with constant 
change. Test validation, laboratory performance, and genetic 
infonnation must all be addressed in appropriate ways, but excessive 
Federal regulation must be avoided. 
Any framework for validating new genetic tests must reflect a 
diversity of issues. For instance, testing for a disease that is caused by 
a single genetic defect, like Huntington Disease, raises different 
validation issues than testing for cancer, which may involve many 
genes. Our approach to validating such tests must be flexible or it will 
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stifle progress and prevent generations of useful infonnation for 
patients. 
Placing additional regulatory requirements on the process at this 
time could undermine the investment required to make these potential 
clinical benefits a timely reality. Existing voluntary collaborations 
between connnercial and academic laboratories and researchers work 
well and have successfully moved tests like those for cystic fibrosis 
(CF) and Huntington Disease (HD) into general use. Cancer testing is 
more complex but can be managed in a similar way. 
Genetic testing laboratory performance standards are regulated by 
the College of American Pathologists (CAP) and the American College 
of Medical Genetics (ACMG) under the Clinical Laboratory 
Improvement Amendment (CLIA) of 1988. Additional regulation of 
lab performance is not necessary. 
Increased education in genetics for primary care physicians and 
other health care providers is crucial to the understanding and 
appropriate use of genetic tests, but adequate resources do not 
currently exist. This is an area where the Federal government can play 
a useful role. 
Finally, insurance reform, including elimination of pre-existing 
condition exclusions and elimination of lifetime caps, will remove 
major limitations to the effective use of genetic diagnostics. Congress 
should address these issues in pending health care reform legislation.1 69 
I am not saying that genetic testing should not have any kind of 
regulation. But I think it can be imposed upon the community to do 
some maj or self-policing. Perhaps certain additional criteria could be 
met through the existing regulatory processes (CLIA, CAP, and so on). 
But to have the FDA involved i n  genetic testing would slow the 
process unbelievably. 
Our market analysis for BRCA shows that there is certainly a 
large potential market. However, an additional reason for not offering 
BRCA testin g  i s  patent ownership. To date, there has been no 
indication that patent filers are willing to license out for 
commercialized diagnostic testing. 
By the way, the academic institutions charge for their testing. So 
there really is not much difference between us, except that officially 
we are for-profit and they are not, although some of them actually are. 
The major difference is in how services are marketed and how the two 
entities are perceived out there in the marketplace. One of our larger 
competitors is an academic lab that charges for services and markets 
169. Statement of Elliott D. Hillback, Jr., Pres. & CEO of Integrated Genetics 
Laboratories, Inc., before the Senate Cancer Caucus (Sept. 29, 1 995). 
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their tests much more aggressively and directly to physicians than we 
do. 
N. UNIFYING 'fHEMEs AND DIVERGING THEORIES ON REGlJl.ATION 
The preceding stories are linked by an overarching theme: the 
commercialization of predictive genetic testing services essentially is 
being left to market forces, academic interests, and the judgment of 
primary care physicians. Beyond this basic message, however, the 
stories raise an entanglement of issues and present disagreement about 
what, if anything, constitutes the appropriate regulatory response to the 
commercialization of predictive genetic testing services. The 
following is an effort to sort through these conflicting opinions and 
draw upon the discussion set forth in Parts II and ill, to present 
arguments for and against direct regulation of predictive genetic testing 
services. 
A Continued Deference to Market Forces 
Advocates of regulatory restraint support maintaining the status 
quo. One of the strongest arguments in favor of this position is that 
IRB review coupled with the incentive to avoid product liability is 
effective-as made evident by OncorMed's extensive protocol 
(attached as App. I). The regulatory effect of legal liability must not be 
underestimated, for biotechnology executives are well aware that 
circumventing the FDA review process sacrifices the liability 
limitations associated with the MDA.170 Under this view, the fact that 
170. See First BRCAI Test Hits the Market, supra note 65, at 4 ("Since FDA does not 
regulate genetic tests, OncorMed and the companies that will follow it encounter few 
regulatory barriers. However, by the same token, their products do not receive the 
certification of safety and efficacy that accompanies regulatory approval."). The MDA 
preempts claims for negligence and failure to warn. See 21 C.F.R § 808. l (d)( l996); H.R. 
REP. No. 853, at 45 ( 1 976) (legislative history). If manufacturers comply with FDA 
requirements and do not commit fraud, state law claims generally are preempted. See supra 
note 6 1 ;  see also Lars Noah, Amplification of Federal Preemption in Medical Device Cases, 
49 Fooo & DRUG L.J. 1 83, 2 1 1  ( 1 994) ("By virtue of the express preemption provision in 
the MDA, medical devices are unique among products which are subject to regulation by the 
FDA."). Bur see Marianne Lavelle, Medical Device Makers ' Liability Shield is Dented, 
NAT'L L.J., July 8, 1 996, at A l  (reporting on Supreme Court holding in Medtronic, Inc. v. 
Lohr, 1 16  S. Ct. 2240 ( 1 996), that FDA regulation (MDA) does not necessarily preempt 
consumer suits over faulty medical devices); Marianne Lavelle, High Court Medical Devices 
Ruling Muddles Matters, NAT'L L.J., Sept. 30, 1 996, at A9 (reporting that "[c]ourts have 
split sharply in their readings of a 1996 Supreme Court decision that many had hoped would 
clear up the issue of when federal regulatory law preempts actions based on state tort and 
other law"). However, liability for clinical trials is raising. See Michael Traynor, As 
Manufacturers Seek Approval for More New Pharmaceuticals, Issue Such as the "Learned 
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some companies, such as IVF, are marketing research-stage predictive 
genetic tests without restraint is a problem of lack of enforcement of 
existing labeling and other regulations, namely CLIA and professional 
standards, and not a legitimate basis for introducing even more 
regulations. Similarly, to the extent that physicians are straying from 
these protocols, failing to properly counsel their patients, and 
overusing investigational genetic testing services lacking PPV, they are 
guilty of practicing poor medicine and should be disciplined 
professionally.171  Physician malpractice, it may be argued, is not a 
legitimate basis for imposing more regulations on biotechnology 
companies. Moreover, to the extent that more regulation is needed, it 
should come in the form of stronger good-medicine standards imposed 
on physicians and enforcement of those standards.172 
The status quo offers some significant public health benefits. 
First, in addition to developing protocols, industry is addressing ethical 
issues associated with the commercialization of genetic technologies, 
and perhaps i s  doing so more effectively than the government could. 
Several multinational pharmaceutical companies have financed ethics 
programs to address these issues. 1 73 Similarly, many biotechnology 
Intermediary " Rule Will Emerge in Litigation involving Clinical Trials, NAT'L L.J., Nov. 18, 
1996, at B6. 
1 7 1 .  "About half of people with a family history of breast or ovarian cancer are likely 
to request genetic susceptibility (BRCA I )  testing when available . . . .  " Breast/Ovarian 
Cancers (Genetics): Many People Prefer Not to Know if They Have Gene Linked to 
Cancers, CANCER RES. WKLY, July 15, 1 996, available in 1996 WL 22863 1 3  (reporting on 
study conducted by the Lombardi Cancer Center, Georgetown University, that emphasizes 
the importance of relaying information about genetic tests themselves to patients).  
Following the discovery that one percent of Ashkenazi Jewish women carry genetic 
predisposition to breast and ovarian cancer and despite consumer demand for the test, 
"almost all leading scientists and two major commercial testing laboratories agreed 
informally not to offer the test for the mutation to the general public because widespread 
testing would do more harm than good." Koenig, supra note 24, at A23. That consensus 
was broken, however, by Dr. Joseph D. Schulman, Director of IVF. Dr. Holtzman, Chair of 
the ELSI Task Force, asserts that Dr. Schulman is  "hoodwinking" women by making the 
IVF test widely available. See Wadman, supra note 5, at C3. The National Breast Cancer 
Coalition and the National Action Plan on Breast Cancer agree that testin g  should be 
confined to research settings. See id. 
172. Consider that the United Kingdom, i n  comparison with the United States, 
regulates more experimental medical technology through good medicine standards. See 
Veronica Henry, Problems with Pharmaceutical Regulation in the United States, 14 J. 
LEGAL MED. 617,  637-38 (1993) ("In Great Britain, investigational and experimental drug 
use requires certification and licensing; however, therapeutic use, by which physicians 
administer drugs to their patients, is excluded from the certification requirement."). 
173. For example, in the Fall of 1 995, SmithKline Beecham (London-based) gave 
Stanford University $ 1  million to start an ethics program in genetics, and the Hastings 
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companies are hiring ethicists and, · at least presumably, taking the 
advice for which they are paying top dollar. 174 
Second, the FDA traditionally has relied heavily on the private 
medical profession when reviewing new products, and legal liability in 
the place of FDA involvement (with resulting limitations on liability 
for compliance) may result in greater quality control. 175 Conflicts 
associated with the case-by-case nature of the FDA review process, the 
discretion allotted individual agents, and close ties between members 
of the medical profession and individual FDA reviewers support 
proposals to rely upon apolitical advisory committees instead of 
existing FDA review mechanisms.176 
Center has launched a program called "Values and Biotechnology" with the financial 
support of Monsanto Co. See Day, supra note 3 1 ,  at A l .  
174. Biotech companies are voluntarily and directly addressing ethics issues arising 
from the commercialization of their technologies. See id. Human Genome Sciences, Inc. 
has hired former opera diva Beverly Sills, who has two children with birth defects and years 
of service as chairman of the March of Dimes. "All over the biotech industry, companies are 
hiring ethicists to try to get a jump on these humanistic tangles. Many people in an industry 
that has the potential to make reality of science fiction are following the rule of look before 
you leap." Id. 
175. See, e.g., Claudia MacLachlan, Spine-Tingling Dispute: Bone Screw Suit Places 
FDA in 4-Way Squeeze, NAT'L L.J., Jan. 8, 1996, at A l  ('"One of the standard defenses is to 
wrap your arms and legs around the ankles of some FDA person and say they knew-and a 
lot of times that is true. "' (quoting William W. Vodel, head of FDA practice at Washington 
D.C.'s Arnold & Porter)). Recently, the FDA was pulled into "a four-way crossfire over the 
way it lets medical devices be used without formal approval. . . . The FDA has also been 
accused of relying on the advice of doctors allegedly on the take from makers of devices the 
doctors had tested." Id. ; see In re Orthopedic Bone Screw Products Liability Litigation, 79 
F.3d 46 (7th Cir. 1 996). This case, which involved the use of screws to affix metal plates to 
the vertebrae of some 300,000 people despite rejections by the FDA of this use i n  1 984 and 
1985, has highlighted the fact that the FDA cannot always be relied upon as an assurance of 
quality control. MacLachlan, supra, at A l .  The problem is that standard of care acceptance 
may be realized without the FDA. On October 4, 1 992, the FDA announced in the Federal 
Register that it had discovered that the plate and screw devices were in widespread use and 
considered standard of care by surgical community. At that time, the FDA requested a study 
by orthopedic professional groups and makers of the spinal implants and, based upon the 
reported results, the FDA liberalized use. Accusations that the study was corrupt are now 
the subject of a case brought by plaintiffs against the device's manufacturers. Specifically, 
attorneys for the plaintiffs i n  a products liability case over the device later accused the FDA 
of relying "in part on medical reports from doctors who stood to profit from the device." 
MacLachlan, supra, at A 1 .  
176. See Claire L .  Ahem, Drug Approval in the United States and England: A 
Question of Medical Safety or Moral Persuasion?-The R U-486 Example, 1 7  SUFFOLK 
TRANSNAT'L. L. REV. 93, 93 (1 994) ("Advancements in the pharmaceutical industry have 
revealed the magnitude of these dissimilarities and the negative effects that result when 
United States drug officials allow nonscientific considerations to affect their analysis of 
promising new drugs."); Henry, supra note 172, at 637-38, (comparing the U.S. and U.K. 
systems and concluding that "[t]he British system is more objective and expeditious than the 
American system. . . . The American system needs to enhance utilization of  apolitical 
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Third, even experimental genetic tests may offer clinical benefits 
to some patients. These benefits include clarification of risk status, 
more accurate diagnosis of symptomatic individuals, detection of 
canier status, and guidance for selecting the most prudent course of 
surveillance treatment. 177 For the first time in decades, cancer 
advisory committees i n  the decisionmaking process, much the same way this has been done 
in the British system."). But see generally ABRAHAM, supra note 7 1 ,  at 246 ('The close 
institutional relationship between the regulators and the pharmaceutical firms in the U.K. 
has been associated with a sympathetic view of scientific data from the pharmaceutical 
industry on the part of the Government scientists and scientific advisers."). See also J. 
Worth Estes, Book Review, 334 NEW ENG. J. MED . 609, 609 (1996) (reviewing JOHN 
ABRAHAM, SCIENCE, POl .. ITICS AND THE PHARMACElITICAL INDUSTRY: CONTROVERSY AND 
BIAS IN DRUG REGULATION ( 1 995)) ("Because the B ritish government wishes to ensure the 
success of its pharmaceutical industry, its regulatory agencies tend to be protective rather 
than adversarial, as they are in the United States, where the government is required to be 
more concerned about protecting patients than about protecting the firms that manufacture 
medicines."). 
177. See ELSI TASK FORCE ON GENETIC TEsTING, supra note l ,  at 1 4  ("A test with a 
lower sensitivity might have value in certain circumstances, but the organization offering the 
test must make clear what the limitations are i n  order to enable providers and consumers to 
make informed decisions about appropriateness."); Olufunmilayo I. Olopade, Editorial, 
Genetics in Clinical Cancer Care-The Future is Now, 335 NEW ENG. J. MED. 1 455, 1455 
("It is no longer unusual for women with newly diagnosed breast cancer to seek genetic 
testing before choosing between mastectomy and lumpectomy combined with radiation 
therapy."); see also id. at I I ("A direct DNA test can be used to diagnose a genetic disease in 
symptomatic individuals, predict future disease in healthy people, detect carriers and also for 
prenatal diagnosis."); Saltus, supra note 1 34, at 25 (noting that some women already 
diagnosed with breast cancer perhaps could benefit from testing to make decisions regarding 
treatment); Wadman, supra note 5, at C3 ('They say negative tests have already allowed 
them to tell women scheduled for preventative breast removal that they don't need the 
surgery."); Weiss, supra note 2,  at Al ( 
For some carefully selected women already diagnosed with breast cancer, a 
positive test can indicate the need for more aggressive therapy. And for a woman 
whose mother or sister had breast cancer from a BRCAl mutation, a negative test 
can provide some reassurance. What remains unproved, however, is that the test 
has any value for the more than 95% of women who do not fit into those 
categories. 
). The breast cancer testing issue has caused division among feminist scholars, some of 
whom feel that impeding the accessibility of genetic tests constitutes paternalism. See 
Wadman, supra note 5 ,  at C3 (discussing the availability to Jewish women of a genetic test 
for breast and ovarian cancer); Weiss, supra note 2, at A l .  In the words of one woman who 
was told that she could not have her BRCAl test results: 
Do they really believe that women who test positive are going to 
inunediately race to the nearest operating room to summarily demand the removal 
of both breasts and ovaries-procedures which, in any event, would require the 
concurrence of a surgeon? They are underestimating our intelligence to the 
millionth degree . . . .  Strangely, men considering surgery for prostate cancer don't 
seem to receive this kind of counsel, even though the benefits of surgery haven't 
been proven and the operation usually leaves men impotent, incontinent or both. 
Wadman, supra note 5, at C3. 
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mortality rates have fallen and, in addition to better treatment, this has 
been attributed to both prevention and improved diagnosis.178 Fourth, 
and perhaps most persuasive, medical science eventually will solve the 
predictability problem.179 The present scheme, which generates patient 
samples and finances research,180 will most rapidly move genetic 
medicine to therapeutics and even gene therapies. More regulations 
could have the exact opposite effect. 
B. Call for Direct Regulation 
Advocates for direct regulation of genetic testing services 
emphasize that, even though these tests are much more likely to be 
misinterpreted than traditional diagnostics due to (1)  the absence of 
scientifically valid PPV, (2) the lack of physician understanding about 
genetics, and (3) the public's interest and faith in genetics enhanced by 
media coverage, biotech marketing, and information (or 
misinformation) from providers, these tests are subject to much less 
regulatory oversight. 181  From a mental health perspective, genetic tests 
for serious diseases may impact patient lives at least as much as 
traditional diagnostics with established PPV This is especially true in 
the absence of reliable studies of the impact of genetic information on 
patients ' lives182 and the present dearth of trained genetic counselors in 
practice.183 In fact, in the absence of coverage, consumers demanding 
access to genetic tests may actively avoid genetic counseling due to the 
178. See Breast Cancer Incidence, supra note 1 34, at 1293-94 (reporting that the 
overall death rate from cancer fell approximately 3 %  between 1991 and 1 995,  and the rate 
of breast cancer fell 6.3 percent). 
179. See Saltus, supra note 134, at 25 (arguing that, with time, the tests will be more 
scientifically reliable and easier to interpret, and that there also will be more health care uses 
for the information). 
180. These research funds are coming out of the pockets of consumers, for most 
insurance companies will not cover the costs of such experimental health care. See Boyle, 
supra note 13 ,  supp. at SS ("While exact data on private insurance coverage are scarce, most 
genetic services-preventive, screening, and counseling-are not covered because the 
interventions are considered either 'investigational' or 'not medically necessary."'). 
1 8 1 .  See generally supra Parts 11.B & C. 
1 82. See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 ,  at 33 ("People at risk 
of disease in high risk families may have built up a complex mechanism to deal with the 
perception that they are affected. . . . Genetic counseling can be extremely time­
consuming."). However, Kaiser Permanente currently is developing a clinical practice 
guideline for BRCAl testing and introducing a confidential patient registry to ensure long­
term follow up. See BRCAJ:  Are You Ready for Clinical Testing?, PERSP. GENETIC 
COUNSELING, Summer 1 996, at 1 2. 
1 83. See Malinowski, supra note 1 25, at 3 5 1 -52 & n . 104. 
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costs it adds. 1 84 Over-reliance on negative test results185 and over­
treatment based upon positive test results 1 86 are strong possibilities, if 
not probabilities. Also, in the absence of adequate consumer 
safeguards to ensure genetic privacy and counseling and awareness of 
these dangers before the decision to undergo genetic testing is made, 
those who subject themselves to genetic testing may find that they also 
are subjected to discrimination from employers and insurers. 187 fu 
addition, family members may be subject to discrimination based upon 
the results of genetic testing they did not even undergo.188 
Advocates for direct regulation also argue that OncorMed's 
prudence in developing a thorough protocol cannot be relied upon as 
established industry practice. Rather than being representative of long­
term industry behavior, these precautions may be a reflection of the 
fact that OncorMed is the first biotechnology company to make 
predictive genetic testing available outside the major research centers 
and, as such, it has been painstakingly careful. Similarly, the influence 
that drug developers and manufacturers exercise over scientific 
research must not be underestimated. Industry influence is not only 
1 84. Many new predictive genetic tests are investigational and, therefore, often are 
paid for out of consumers' pockets. See Bl.Arr, supra note 2 1  ("While genetic counseling is 
necessary to make informed decisions about clinical genetic tests, as a sole service, it is often 
not covered by insurance."). Accordingly, it is  unlikely that consumers are going to seek out 
counseling due to the added cost. See Malinowski, supra note 125, at 351 & n. l 06; see also 
First BRCAJ Test Hits the Market, supra note 65, at 3 ("While it may be difficult to find two 
people who agree on all aspects of what is  to be done, virtually all the opponents of 
immediate commercialization of genetic testing agree that counseling patients before and 
after they are tested is  anything but a straightforward matter."). 
1 85. See Wadman, supra note 5, at C3 ("Scientists argue that testing in nonresearch 
settings is fraught with peril. Negative test results, they say, could lull women into a false 
sense of security, when in truth 90 to 95 percent of breast and ovarian cancers aren't 
inherited but occur spontaneously."). 
1 86. The investment in technology to identify breast cancer has not been 
accompanied by similar investment to understand its growth and spread. See Plotkin, supra 
note 1 34, at 54-55. The failure to appreciate cell growth differences in breast cancer, 
coupled with mammography, may have resulted in over-diagnosis and treatment-including 
unnecessary mastectomies. See id. at 70. The end result is that breast cancer is twice as 
likely to be diagnosed today as it was 60 years ago, but mammography studies show no 
overall difference in mortality from breast cancer between treatment and control groups. See 
id. at 69 (citing Swedish, Irish, and Canadian studies). Widespread BRCA testing could 
greatly exacerbate this problem. 
187. See generally supra note 58. See also Barash & Alper, supra note 58, at 43; 
Geller, supra note 58, at 7 1 .  
1 88.  See Act Concerning Genetic Testing and Privacy and Medical Underwriting, 
N.J. S.B. 695 & 854, at § 2.d ( 1996) ("An analysis of an individual's DNA provides 
information not only about an individual, but also about the individual's parents, siblings 
and children, thereby impacting family privacy, including reproductive decisions."). 
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impacting the course of science, 189 but is tainting the safeguard of 
scientific peer review. 190 In this modem age of privatized R&D, 
academic institutions and their individual researchers are highly 
susceptible to the influence of the biotechnology industry and may 
even hold royalty interests in the industry's products.191 Accordingly, 
1 89. There is fear in the United States that creativity and objectivity in basic science 
is being lost due to the privatization of R&D. Rather than allowing researcher discretion 
and the raising of a general floor in science, basic science is being directed by corporate 
decisions to pursue and develop research discoveries solely according to their commercial 
viability. See, e.g. , ABRAHAM, supra note 7 1 ,  at 245 ("Since the career structure of academic 
medics rewards them for publications, there is an institutional incentive for such medics to 
work co-operatively with an industry that can provide the funding for publishable 
research."); Christine Gorman, Has Gene Therapy Stalled?, TIME, Oct. 9, 1 995, at 62, 62-63 
(noting that, while gene therapy holds extraordinary promise, enthusiasm and financial 
pressures may have caused a premature push to market that is sacrificing basic science and 
human safety for a quick return on investment). See also Malinowski & O'Rourke, supra 
note 20, at 187 (discussing the concern that the alliance nature of the biotech industry may 
be skewing the course of basic science). This concern has been substantiated in part by a 
study published in the New England Journal of Medicine based upon data collected from 
2,052 faculty members from October 1994 to April 1 995. According to the study, "faculty 
members receiving more than two thirds of their research support from industry were less 
academically productive than those receiving a lower level of industrial support" and 
"faculty members who have research relationships with industry are more likely to restrict 
their communication with colleagues." David Blumenthal et al., Participation of Life­
Science Faculty in Research Relationships with Industry, 335 NEW ENG. J. MED. 1734, 
1734 (1996). 
190. See Ralph T. King, Jr., Bitter Pill: How a Drug Finn Paid For University Study, 
Then Undermined It, WALL ST. J., Apr. 25, 1996, at A l .  There is anecdotal evidence that 
industry is tampering with scientific integrity. The "Synthroid affair" exemplifies the danger 
of industry-financed research. A manufacturer paid $250,000 to finance research to 
establish that cheaper drugs were not as effective as its product. When the researcher · 
attempted to publish findings of bioequivalency between the drug and other, much cheaper 
drugs, the manufacturer worked aggressively to discredit the research. See id. ('The 
Synthroid affair illustrates what some leading scientists decry as increasingly frequent 
corporate attacks on open scientific debate, at a time when industry-supported research is 
crucial because of a shrinking government role in medical research."). Similarly, "[i]n a 
recent article in the New England Journal of Medicine, Steven A. Rosenberg, chief surgeon 
of National Cancer Institute, cited what he said were four instances of promising research 
being squelched or slowed by corporate sponsors' demands for secrecy to preserve possible 
competitive advantage." Id. 
191 .  See David Blumenthal et al., Relationships Between Academic Institutions and 
Industry in the Life Sciences-An Industry Survey, 334 NEW ENG. J. MED. 368, 368 ( 1 996) 
("Ninety percent of companies conducting life-science research in the United States had 
relationships involving the life sciences with an academic institution in 1 994. Fifty-nine 
· percent supported research in such institutions, providing an estimated $ 1 .5 billion, or 
approximately 1 1 .  7 percent of all research-and-development funding received that year."); 
see also Steven A. Rosenberg, Secrecy in Medical Research, 334 NEW ENG. J. MED. 392, 
392-93 (l 996) ( 
The conduct of medical research is in increasing jeopardy. . . . Secrecy 
about methods and results has become a common and accepted practice . . . .  
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the influence of the biotechnology industry over public health policy 
must be checked, not augmented by a carte blanche federal regulatory 
approach. 
C. Drawing Conclusions 
The present regulatory scheme for commercialization of 
predictive genetic testing services consists essentially of reliance on 
market forces, legal liability, and the judgment of primary care 
physicians. Through access to patient samples and the opportunity to 
capture the costs of research, this approach is financing and advancing 
biotechnology research. Innovative therapeutics and gene therapies for 
life-threatening and widespread diseases such as breast cancer are 
becoming vivid possibilities. 
Nevertheless, the research-stage nature of predictive genetic tests, 
such as the existing tests for B RCA mutations, and resulting 
uncertainties make these tests currently unacceptable for broad 
commercialization.192 Legal liability places the burden of quality 
assurance on health care consumers who are the people that need to be 
protected, 193 and the transaction costs of shaping public health policy 
through litigation can be immense. Indeed, several cancer 
organizations and Jewish community groups have drafted position 
statements opposed to the commercialization of predictive breast 
cancer testing given the lack of safeguards to ensure oversight and 
)
. 
The increasing involvement of for-profit biotechnology companies in 
medical research has provided new sources of funding, but with this involvement 
has come an emphasis on the ethical and operational rules of business rather than 
on those of science. 
1 92. See Mark et al. ,  supra note 1 33,  at 405 ("Predictive testing should be considered 
investigational, and testing for purposes other than health care should be discouraged."). 
Despite the truth o f  the statement, it has become almost cliche in circles of genetic experts to 
say that we should have learned from the sickle cell experience in the early 1 970s in which a 
screening program caused widespread anxiety and many breaches of confidentiality. See 
Brom, supra note 27, at 129; supra note 1 26. 
193. Law should be used to prevent predictable problems and minimize the harm. 
See Annas, supra note 14, at 22 (rejecting laissez-faire strategy to let the market detennine 
which genetic tests are done on the grounds that law should be used to prevent problems and 
"lawsuits for breaches of privacy have not often been pursued (because the private 
information is usually made known to even more people in the process)"). As observed by 
Professor Paul Starr, "[t]he very circumstances of sickness promote acceptance of 
[physicians' ]  judgment." PAUL STARR, TI-IE SOCIAL TRANSFORMATION OF AMERICAN 
MEDICINE 5 (1 982). 
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accuracy, informed consent, and confidentiality. 194 Regulatory 
safeguards are needed to ensure that predictive genetic technology, 
which offers much promise, does not detract from public health 
because it is applied in a shortsighted, irresponsible fashion. 
Regardless of the failures and shortcomings of FDA regulation of 
traditional diagnostics, medical and public health officials must 
directly address the issue of quality assurance for predictive genetic 
testing services. They must introduce and enforce consumer 
safeguards tailored to this innovative technology. 
V. PROPOSALS FOR CHANGE 
Public health education developed with consumer input must be 
included in any strategy to regulate the commercialization of genetic 
testing services. 195 Nevertheless, a broader strategy is needed. Before 
sorting through the numerous options, 196 medical and public health 
officials must determine which approach or combination of 
approaches is likely to prove most effective. A fundamental point of 
differentiation is between protecting consumers ( 1)  through added 
market review and approval restraints that more carefully monitor 
market access to health care consumers or (2) through the health care 
profession as a matter of good-medicine standards. In other words, the 
two fundamental regulatory approaches (which may be used 
conjunctively) are (1) to introduce restraints to keep health care 
194. See, e.g., AMERICAN CANCER SOCIETY, MASSACHUSETTS DIVISION, GENETIC 
'fEsnNG: PATIENT PRIVACY AND DISCRIMINATION CONSIDERATIONS ( 1 995); DRAFT 
STATEMENT, THE JEWISH WOMEN'S COALITION ON BREAST CANCER ( 1 996) ("The recent 
identification of a genetic variation that may predict breast cancer is provoking immense 
anxiety and obscuring vital information."); DRAFT STATEMENT, HADASSAH, BRCAl GENE, 
GENETIC TEsTING AND INSURANCE DISCRIMINATION ( 1996) ("Hadassah is . . .  concerned that 
this new genetic information or individual's requests for genetic counseling services may 
result in higher health insurance premiums, changes in terms or conditions, or outright 
denial or cancellation of coverage."); MASSACHUSETTS BREAST CANCER COALITION, WHAT 
You NEED TO KNOW BEFORE CONSIDERING GENETIC TESTING FOR HERITABLE BREAST 
CANCER 1-2 (1996) (identifying the following considerations: (1) the potential advantage of 
the test to an individual is limited, (2) there is no known effective prevention for breast 
cancer, (3) a positive test result does not mean that you will get breast cancer, (4) a negative 
test result does not mean that you will not get breast cancer, and (5) getting tested may carry 
psychological, social, financial, and legal ramifications). 
195. See generally BLATT, supra note 2 1 .  
196. The mechanism for regulation recognized b y  the ELSI Task Force includes: 
(1) adoption of industry-wide codes or policy statements; (2) recommendations from 
professional societies; (3) extension of existing state or federal regulations to cover unique 
areas of genetic testing; and (4) new legislation. See ELSI TASK FORCE ON GENETIC 
TEsTING, supra note 1 ,  at 37. 
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products that unduly endanger consumers off of the market or (2) a 
"good medicine" regulatory approach that uses professional self­
regulation (peer review and norms) and legal liability. The principles 
and recommendations proposed by the National Task Force combine 
these approaches, with an emphasis on the good medicine approach: 
1997] GENETIC TESTING SERVICES 1289 
TABLE I 
HlGlillGIITS: PROPOSED RECOMMENDATIONS OF TIIB TASK FORCE ON 
GENETIC TEsTINd 97 
KEY PRINCIPLES 
V AllDTIY AND 
UTIUIY OF GENETIC 
TESTS 
LABORATORY 
QUAlllYAND 
CEIUIFICATION 
PROFESSIONAL 
COMPETENCE IN 
GENETICS 
RARE GENETIC 
DISEASES 
INFORMED CONSENT 
AND 
CONFIDENTIAllI'Y 
I 
As a prerequisite for acceptance in clinical practice, 
data sufficient to demonstrate clinical benefits and 
risks from both positive and negative results must be 
collected. 
An IRB must approve the protocols used for genetic 
tests. 198 
Despite the CLIA certification requirement imposed 
on most clinical laboratories, "current regulations do 
not adequately ensure the quality of genetic 
testing."191) 
"Health care professionals involved in the provision of 
genetic tests should be well-informed about their 
implications, benefits and risks."200 
"[N]ot all providers in practice today may have 
adequate competence to offer and interpret genetic 
tests. "201 
"At a time when genetic tests for common complex 
disorders are increasing, tests for rare disorders may 
be developed at a slower rate than in the past."202 
"Informed consent for a validation study must be 
obtained whenever the specimen can be linked to the 
subject from whom it came."203 
'The responsibility for providing information to the 
individual lies with the referring £rovider, not with the 
laboratory performing the test."2 
1 97. This summary is based upon Proposed Recommendations of the Task Force on 
Genetic Testing, Meeting Notice, 62 Fed. Reg. 4539, 453 9-47 (1 997). 
1 98. See id. at 4540. 
199. Id. 
200. Id. 
201 .  Id. 
202. Id. 
203. Id. 
204. Id. 
1290 
RECOMMENDATIONS I 
A GENEFICS 
ADVISORY 
COMMfITEE 
NEED FOR INTERIM 
ACTION 
205. Id. 
206. Id. at 4541 .  
207. Id. 
208. See id. 
209. See id. 
2 10. Id. 
2 1 1 .  See id. 
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"Respect for personal autonomy is paramount. People 
being offered testing must understand that testing is 
voluntary."205 
"Results should be released only to those individuals 
to whom the test recipient has consented or 
b 1 d . . . ,,206 su sequent y requeste m wntmg. 
"Health care providers have an obligation to the 
person being tested not to inform other family 
members without the permission of the person tested . . ,,207 except m extreme crrcumstances. 
The Secretary of HHS should create a federally 
chartered Advisory Committee on Genetics and 
Public Policy ("Advisory Committee") whose 
members should include stakeholders m genetic 
testing. 208 
The Secretary also should utilize an interagency group 
to assist the Advisory Corrunittee and develop 
coordinated and consistent genetic testing policies.209 
The Secretary of HHS should "use existing agencies 
and policies to ensure that the public will have 
adequate protection from predictive genetic tests that 
have not been adequately validated and whose clinical 
utility has not been established."21 0 
To accomplish this, the Secretary may either ( 1 )  use 
its authority under the MDA or (2) reimburse under 
Medicaid and Medicare only when genetic tests are 
performed in laboratories that can establish that the 
test has been clinically validated and that they are 
qualified to perform them.2 1 1  
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ASSURING THE 
V AIJDllY AND 
UTTUIYOFNEW 
GENETIC TESTS 
ASSURING 
LABORATORY 
QUAllTY 
2 1 2. Id. at 4544. 
2 1 3. Id. 
A National Genetics Board (NGB) should be created 
"to assure the protection of human subjects in the 
development of genetic tests with the potential to 
d. fu d" .. 212 pre ict ture isease. 
"NGB would develop a checklist that would enable 
local IRBs to identify protocols that meet criteria for 
stringent scrutiny. "213 
The FDA should establish a Genetics Advisory Panel 
under the MDA that requires new genetic tests to meet 
criteria for stringent scrutiny.
214 
CDC, in cooperation with NCHGR, should expand 
monitoring of genetic disorders to provide data on the 
validity of tests and post-test interventions and 
establish procedures for tracking those who undergo 
genetic testing.215 
The FDA should grant conditional premarket 
approval for genetic tests with the potential to make 
significant public health contributions and place the 
burden on developers to collect data and make it 
available to the FDA.216 
NGB should serve as a clearinghouse for technology 
assessments and make recommendations on appro­
priate use of genetic tests.217 
A national accreditation program of quality assurance 
and proficiency testing for genetic tests equivalent to 
or more stringent than those of New York State and 
the College of American Pathologists/ American 
College of Medical Genetics (CAP/ACMG), should 
be established under CLIA. The accreditation 
program should include proficiency testing and 
inspection of laboratories that perform genetic tests.218  
214. See id. at 4544-45. 
215 . See id. at 4545. 
2 1 6. See id. 
217. See id. 
2 1 8. See id. 
1292 
PROVIDER 
COMPETENCE 
219.  See id. 
220. See id. 
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Until a national accreditation program is established 
under CLIA, the CAP/ACMG Molecular Pathology 
program, expanded to encompass all genetic testing 
methods currently in use, should be implemented as a . al 2 19  nation program. 
A Genetic Advisory Committee to CLIA should be 
established to help address the deficiencies of CUA. 
The work of this committee should be coordinated 
with other HCFA programs and the work of FDA, 
CDC, and other federal agencies involved m 
establishing policies for genetic testing. 220 
CAP/ACMG should seek input from consumer groups 
such as the Alliance of Genetic Support Groups and 
National Society of Genetic Counselors (NSGC) 
when setting standards.221 
CAP/ACMG should periodically publish and make 
public a list of laboratories perfonning §enetic tests in 
compliance with its voluntary program.2 2 
"Managed care organizations and other third-party 
payers should limit reimbursement for genetic tests to 
the laboratories on the published list . . . . "223 
"[E]fforts should be made to harmonize international 
laboratory standards to assure the highest possible 
laboratory quality for genetic tests."224 
'The Task Force endorses the recent establishment of 
a National Coalition for Health Professional 
Education in Genetics by the American Medical 
Association, the American Nurses Association, and 
the NCHGR."225 
A core curriculum in genetics should be developed.226 
22 1 .  See id. at 4545-46. 
222. See id. at 4546. 
223. Id. 
224. Id. 
225. Id. 
226. See id. 
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RARE GENETIC 
DISEASES 
227. See id. 
228. Id. 
229. See id. 
230. See id. 
23 1 .  ld. at 4546-47. 
232. Id. at 4547. 
233. Id. 
234. Id. 
Certification and other credentialing mechanisms 
227 should be used to promote competency. 
"Predictive genetic tests requiring stringent scrutiny, 
as previously described, should be among those for 
h
. 
h "al d "al ed d "228 w 1c spec1 ere ent1 s are ne e . 
Primary care providers and other nongeneticist 
specialists should be involved in genetic testin g  but 
only after gaining sufficient training and 
knowledge. 229 
Credentialing bodies such as the Joint Commission on 
Accreditation of Healthcare Organizations (JCAHO) 
and the National Committee for Quality Assurance 
(NCQA) should be utilized.230 
"Except when time is of the essence, such as with 
certain prenatal genetic tests, obtaining informed 
consent and actually performing the test should be 
delayed several days after the test is offered and 
information given to the patient."231 
''The quality of laboratories providing tests for rare 
diseases must be assured, and a comprehensive system 
to collect data on rare diseases must be 
established. "232 
''The Task Force recommends that NIH give [the NIH 
Office of Rare Diseases (ORD)] a mandate to 
coordinate . . .  public and private efforts to improve 
awareness of rare genetic diseases. "233 
"ORD should identify laboratories world-wide that 
perform tests for rare genetic diseases, the 
methodology employed, and whether the tests they 
provide are in the investigational stage, or are being 
used for clinical diagnosis and decision making. "234 
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"ORD should also be responsible for assuring that 
tests for rare genetic diseases, which have been 
demonstrated to be safe and effective, continue to be 
available . . .  :ms 
"[A]ny laboratory performing any genetic test on 
which clinical diagnostic and/or management 
decisions are made should be certified under 
CLIA."236 
"Directories of laboratories providing tests for rare 
diseases should indicate whether or not the laboratory 
is CLIA-certified and whether it has satisfied other 
quality assessments, such as the CAP/ACMG 
program. ,,237 
In an era of deregulation, and in light of the deficiencies of CLIA 
and a general failure to enforce CLIA regulations with any consistency, 
the good-medicine approach to protecting consumers should be given 
careful consideration.238 This provider-centered approach could prove 
highly effective for physicians to control consumer access to predictive 
genetic testing services. Their involvement is absolute, meaning that 
consumers cannot have predictive genetic tests run on their samples 
without a primary care physician "middleman" making the procedure 
available. Lack of physician knowledge about the predictive services 
they are discussing with and making available to their patients, and the 
resulting lack of appreciation for the limitations of the technology and 
its impact on patients' lives, is simply inexcusable. Under no 
circumstances should physicians be making health care technology 
available unless they fully understand that technology. Patients, too, 
must be given information regarding the nature of investigative testing. 
Appropriate pretest counseling must be mandated. 
The willingness of physicians to stray from such basic 
responsibilities may reflect the fact that many consumers are paying 
for investigational genetic testing services out of their pockets (due to 
both the refusal of insurers to cover experimental services and 
235. Id. 
236. Id. 
237. Id. 
238. See Meeting Minutes, supra note 1 ,  at 7 (stating that one member "expressed the 
view that CLIA is ill-equipped for overseeing PT for genetics labs, and suggested that in this 
era of de-regulation, professional genetics organizations may be better suited to the task"); 
see also Proposed Recommendations of the Task Force on Genetic Testing, Meeting Notice, 
62 Fed. Reg. 4539, 4545 (1997) (discussing the insufficiencies ofCLIA). 
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consumer fears of genetic discrimination). Under this payment 
arrangement, physicians do not have to account to insurers and 
managed-care administrators for the costs of genetic testing services. 
Although consumer demand for access to predictive genetic testing 
services may become (or already may be) significant, medical and 
public health officials cannot accept consumer demand as an excuse 
for the practice of substandard medicine.239 Acceptance of such an 
excuse would carry tremendous ramifications,240 especially in an age 
of managed care when physician compensation is tied to the number 
of patients a physician maintains. Other potential conflicts of interest 
are equally troubling.241 Similarly, the physician-patient relationship 
does not allow the benefits from advancements in research, regardless 
of how profound they may be, to serve as an acceptable rationale for 
the practice of irresponsible medicine. 242 
hnplementation of the laboratory quality assurance 
recommendations of the ELSI Task Force (meaning a CLIA laboratory 
accreditation program modeled after the CAP/ ACMG Molecular 
239. Consumers cannot be entirely relied upon to assess their health care needs and 
the quality of the care they receive. See generally Jason Ross Penzer, Note, Grading the 
Report Card: Le.ssons from Cognitive Psychology, Marketing, and the Law of Information 
Disclosure for Quality Assessment in Health Care Reform, 1 2  YALE J. ON REG. 207 ( 1995) 
(discussing the limitations of consumer-directed infonnation disclosure proposals as a 
quality assurance system). See, e.g. , David L. Kasennan, Reimbursement Rates and Quality 
Care in the Dialysis Industry: A Policy Discussion, 8 ISSUES LAW & MED. 8 1 ,  82 ( 1 992) 
(noting that consumers tend to be more satisfied with shorter dialysis running times, even 
though reducing running times correlates with increased incidents of hospitalization and 
mortality). 
240. See generally Malinowski, supra note 1 25 (noting that managed care affects the 
physician's relationship with the patient in that a large amount of discretion in 
decisionmaking belongs to the health care provider). 
241.  See ELSI TASK FORCE ON GENETIC TESTING, supra note I ,  at 34 (Principle III- 17  
states i n  p art  that 
). 
Any actual or potential conflict of interest should be disclosed to persons being 
offered genetic testing. . . . One situation arises when the referring health care 
provider, or a provider/investigator who has developed a test, has a financial stake 
in a clinical laboratory. Another situation arises when those counseling people 
about testing are remunerated from funds generated by performance of the test 
itself and not entirely from their counseling activities. 
242. See generally David Orentlicher, Health Care Reform and the Patient-Physician 
Relationship, 5 HEALTH MATRIX 141 (1995) (discussing concerns that health care reform 
would impinge on patient-physician relationship). The paradox between advancing medical 
science to benefit all children at the sacrifice of individual children who are the subjects of 
research is addressed in Mclean, supra note 1 9, at 1 14 ('The paradox then may be that in 
order to protect some children, we need to use other children as subjects of research to gain 
the knowledge necessary for prevention and therapy."). 
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Pathology Program) to ensure sequencing proficiency must be 
accompanied by comprehensive genetic medicine measures. Medical 
and public health officials must introduce and enforce good medicine 
guidelines that are carefully tailored to directly address predictive 
genetic testing services.243 For example, federal regulators should 
consider imposing a mandatory minimum PPV standard for genetic 
testing services performed outside of major academic research centers 
when results are made available to those who undergo the testing. 
Moreover, written proof of compliance-a written showing of PPV­
should be a prerequisite for charging to recover costs. Similarly, 
providers should be required to establish competence in genetics as a 
prerequisite for reimbursement for the genetic testing services they 
provide. 244 
243. The need to have regulations tailored specifically to genetics has been 
recognized by many, including Dr. Holtzman, Chair of the ELSI Task Force: 
"Genetic tests have many distinct, unique problems that cry out for a 
separate regulatory category," noted Holtzman. For example, tests used for 
predictive purposes are not used primarily in sick people, as are most other 
diagnostic tests, but rather to predict future disease. Moreover, physicians often 
have little in the way of clear-cut i nterventions to offer when a test reveals that a 
patient is predisposed to develop a gene-related disorder. Predictive genetic tests 
also may involve issues of prenatal testing and termination of pregnancy, and they 
have implications not only for the individual being tested but for family members 
as well. 
Stephenson, supra note 1 5, at 1662. In the area of FDA reform, industry is requesting this 
same level of detail. See Fox, supra note 82, at 698; see also Translating Advances in 
Human Genetics into Public Health Action (undated) (background document prepared for a 
meeting to discuss genetics in public health at the Center for Disease Control and Prevention 
on January 27-28, 1997) (on file with authors). An Ad hoc Task Force on Genetics in 
Disease Prevention was appointed by the CDC Director in September of 1996 to (I) develop 
a strategic plan for CDC-wide genetics programs; (2) coordinate and support program efforts 
involving multiple centers, institutes, and offices at the CDC; and (3) convene constituents 
and consultants to obtain input on strategic planning and priorities for CDC activities related 
to genetics in public health. The stated mission is to "integrate knowledge of human 
genetics into effective and ethical public health actions that promote health and prevent 
disease and disability. CDC, in collaboration with its partners, will accomplish this mission 
by assessing the public health impact of human genetic variation and its interaction with 
modifiable risk factors; developing a sound framework of public health policies, 
recommendations, and guidelines for the use of genetic tests and services; developing and 
evaluating population-based prevention programs that include genetic tests and services in 
the prevention of disease and disability; and disseminating genetics information and 
providing public education and professional training." Id. 
244. This proposal has received support from members of the ELSI Task Force. See 
ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 ,  at 25. Because the field is evolving 
and advancing so rapidly, even after making such a showing, physicians should be subjected 
to continuing education requirements in genetic medicine. See id. at 23-24 ("Principle III-2: 
Some documentation of continuing education in the area of human and medical genetics 
should be required for physicians offering genetic tests, including primary care providers."); 
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Such standards must be introduced nationally to avoid an 
industry "race to the bottom" at the state level. Specifically, a failure 
to introduce national standards is likely to instill the wrong public­
health incentives by rewarding states that adopt a laissezjaire 
approach to attract industry. Standards also must be explicit enough to 
be enforceable. One of the advantages of express quality standards or 
codes of practice is that they will remove the- amorphous standard of 
care ("the rest of the profession is doing it") defense to liability.245 
With more specific standards in place, physicians will be liable for not 
adhering to these standards, regardless of what the rest of the 
profession is doing. 
There is ample support within the medical profession for such 
standards, most notably from Francis Collins, head of the HGP.246 
Ironically, many medical professionals vocally oppose making BRCA 
see also Proposed Recommendations of the Task Force on Genetic Testing, Meeting Notice, 
62 Fed. Reg. 4539, 4546 ( 1997) (proposing the development of a satisfactory curricula and 
examination and recertification programs). 
245. The United States is like the United Kingdom in that, absent specific codes of 
practice, the test for liability remains effectively a professional one: 
The test . . .  effectively states that a doctor will not be negligent if she acts 
in accordance with a practice held to be reasonable by a responsible body of 
medical opinion. Therefore, it could be said, although somewhat simplistically, 
that as Jong as some doctors are behaving in a certain way, then no liability will 
attach . . . .  
This makes it likely that a responsible body of medical opinion will be 
found to endorse whatever the individual doctor has or has not done, thereby 
virtually ensuring that legal liability will not be attributed. However, it should be 
said that there is an increasing trend in contemporary medicine to develop codes 
of practice that might be thought of as codes of best practice. If such codes are 
developed in relation to genetic screening, i t  will become harder to argue in favor 
of the doctor who deviates from that code . . . .  
Mclean, supra note 1 9, at 1 26-27. 
246. See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 ,  at 1 5  ("Professional 
societies, such as the American College of Medical Genetics, the American Society of 
Human Genetics, and the Council of Regional Networks for genetic Services have published 
statements regarding appropriate and inappropriate use of specific tests."); Collins, supra 
note 2, at 188 ("[I]t i s  critical that we create safeguards to ensure that the benefits of testing 
exceed the risks."); see also Saltus, supra note 1 34 ("Dr. Francis Collins, the head of the 
National Center for Human Genome Research, wrote in a medical journal last January that 
he was concerned about commercial motives spreading the test outside research programs. 
Last week he said he still believes testing should be under a research umbrella 'until such 
time as we have better answers' about its usefulness."); Weiss, supra note 2 ("[S]everal 
prestigious scientific organizations-including the American Society for Human Genetics, 
the National Advisory Council for Human Genome Research and the National Action Plan 
on Breast Cancer, which is coordinated by the U.S.  Public Health Service-have come out 
against commercialization of the BRCAl test, the first crude predictor of cancer risk to come 
on the market."). 
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testing available to consumers outside the major research centers, even 
though the medical profession shares responsibility for this occurrence 
by failing to effectively self-regulate.247 Moreover, generating tailored 
standards at a national level with professional and consumer input has 
been made more possible through recent advances in communication. 
In fact, in an age of global communication, it also is possible to 
review, and perhaps adopt, modified versions of health care quality 
standards from abroad for innovative technologies that have been 
proven effective in practice.248 One possibility is the U.K.'s  standards 
(and underlying research) regarding genetic diagnosis for late-onset 
disorders in children.249 
Still, thoughtful standards alone may not be enough to counter 
the pressures on providers from consumers, behind-the-scene managed 
care administrators who want to keep consumers enrolled while 
minimizing costs, and industry. Therefore, to make the genetic-test 
quality standards imposed on practicing physicians enforceable, the 
introduction of codified professional standards must be accompanied 
by regulatory restrictions on predictive genetic testing.250 In light of 
247. See Saltus, supra note 1 34, at 25; Weiss, supra note 2, at A l .  
248. See Malinowski, supra note 29, at 1 22. 
249. Professor George Annas is attempting to organize a Global Physicians and 
Lawyers for Human Rights Network to introduce enforceable international standards for 
medical technology such as genetic testing. See Vicki Brower, lawyers, Physicians Seek 
Genomics Rules, 1 5  NATURE BIOTECHNOLOGY IO  ( 1 997). The International Bar 
Association, the world's largest legal organization for lawyers, supports a treaty proposed to 
set minimum standards for the use of genetic information. See id. This treaty was released 
November 1 996 i n  Berlin, Germany. See id. ; see also Mindy H. Chapman, Comment, RX: 
Just What the Doctor Ordered: International Standards for Medical Devices, 14 Nw. 1. 
INT'LL. & Bus. 566 ( 1 994). 
250. See Weiss, supra note 2, at A l  ( 
At the [ELSI Task Force] meeting last month, representatives of the 
biotechnology industry said it is the doctor's job to make sure that patients 
understand the risks and benefits of being tested. Doctors said they were still 
getting up to speed in genetics and would be unable to stem the tide of patient 
demand if testing were not subject to regulatory restrictions. And insurers said 
they would go out of business if they were restricted from having access to genetic 
information. 
); FDA Needs to Regulate, supra note 63, at 1 627 ( 
The US Food and Drug Administration (FDA, Rockville, MD) needs to muster 
the political will to take up the regulation of genetic testing, not just of diagnostics 
manufactured as kits, but also of the in-house protocols ("home brews") that 
constitute most susceptibility tests. 
Although the US Health-Care Financing Administration does have some 
oversight (under the Clinical Laboratory Improvement Amendment of 1 988), as 
do institutional review boards at various institutions, the oversight provided varies 
widely and does not inspire confidence i n  the end results. 
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the public and political pressures on the FDA, such regulation might 
best be introduced through the CDC, FfC, HCFA, or HHS by, for 
example, modifying CLIA. To minimize duplication of regulatory 
efforts, there must be horizontal regulatory coordination at the federal 
level and vertical coordination between federal and state efforts. This 
coordination cannot be accomplished without the establishment of a 
federal body with the sole responsibility of achieving this objective 
and the political independence and authority to do so. 
One logical option is to introduce complementary criteria on 
research laboratories (meaning any laboratory perfonning predictive 
genetic testing) regardless of whether the testing they perform is 
offered as research, investigational, or off-label. Like physicians, 
research . laboratories control access to predictive genetic testing 
services, in that their involvement also is absolute. Accordingly, 
careful consideration should also be given to the laboratory-quality 
principles developed by the ELSI Task Force, which are attached in 
part as Appendix II, and the more recent Proposed Recommendations 
summarized in Table I. Another option is to introduce unifonn 
proficiency testing (PT).251 As suggested by the ELSI Task Force, 
such a requirement could be enforced by making it a precondition for 
reimbursement for testing services.252 In its more recent 
recommendations, the Task Force has proposed introducing a registry 
of laboratories in compliance with national standards, coupled with 
limiting reimbursement by third-party payers to tests performed by 
). 
25 1 .  See ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 ,  at 7 ('There was a 
general consensus among Task Force members that, be i t  mandatory or voluntary, a uniform 
national genetics PT program would be preferable to the assortment of approaches used 
today."). Some members of the ELSI Task Force have suggested that: 
[W]hile CLIA does not require PT [proficiency testing] for genetic testing, genetic 
labs would be subject to CLIA's quality assurance (QA) requirements. Under QA 
inspection, laboratory surveyors could ask for evidence of quality testing, and may 
obtain the results of voluntary PT by the lab. (Labs cannot conceal poor PT 
results from surveyors.) If the voluntary PT results showed the lab was deficient, 
HCFA could take appropriate measures under CUA to make sure the lab 
improves. Such measures could include a plan of correction, on-site monitoring, 
"cease and desist" orders , or perhaps even court action. Lebovic emphasized that 
mandatory PT under CLIA is intended as more of an educational tool than a 
punitive device. Still, revising CLIA to require that genetics labs undertake PT 
would help insure the quality of their testing. 
Meeting Minutes, supra note 1 ,  at 6-7. 
252. See Meeting Minutes, supra note 1 ,  at 7 .  
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laboratories on the list.253 Regardless of what medical-science, quality­
assurance safeguards are introduced on the federal level, there must be 
recognition of the fact that genetic science is constantly and rapidly 
evolving. Accordingly, all review must be ongoing.254 
Federal standards also must be introduced to ensure that the IRB 
mechanism carries legitimacy.255 At the very least, the CLIA 
provisions calling for the use of IRBs and giving them authority must 
be expanded to address their composition and to establish standards 
for approval of any human research ,  federally funded or not. In light 
of the authority IRBs carry and because they are the primary 
mechanism assuming the sufficiency of the scientific process and 
protecting the rights of participatin g  subjects, there must be prescribed 
elements for structuring IR.Bs that promote impartiality and the 
enforcement of good-medicine standards. The discretion allowed 
institutions when constructing IRBs must be curtailed.256 Strict 
253. See Proposed Recommendations of the Task Force Genetic Testing, Meeting 
Notice, 62 Fed. Reg. 4539, 4546 (Nat ' l  Insts. Health 1 997). 
). 
254. See ELSI TASK FORCE ON GENETIC TESTING, supra note l ,  at 36 ( 
Principle IV- l :  All elements of the genetic testing process need ongoing review 
and oversight. Ongoing review of the genetic testing process is needed to ensure 
the integrity of testing programs and to avoid potential abuses. . . . An expanded 
role of institutional review boards, the recognition of genetics as a discrete entity 
by CLIA administrators and FDA, and the creation of a special national body with 
authority to review genetic testing are some options, which are not mutually 
exclusive, currently under consideration. 
What patients should be told about a test and its results may change considerably due to the 
research nature of the testing and ongoing data collection and compilation. This is the cost 
of making service available before thorough clinical study and under tight restrictions. 
255. The i ncredible lack of such standards is summarized in Palca, supra note 70, at 4 
Since federal agencies clearly aren't prepared to oversee research themselves, they 
usually turn to IRBs to do the job. . . . I n  some cases, the board's workload is 
such that it spends only one or two minutes on each study under review, and for 
most IRBs that workload will increase . . . .  
. . . Collegial ties among IRB members and researchers whose work they 
were being asked to review could hamper an IRB member's ability to critically 
evaluate protocols. 
). See also Proposed Recommendations of the Task Force on Genetic Testing, Meeting 
Notice, 62 Fed. Reg. at 4544 ('The Task Force is concerned that the high workload of IRBs, 
their variability in community representation, in evaluating protocols, and in expertise 
gennane to the review of genetic tests, as well as the conflicts of interest that can arise in 
local review, impairs current review of genetic tests that warrant stringent scrutiny."). 
256. As recognized by some members of the ELSI Task Force, entities constructing 
IRBs have significant discretion: 
[T]he subject of IRBs is rife with questions. Who should sponsor IRBs? Who 
should sit on IRBs? Are all IRBs equipped to oversee investigational use of 
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conflict-of-interest and disclosure requirements are needed, including 
requirements that any compensation for participation in IRBs be 
reported and. disclosed publicly. Also, the composition of IRBs should 
be regulated to the extent necessary to ensure rigorous, intellectually 
honest, and scientifically valid review. The importance of such 
regulation is made especially acute by the proposed disbanding of the 
Recombinant DNA Advisory Committee (RAC), "a venerable panel 
of scientists, ethicists and other experts at the National Institutes of 
Health that for two decades has shined the spotlight of public 
accountability on the genetics revolution."257 The peer review nature 
of IRBs suggests that the traditional research/clinical division in 
medicine should be bridged for IRB standards by collaboration 
between professional organizations that focus on both research and 
genetic tests? Should more than one IRB be used? Are there conflict-of-interest 
problems with IRBs established by entities with a financial stake in the products 
being reviewed? 
. . .  Dr. Murphy of OncorMed explained that her company has created an 
IRB group, and has no interaction with the IRB other than for review of 
OncorMed's protocols. . . .  The IRB qualifies under both Health & Human 
Services and FDA IRB regulations, and its members include two pathologists, a 
bioethicist, a nurse, a consumer and a lawyer plus a variety of ad hoc experts who 
rotate for different protocols. 
Meeting Minutes, supra note 1, at 4-5. See generally ABRAHAM, supra note 71 (reporting a 
lack of impartiality between science community representatives on IRBs and researchers 
responsible for the science at issue, as there is a revolving door and often professional and 
financial entanglements between those two groups). 
257. Rick Weiss, It May be Over for Biotech Oversight Panel, WASH. POST, May 29, 
1996, at Al7 ("The Recombinant DNA Advisory Committee [RAC) . . .  is poised to get its 
plug pulled."). Despite its .accomplishments, which include ( 1 )  the first guidelines for 
scientists wishing to create genetically engineered microbes; (2) the first formal review 
system for proposals to insert new genes into people; and (3) the first approval of a human 
gene therapy experiment, RAC faces a proposal in the federal register by NIH Director 
Harold Varmus to disband it. See id. The rationale underlying this proposal is that "most 
proposals today are straightforward enough that they can be reviewed directly by the Food 
and Drug Administration." Id. One intended outcome is more reliance on IRBs (rather than 
RAC), though reliance on IRBs has been the source of both concern and public criticism: 
Abbey S. Meyers, Pres. of the National Organization for Rare Disorders, 
rejected Varmus's contention that institutional review boards at the universities 
where gene therapy experiments are conducted can be counted on to weed out 
unworthy studies. Those boards have neither the expertise nor the incentive to 
critically assess gene therapy experiments . . . . They are being reviewed by 
people who don't know anything about it but are desperate for their institution to 
become a gene therapy center. . . . We have seen informed consent forms 
approved by IRBs that are unbelievable . . . .  
Id. It is important to note, however, that RAC will continue one of its major missions 
maintenance of a registry of all gene therapy experiments underway in the country. See id. 
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clinical aspects of medicine, such as the American Medical 
Association and the National Hospital Association. 
Even if enacted, reforms that conclusively control the quality of 
predictive genetic testing services at the national level through 
restrictions on their delivery-though a considerable improvement­
still would not be adequate. The burgeoning nature of the 
biotechnology industry and the field of biomedical science mandates 
that there be no assumption of compliance with and enforcement of 
such regulations. Instead, public health officials must assume that 
consumers will have access to genetic testing and that genetic 
information will be generated in an increasing fashion. Accordingly, 
reforms such as those proposed above must be accompanied by the 
introduction of a regulatory infrastructure to protect consumers from 
abusive uses of genetic information. Without such reform, "[a]nswers 
to the next series of clinical questions may be jeopardized by the 
injudicious use of genetic testing by physicians and continued concern 
about the possibility of discrimin ation on the basis of the results."258 
National legislation governing the use of genetic information by 
insurers also is needed to overcome both regulatory disparities 
between the states and the preemptive effect of the Employee 
Retirement Income Security Act of 1 974 (ERISA).259 Otherwise, 
those who choose to undergo genetic testing while a resident of a state 
limiting the use of genetic information may find themselves unable to 
obtain insurance coverage when they move to another state.260 Such 
regulation has been introduced to prevent employers from 
discriminating on the basis of genetic information.261 Also, legislation 
258. Olopade, supra note 177, at 1455.  
259. 29 U.S.C. §§ 1 001- 1461 ( 1 994). "Health care insurance may be declared an 
employee benefit when employers self-insure, thereby subjecting the insurance provided to 
regulation under ERISA." Malinowski , supra note 1 25, at 35 1 n . 143 ;  see also Roberta 
Casper Watson, Fiduciary Issues in the Administration of Health Plans, in ALl-ABA 
COURSE OF STUDY MATERIALS: FIDUCIARY RESPONSIBILITY ISSUES UNDER ERISA-1996, 
June 6, 1996, at 1 007. Though recent federal cases have held that ERIS A preemption is not 
an absolute defense to claims of medical malpractice, the statute generally has been 
interpreted to preempt state laws and regulations. See Malinowski, supra note 1 25, at 351 
n.143. 
260. See NBC Nightly News (NBC television broadcast, July 20, 1996), available in 
1996 WL 1 03025 1 1  ("Although Ruth wants a genetic test, she says she doesn't dare, 
because each state has different rules when it comes to privacy. RUTH: If  I' ve, while in 
New Jersey, gone ahead and done this-the genetic testing, and then at a later point we 
move, I've exposed myself."). 
261 .  In March 1995, the EEOC issued a new compliance manual, in which it 
included people who experience discrimination due to their genetic profiles for protection 
under the Americans with Disabilities Act (ADA), 42 U.S.C. §§ 12 101 - 1 22 1 3  ( 1 994). See 
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has been proposed to place similar restrictions on insurers. This 
legislation includes the nondiscrimination provision in the health 
insurance reform bills that address genetic information and that were 
passed by the House and Senate during the last Congress. 262 In August 
1996, President Clinton signed a version of these bills into law as the 
Health Insurance Portability and Accountability Act.263 
Nevertheless, absent comprehensive consumer protection from 
genetic discrimination at the federal level, the protection of citizens 
and regulation of the insurance industry rests well within the purview 
of the states' public health responsibilities. Moreover, while Congress 
has been contemplating protective measures, states have been enacting 
them.264 Some states, including Massachusetts, are contemplating 
innovative measures.265 State public health officials should promote 
EEOC COMPLIANCE MANUAL, supra note 127, § 902.8(a); see also Annas, supra note 14, at 
1 9-22 (discussing genetic testing and potential privacy concerns); Lord, supra note 22, at 
86; Richard Saltus, US Ruling Bars Discrimination Based on Genes; Prohibits Employer 
from Denying Job Because of Predisposition to Illness, BOSTON GLOBE, Apr. 1 1 ,  1 995,  at 4 
("Now, a federal conunission has ruled that employers cannot deny a job or fire someone 
because of his genes. The ruling covers only employment, not health or life insurance, but 
consumers and researchers say it's an important precedent."). Genetic alterations are 
deemed "disabilities" in that those who have them are perceived as having a p hysical or 
mental impairment that substantially limits one or more of a person's major life activities. 
See Lord, supra note 22, at 86. An employer may, however, be able to exclude a category of 
employees from certain exposure based upon his or her genotype, and "section 50l (c) of the 
ADA permits employers to observe the terms of a bona fide health insurance plan based on 
underwriting risks and classifications, provided there is no 'subterfuge' to evade the 
purposes of the act." Id. 
262. See supra note 82 (addressing Kassebaum-Kennedy sponsored bill). But see 
Piercey, supra note 1 27,  at 1 (reporting that, based upon alleged "internal documents" from 
the Health Insurance Association of America (HJAA), "Kennedy claims that, while genetic 
information and other health factors could not be used to deny coverage, they might be used 
to 'design' coverage"). 
263. Pub. L. No. I 04-1 9 1 ,  I 10 Stat. 1936 ( 1 996); see also supra note 1 27 (discussing 
the Act). 
264. As of July 1 996, notable state efforts included: 
I .  laws barring both employers and insurance companies from discriminating 
against individuals based upon the results of genetic testing enacted in New 
Hampshire, New York, Oregon, and Wisconsin; 
2. laws prohibiting employers from using genetic information to discriminate 
against employees or job applicants enacted in Iowa and Rhode Island; and 
3. pending bills in California, Massachusetts, Michigan, New Jersey, and 
Pennsylvania. 
See New York Bill Prohibiting Genetic Discrimination Signed Into Law, WEST'S LEGAL 
NEWS,  July 3 1 ,  I 996, at 7845, available in I 996 WL 423290; see also Genetic Testing 
by Employers, Labor Organizations, and Licensing Agencies, 1996 N.Y. Laws Ch. 204, 
§ I .  
265. See supra note 1 88. Massachusetts i s  contemplating ( l )  delegation o f  ongoing 
quality assessment and implementation of effective informed consent standards to the 
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legislation to protect consumers in the absence of federal legislation 
and supplement any federal protections that are eventually enacted. 
State responsiveness and ingenuity is especially needed to address 
infonned consent for genetic testing and the broader issue of genetic 
counseling.266 The best state solutions to these challenges ultimately 
could become national ones. 
When proceeding to implement reforms such as those identified 
above, legislators and medical and public health officials must 
anticipate the reaction of the biotechnology industry and proceed with 
market sensitivity.267 At both the state and federal levels, the 
biotechnology industry is recognized as an important sector in the 
Department of Public Health, (2) consumer control over genetic information, such as the 
option to have this information separated from medical records, and (3) a five-year 
moratorium on the use of genetic information by insurers coupled with a provision that 
would place the burden on insurers to have actuarial data in hand to establish the validity 
and predictability of genetic tests before they may use the resulting information in any way. 
See Observation by Michael Malinowski, Member of the Massachusetts Legislature's 
Special Committee on Genetic Information Policy; see also Richard Saltus, Genetic Privacy 
Bill in Works, BOSTON GWBE, Feb. 2, 1 997, at B2. 
266. The Draft Interim Principles identified by the ELSI Task Force include the 
following: 
Principle III-5: Informed consent for a validation study must be obtained 
whenever the specimen can be linked to the subject from whom it came. 
Under FDA regulations informed consent is needed in the investigational 
stage of device development, except when wai ved by an IRB. 
Principle III-7: Health care providers must describe the features of the 
genetic test, including potential consequences, to potential test recipients prior to 
the initiation of predictive testing in clinical practice. 
The informed consent process contributes importantly to the education of 
people who are offering testing. 
The responsibility for providing information to the individual lies with the 
referring provider, not with the laboratory performing the test. 
ELSI TASK FORCE ON GENETIC TEsTING, supra note 1 ,  at 27-28. For a discussion of patient 
autonomy in the context of genetic counseling, see Robert Wachbroit & David Wasserman, 
Patient Autonomy and Value-Neutrality in Nondirective Genetic Counseling, 6 STAN. L. & 
PoL'Y REv. 1 03 ( 1 995). 
267. See M eeting Minutes, supra note 1, at 2 ( 
Dr. Holtzman commented on the importance of resolving regulatory and 
other uncertainties, because genetic tests may not reach the marketplace unless 
venture capitalists have the confidence to invest sufficient funds in their 
development. For small firms which lack the financial resources and regulatory 
expertise required to bring a test to market, a joint venture with a large 
pharmaceutical firm may be the only practical solution. 
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United States's economic future,268 and many of the products being 
developed by that sector could greatly improve public health. 
However, the diverse nature of the biotechnology industry and its 
multitude of products should enable reforms necessary to ensure the 
responsible application of predictive genetic testing services to be 
enacted, assuming a market-sensitive approach is followed. 
Initiatives to enact such reforms actually may benefit from 
industry insight or prompt industry to introduce self-reforms that are 
equally effective. Although the guiding incentive of the industry 
ultimately is profit, that incentive may be used to bring about the 
consumer-protection regulation that is needed. For example (albeit to 
preserve and increase consumer demand) biotechnology companies 
have joined patient-advocacy groups in lobbying policy makers to 
reform the FDA review process269 and prohibit insurance companies 
from using genetic information.270 Similarly, OncorMed developed its 
elaborate, thoughtful genetic testing protocols at great expense to 
"Coase around" FDA regulations that impede access to consumers 
and, at times, unduly impede the advancement of life science. 
Whichever proposals ultimately are adopted to regulate the 
commercialization of predictive genetic testing services, public health 
officials should make heavy reference to supportive provisions from 
responsible protocols developed by the biotechnology industry and its 
academic allies both to win industry support and to quell opposition. 
VI. CONCLUSION 
In Oedipus Rex, the character Tiresias has the ability to see into 
the future as if it were yesterday. Tiresias's divine gift of vision, 
however, gives him no ability to change what he sees. In his words to 
King Oedipus, "Wisdom is a curse when wisdom does nothing for the 
man that has it."271 Without established PPV, predictive genetic tests 
offer much less certainty than Tiresias's vision. Although biomedical 
268. See generally Malinowski & O'Rourke, supra note 20 (noting that technology is 
becoming commercially viable, and companies are investing more resources to enforce their 
patents). 
269. See MICHAEL J. MALINOWSKI, INTERNATIONAL GUIDE TO THE LAW, BUSINESS AND 
REGULATION OF BIOTECHNOLOGY (forthcoming 1997). 
270. See Piercey, supra note 127, at I ("Biotechnology companies and patient 
advocacy groups lobbied lawmakers to include language barring genetic discrimination 
because many see it as a necessary precondition for the widespread use of genetic testing."). 
27 1 .  SOPHOCLES, OEDIPUS THE KING 37 (Stephen Berg & Diskin Clay trans., Oxford 
Univ. Press ed. 1978). 
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science carries the promise of therapeutics and gene therapies, in their 
absence, the present inability to change the future remains. 
This Article has analyzed the commercialization of predictive 
genetic testing for BRCA alterations linked to breast and ovarian 
cancer. Beyond addressing this contemporary and pressing problem, 
the objective has been to illustrate the public health implications of the 
premature commercialization of this technology, to identify regulatory 
shortcomings, and to introduce proposals for change. As has been 
emphasized throughout this Article, BRCA testing simply marks the 
beginning of widespread predictive genetic testing. 
Predictive genetic tests without established PPV are unacceptable 
for broad commercialization. Such tests are highly subject to 
misinterpretation by those who undergo them and by the health care 
providers who make them available. They are the equivalent of 
biological tarot cards. 
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Public health officials must directly address the issue of quality 
assurance for predictive genetic testing services. They must introduce 
consumer safeguards tailored to this innovative technology and, more 
importantly, they must enforce them. This Article has proposed 
numerous regulatory reforms to control access to and the quality of 
predictive genetic tests. Many of these proposals center on remaining 
faithful to the practice of good medicine. 
Advances in biomedical research offer many patients hope, not 
harm. The threat that accompanies this medical technology comes 
from the temptation to use it prematurely and irresponsibly. Just as 
physicians should not sell a drug or diagnostic to their patients that 
they do not understand (and, therefore, cannot measure the benefits 
of), physicians should not be making research-stage predictive genetic 
tests available without the precautions necessary to avoid doing hann. 
Predictive genetic testing simply i s  at the vanguard of an era of 
unprecedented progress in medicine attributable to genetic science. 
For centuries, the adage "First, do no harm" has guided the medical 
profession. The profession and the adage have endured jolting 
advances in medical technology-from anesthesia, to antibiotics, to 
vaccinations. Similarly, if contemporary public health officials look to 
this adage, they will find guidance. Promoting and enf arcing the 
practice of responsible medicine continues to be the answer. 
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APPENDIX I 
Excerpt from Letter Summary of the OncorMed ProtocoI272 
Patients who are eligible for testing under this protocol are: 
I .  persons with breast and/or ovarian cancer who have two or 
more first- or second-degree* blood relatives (related 
through a single lineage) with either breast or ovarian 
cancer, 
2. persons with breast and/or ovarian cancer which developed 
at an early age ( <45 years), 
3. persons with breast and/or ovarian cancer with multiple 
primary cancers or bilateral disease, 
4. males who develop breast cancer at any age, 
5. relatives of persons with documented mutations m the 
BRCA 1 or BRCA2 gene. 
* first-degree relative: parent, siblings, offspring; second-degree relative: aunt, uncle, grandparent, 
grandchild, niece, nephew, half-sibling 
Patients who may not be tested are: 
1. a person under the age of 18 years, 
2. a cognitively impaired person or one who is unable to 
provi de informed consent, 
3. someone who has a psychological condition precluding 
testing. 
To test a patient under this protocol, the physician would agree to: 
0 Call in or fax the family history to OncorMed before testing. 
Pathological verification of the history should be obtained 
whenever possible. 
0 Identify a genetic counselor to evaluate the family history, 
explain inheritance, discuss the benefits, risks, limitations, 
and psychosocial impact of testing; a medical and surgical 
oncologist to discuss management options; and a mental 
health specialist to help in the decision to test, to provide 
support during the testing process, or to help adjust to the 
results. The patient should be offered these referrals both 
272. This summary was taken from the Hereditary Breast Cancer Testing Packet 
received from OncorMed in January 1997. OncorMed, Inc. may be contacted at 205 Perry 
Parkway, Gaithersburg, Maryland 20877. The company may also be contacted by telephone 
at 301 -208- 1 888 or facsimile at 301 -926-6329. 
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before and after testing. OncorMed can help you locate a 
genetic counselor in your area, if needed. 
0 Ensure that informed consent is obtained and that the patient 
receives pre- and post-test counseling by one or more 
professionals knowledgeable about the genetics and 
management of hereditary breast cancer syndromes. 
0 Give the test results to the patient in person and develop a 
management plan with the patient. 
0 Refer the patient to the specialists you have identified as 
needed, provide psychological support, and assist in 
informing relatives if appropriate. 
We have provided a number of items which may help you counsel and 
test patients under this protocol. 
0 A testing flow diagram which outlines the protocol and 
which you can keep as part of your records to document 
progress though the testing process. 
0 A physician Q&A with information on BRCA 1 and BRCA2 
and on testing patients. 
0 A patient Q&A describing testing which can be given to 
patients. Encourage the patient to take the Q&A and the 
consent home to review prior to agreeing to be tested. 
0 Counseling checklists which you can use to be sure all 
relevant information is covered during the pre-and post-test 
counseling sessions and which can be given to the patient as 
a summary of the counseling. 
0 A clinical history form and consent which should be signed 
and returned with the blood sample if the patient agrees to 
testing. 
APPENDIX Il273 
ELSI TASK FORCE DRAFf INTERIM PRINCIPLES FOR 
LABORATORY QUALITY 
The ELSI Task Force identified 4 categories for considerations related 
to laboratory quality: ( 1 )  biologic materials and components, meaning 
the reagents and equipment used by the laboratory; (2) laboratory start­
up, meaning the introductions of new tests; (3) laboratory practice, 
273. ELSI TASK FORCE ON GENETIC TESTING, supra note 1 ,  at 16-22. 
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meaning the actual performance of tests, personnel, internal quality 
control, and quality assurance mechanisms; and (4) laboratory 
oversight, meaning proficiency testing, accreditation, and inspection. 
The Task Force issued the following principles: 
A. Components and Biologic Materials 
Principle 11-1 :  A genetic test must be analytically validated for 
each analyte it is intended to measure. It is ultimately the 
responsibility of each laboratory director to ensure analytic validity . 
. . . [T]here is minimal external oversight of the components used 
in genetic testing, except for those in FDA-approved kits or other 
devices. Although the Task Force is considering policies to change 
this picture, for the moment the laboratory supervisor must be 
responsible for assuring the performance characteristics of the 
components used in the laboratory's testing repertoire. Under the 
authority of CLIA (or of states that are at least as rigorous as CLIA), 
government surveyors are supposed to determine whether laboratories 
have developed new tests and, if so, to then review their data for 
analytic validation . . . .  
Principle II-2: Appropriate specimens from patients, carriers, and 
controls should be available through a centralized system in order to 
facilitate their availability to aid in analytical validation, improving 
quality, or other needs. 
B. Start- Up 
Principle 11-3 :  Laboratories can offer new genetic tests only after 
their analytical and clinical validity have been established by that 
laboratory or elsewhere. 
Principle 11-4: Before routinely offering genetic tests that have 
been clinically validated, a laboratory must conduct a pilot phase in 
which it verifies the performance characteristics of its test. 
Principle II-5: Prior to beginning routine patient testing, the 
laboratory must review and evaluate the data collected in the pilot 
phase. 
Principle 11-6: Research laboratories that provide physicians with 
results of genetic tests, which may be used for clinical decision 
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making, must validate their tests and be subject to . the same internal 
and external review as other clinical laboratories. 
C. Practices 
. . . The potential for errors in referral, the choice of an 
appropriate test, the probabilistic, predictive, and conditional nature of 
test results place a greater burden on communication between the 
laboratory and the provider ordering and/or receiving results than is the 
case for many other types oftests . . . .  
Principle II-7: Because of the complexities in assessment and 
interpretation, requisitions for genetic tests require more intake 
infonnation than those for most other clinical laboratory tests. 
. . . If information that is critical to the performance or the 
interpretation of the test cannot be obtained, the specimen should be 
rejected . . . .  
Principle Il-8: Genetic test results must be written by the 
laboratory in a form that is understandable to the nongeneticist health 
care provider. 
. . . Laboratory reports must include sufficient information in 
order for the referring provider to interpret the results appropriately to 
the person tested or, in the case of minors, to their parents . . . .  
Principle Il-9: Personnel serving as directors or technical 
supervisors of genetic testing laboratories must have formal training in 
human and medical genetics. 
Principle II- 10: Training programs for laboratory 
technicians/technologists should include more human and medical 
genetics content than is currently available . 
. . . Several fonnal training programs for cytogenetics technical 
staff are available, but there are only one or two certificate-or 
diploma-track genetics training programs for technicians or 
technologists in the U.S . . . .  
D. External Review 
Principle II- 1 1 :  A national accreditation program for laboratories 
performing genetic tests, which includes on-site inspection and 
proficiency testing, is  needed to promote standardization. 
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Principle Il-12: Genetic testing laboratories must participate in 
proficiency testing (PT) programs for each of its tests, if available. 
When no relevant proficiency testing programs exist, laboratories 
must, whenever possible, participate in inter-laboratory comparison 
programs and help develop them if none exist in their particular area of 
testing. Proficiency testing programs should be broadly based since 
the number of genetic disorders is very large and the analytical 
approaches to testing are numerous. Laboratories and inspectors 
should use PT results to help a laboratory improve its quality. 
In mandatory PT programs, some punitive action is taken if 
laboratories that "fail" do not improve their performance on 
_subsequent rounds. 
